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The hepatocyte is one of the major secretory cell types in the body. It fulfills 
many of the liver's essential functions in protein secretion, lipid storage and transport, and 
excretion. Some of these functions are carried out via polarized secretion of simple 
protein cargo, such as serum albumin, or large macromolecular lipid-protein complexes, 
the lipoproteins. The hepatocyte is also the site of infection of several hepatotropic 
viruses. Of these, hepatitis C virus (HCV) is peculiar due to its close structural and 
functional association with the hepatic lipoproteins. All these cargoes are transported 
from the endoplasmic reticulum (ER) to the cell surface by the vesicular secretory 
pathway, yet insufficient knowledge exists regarding the molecular regulation of their 
secretion by the hepatocyte. Furthermore, differential modalities of regulation may be 
involved in the shuttling of such a diverse set of cargoes as albumin, the lipoproteins and 
HCV.  
The work presented here head-starts a comprehensive examination of how the 
hepatocyte regulates the secretion of the following cargoes: serum albumin, the 
apolipoproteins E and B100 (ApoE and ApoB100, respectively, both lipoprotein 
components, and surrogate markers for these complex macromolecular particles), and 
HCV, a lipoprotein-associated virus. I propose to combine genetic, biochemical, 
virological and imaging approaches to identify which vesicular secretory pathways are 
utilized by each of these cargoes. These approaches include inactivation of specific 
vesicular transport pathways, accompanied by measurements of their effects on cargo 
secretion efficiencies, and establishment of functional fluorescent protein-tagged cargo 
markers to be used in live cell imaging experiments.  
I begin by describing a dominant negative (DN) Rab GTPase screen that I 
performed to identify Rab proteins involved in ApoE, ApoB100 or albumin secretion. 
The small Rab GTPases control individual steps of vesicular transport. I analyzed how 
expression of individual dominant negative Rab proteins affected cargo secretion 
compared to expression of their wild type (WT) counterparts. I identified several Rabs 
that caused significant changes in secretion, many of which had previously been 
described as regulators of various exocytic vesicular transport steps. 
I next present ongoing work that aims to define the involvement of the Rabs 11a, 
11b, 8a, and 8b in hepatic cargo secretion. Their dominant negative mutants exhibited 
some of the largest secretion phenotypes in my dominant negative Rab screen. These 
Rabs have been implicated in various aspects of post-Golgi secretion in polarized and 
non-polarized cell types. I thus discuss the implications of their involvement in cargo 
secretion in the polarized hepatocyte and outline my ongoing efforts to define the 
parameters of this involvement. 
I also investigated the function of Rab1b in hepatic secretion. I show that 
inactivation of Rab1 function, by expression of a set of dominant negative mutants, or by 
expression of a bacterial effector which affects Rab1 function, led to impairment of 
albumin, ApoE, ApoB100 and HCV secretion. I implicate Rab1, for the first time to my 
knowledge, in the transport of these cargoes. I also document differences in the 
sensitivity of cargo secretion to the various means of Rab1 inactivation. ApoE secretion, 
in particular, was insensitive to several means of transport inactivation, consistent with 
existing models of differential regulation of hepatic cargo transport.  
Lastly, I functionally characterize an ApoE-green fluorescent protein fusion 
(ApoE-GFP). I show that while ApoE-GFP does not support infectious HCV release, a 
hallmark function of untagged ApoE, ApoE-GFP nevertheless reproduces several known 
behaviors of ApoE that have been associated with lipoprotein release. I thus conclude that 
ApoE-GFP may be a useful marker for live cell imaging of lipoprotein release.  
This work therefore identifies potential regulators of hepatic cargo transport, 
establishes molecular tools useful for the continued study of cargo secretion in 
hepatocytes and elsewhere, and advances the understanding of the involvement of Rabs 
11, 8, and, in particular, Rab1, in the regulation of hepatic cargo transport. I propose that 
this work forms a solid foundation for extensive studies on how these biomedically 
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1.1 General overview 
This thesis describes my efforts, part of a larger and more ambitious endeavor, to 
molecularly characterize the regulation of the secretion of some complex and 
biomedically important hepatocyte-derived cargoes. My work focused on understanding 
the release of the following hepatic cargoes: serum albumin, the lipoprotein components 
ApoE and ApoB100, and the lipoprotein-associated HCV. My work also touched on the 
regulation of intracellular secretory vesicular transport, in part in the context of cell 
polarization. To place these efforts into greater context, and to introduce relevant facts 
and concepts regarding the major players in this work, I start by providing some 
background information. I first introduce some general principles of intracellular 
vesicular traffic regulation and I mention peculiarities of transport regulation in polarized 
cell systems. Since the greatest part of my work focused on how members of the Rab 
family of small GTPases control hepatic cargo secretion, I describe the general functional 
principles applicable to these proteins in greater details, and also introduce some widely 
used methods to investigate Rab function. I next discuss the hepatocyte, the cell type 
whose secretory function I investigate, and draw connections between its organization 
and the processes it carries out. I more extensively introduce the hepatic secretory 
cargoes that this work focuses on, namely serum albumin, the hepatic lipoproteins, and 
HCV. For HCV, I place particular emphasis on the functional association between the 
virion assembly and release portions of the viral life cycle, and the assembly and release 
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of the hepatic lipoproteins. I conclude by summarizing the goals of this project, the study 
of which will be expanded upon in greater detail in the following chapters.  
1.2. Intracellular vesicular transport 
A hallmark organizational principle governing eukaryotic cell structure and 
function is compartmentalization. For example, the nucleus stores and expresses genetic 
information, the ER fulfills numerous biosynthetic functions, mitochondria deal with 
energy production, and lysosomes carry out many degradative processes. Functional 
segregation is in part achieved by encasing the respective functions in membranous 
compartments: the membrane-bound organelles. Integration of function also requires 
communication between the various systems, ensuring that distinct or even opposite 
processes, such as protein synthesis and degradation, nevertheless occur under 
harmonious regulation.  
An important process that ensures communication between distinct organelles and 
integration of their functions is vesicular transport (Bonifacino and Glick, 2004; Palade, 
1975).  The paradigm is simple, as depicted in Figure 1.1A: a portion of the limiting 
membrane of a donor organelle pinches off as a sealed vesicle, or even as a bigger and 
pleiomorphic tubulo-vesicular structure. This transport carrier then travels to a target 
compartment, tethers to it, and the carrier and target membranes fuse, thus releasing the 
contents of the carrier. The cargo transported may be a soluble lumenal component, such 
as a secreted protein, a membrane-associated molecule, such as a transmembrane 








Figure 1.1. Principles of intracellular vesicular transport. (A) Simplified schematic of 
vesicular traffic between membrane-bound intracellular organelles (for detailed model 
see Figure 1.3). A vesicle loaded with cargo pinches off a donor organelle membrane, 
then travels to a target compartment, where the vesicle and target membranes fuse, 
releasing the cargo. (B) Simplified depiction of major vesicular transport pathways. 
Green, the biosynthetic or secretory pathway; orange, the endocytic pathway. ERGIC, 
ER-Golgi intermediate compartment; TGN, trans-Golgi network; PM, plasma membrane; 
EE, early endosome; LE, late endosome; Ly, lysosome; RE, recycling endosome; RR, 
rapid recycling from an early endosome; SR, slow recycling from a recycling endosome. 
Figures adapted by permission from Macmillan Publishers Ltd: Nature Rev. Mol. Cell. 
Biol. (Stenmark, 2009) ©2009. 
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In an overly simplified model of intracellular transport, several major vesicular 
transport pathways can be easily identified (Figure 1.1B). The secretory (or biosynthetic) 
route transports cargo from a major biosynthetic site, the ER, to the plasma membrane 
(Palade, 1975). Important way stations along this route are the protein synthesis 
organelle, the ER, as well as the Golgi system and the trans-Golgi network (TGN), where 
cargo sorting and processing may occur (Brandizzi and Barlowe, 2013; Glick and 
Nakano, 2009; Guo et al., 2014). The degradative route, on the other hand, commences at 
the plasma membrane with an endocytic event (Doherty and McMahon, 2009). The 
endocytosed cargo is then shuttled through a succession of endosomes (Huotari and 
Helenius, 2011) before it is delivered to lysosomes, where final degradation occurs 
(Luzio et al., 2007). Endocytosed cargo may also be recycled in one of two predominant 
ways: in rapid recycling, the cargo returns back to the plasma membrane directly from an 
early endosome; in slow recycling, the cargo first travels to a specialized recycling 
endosome, from where it can then return to the plasma membrane (Grant and Donaldson, 
2009; Ren et al., 1998). Importantly, none of these pathways functions in isolation. For 
example, the last steps of recycling perform a function similar to that of the late secretory 
pathway, namely delivery of cargo to the plasma membrane. Indeed, some biosynthetic 
cargoes may traverse the recycling endosome during their secretion (Ang et al., 2004). 
The interconnectedness of the major intracellular transport pathways is also evident in the 
delivery of biosynthetic cargo to the endolysosomal degradative or related compartments 
(Anitei et al., 2010; Bonifacino and Traub, 2003; Raposo et al., 2007).  
While this simplified description introduces some of the major players and 
functions that occur at various stages of vesicular transport, the structural and functional 
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details of this system are much more complex. More minute functional and structural 
divisions of the vesicular transport system exist. For example, ER-derived vesicles may 
fuse together to form an ER-Golgi intermediate compartment (ERGIC) before they reach 
the Golgi system (Appenzeller-Herzog and Hauri, 2006; Xu and Hay, 2004). Similarly, 
the transition from endocytic vesicles to lysosomes may include several functionally and 
structurally distinct stages, from early to late endosomes and then to lysosomes (Huotari 
and Helenius, 2011). Post-Golgi secretory intermediates may include specialized vesicles, 
such as those loaded with neurotransmitters, endocrine hormones, or cytotoxic immune 
cell products, whose release is tightly regulated (de Saint Basile et al., 2010; Sudhof, 
2004). Conceptually, the progression from one compartment to another may be viewed as 
delivery of cargo to a pre-existing target compartment. The same process may be also 
described as the transformation, or maturation, of a given vesicular compartment. For 
example, transport vesicle fusion may lead to the formation of the compartment, as in the 
case of ERGIC formation following fusion of ER-derived vesicles (Appenzeller-Herzog 
and Hauri, 2006; Xu and Hay, 2004) or of early endosome formation following 
homotypic fusion of endocytic vesicles (Bucci et al., 1992; Gorvel et al., 1991). Because 
they lose certain vesicle-specific markers and properties, and acquire new ones, such 
intermediate compartments may be viewed as being formed by maturation of the original 
carriers. Regardless of whether membrane transport occurs through cargo shuttling from 
one compartment to another, through maturation of the cargo transport carrier, or through 





1.3. Vesicular transport in polarized cells 
The simplified eukaryotic transport system described above assumes that all sides 
of a cell are identical. Often this is not true, as many cells have a polar structural and 
functional organization. An intensely studied type of polarity is that found across 
columnar epithelia (Rodriguez-Boulan and Macara, 2014), but neurons (Namba et al., 
2015) and migrating cells (Petrie et al., 2009) are also the focus of extensive 
investigation. In columnar epithelia, such as those lining the digestive or respiratory 
tracts, a sheet of cells separates two distinct environments: the tissue-facing side of the 
epithelial sheet, which comprises the juxtaposed basal surfaces of individual cells, and 
the outside- or lumen-facing side of the epithelial sheet, which comprises the juxtaposed 
apical surfaces of individual cells (Figure 1.2A). The apical surface of a cell is separated 
from the contiguous basolateral surface by tight junctions (Farquhar and Palade, 1963). 
These tight junctions (Figure 1.2B) simultaneously restrict trans-epithelial diffusion and 
prevent mixing of apical and basolateral membrane components (Madara, 1998; Shin et 
al., 2006). The tight junctions alone would likely not be able to maintain polarity if the 
cells did not possess mechanisms that allow them to concentrate basolateral and apical 
components at the appropriate poles (Goldenring, 2013; Rodriguez-Boulan and Macara, 
2014). Such mechanisms include polarized secretion (Figure 1.2B), by which apical 
markers are transported from the TGN directly to the apical surface, and basolateral 
markers are transported directly to the basolateral surface. Cells may also target cargo to 
the correct surface by transcytosis (Preston et al., 2014; Rojas and Apodaca, 2002). In 
this case, cargo initially delivered to one surface is endocytosed and transported across 
the cell to the opposite surface (Figure 1.2C-D). The presence of polar surfaces 
 
7 
complicates endocytic recycling the most, and several partly interconnected endosome-
type compartments have been identified and shown to control recycling and, in some 
cases, biosynthetic transport at both poles (Goldenring, 2013, 2015). Thus, basal early 
endosomes function in recycling and some secretory transport to the basolateral surface, 
apical early endosomes and apical recycling endosomes function at the apical pole, and 
common recycling endosomes function in both recycling and transcytosis (Figure 1.2C-
E). The recycling endosome system may be composed of separate membrane 
compartments, or may consist of a contiguous compartment with specific functions 
performed by distinct domains (Goldenring, 2015; Sonnichsen et al., 2000).  
 
 
Figure 1.2. Polarized transport. (A) Schematic representation of a columnar epithelium. 
Cells are packed tightly in a monolayer, with the apical surfaces (top, green) facing a 
lumenal or exterior space, and the basolateral surfaces (bottom) facing the interior. Figure 
adapted from (Treyer and Musch, 2013), with the permission from Wiley-Blackwell. 
Copyright © American Physiological Society. (B-E) Selected types of post-Golgi 
vesicular transport occurring in polarized cells. Figures adapted by permission from 
Macmillan Publishers Ltd: Nature Rev. Cancer (Goldenring, 2013) ©2013 (B) Apical 
and basolateral secretion from the Golgi compartment. (C) Apical to basolateral 
transcytosis. (D) Basolateral to apical transcytosis. (E) Apical and basolateral recycling; 
TJ, tight junction; AJ, adherens junction; AEE, apical early endosome; BEE, basolateral 
early endosome; ARE, apical recycling endosome; CRE, common recycling endosome. 
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1.4. Regulation of vesicular transport 
The vesicular transport steps that connect the major organelles of the secretory 
pathway are regulated according to well-established principles. The process encompasses 
cargo sorting at the donor compartment into a budding vesicle, vesicle scission, transport, 
tethering to the target compartment, and fusion of the vesicle and target compartment 
membranes (Figure 1.3).  
Vesicle budding, accompanied by recruitment of a vesicle coat complex to the 
nascent transport carrier, is followed by scission of the vesicle membrane form the donor 
compartment membrane (Figure 1.3a-b). Transmembrane cargoes may be recognized by 
the sorting machinery due to specific amino acid sorting signals that they possess in their 
cytosolic domains. Soluble cargoes, on the other hand, may bind to transmembrane 
sorting receptors, such as the KDEL receptor (Lewis and Pelham, 1992) or the manose-6-
phosphate receptor (Guo et al., 2014). These receptors in turn possess cytosolic sorting 
signals required for transport (Dancourt and Barlowe, 2010; Guo et al., 2014).  
Recruitment of the vesicle coats to the site of vesicle budding may be initiated by 
the GTP-loaded, active form of a small GTPase of the Sar/Arf family (Gillingham and 
Munro, 2007). Sar1 GTPases recruit coat protein complex II, or COPII, at the ER to 
mediate anterograde traffic to the Golgi (Aridor et al., 1995; Gillingham and Munro, 
2007; Kuge et al., 1994; Nakano and Muramatsu, 1989; Stagg et al., 2006; Stagg et al., 
2008). The Arf1 (ADP ribosylation factor 1) GTPase recruits the coat protein complex I, 
or COPI, at Golgi membranes to mediate intra-Golgi transport and retrograde ER-to-
Golgi transport (Aridor et al., 1995; Gillingham and Munro, 2007; Presley et al., 2002; 
Stearns et al., 1990). Arf proteins may also recruit adaptor protein (AP) complexes and 
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clathrin cages that mediate late exocytic transport out of the TGN compartment 
(Gillingham and Munro, 2007; Guo et al., 2014). Lastly, several factors may induce 
vesicle scission from the donor compartment, including the large GTPases of the 
dynamin family (Campelo and Malhotra, 2012; Morlot and Roux, 2013; Schmid et al., 
2015). Some of these events may occur sequentially, while others may occur 
simultaneously. Thus, vesicle scission from the donor compartment obligatorily occurs 
after cargo sorting, but cargo sorting may occur concurrently and in conjunction with 
vesicle coat formation (Macro et al., 2012), or cargo may be recruited to pre-existent 







Figure 1.3. Details of vesicular transport. Detailed depiction of the steps involved in 
vesicular transport between a donor and a target organelle. (a) Cargo is sorted into a 
budding vesicle while coat proteins promote budding. (b) After scission, the coat proteins 
are released. (c) The vesicle travels along the cytoskeleton; (d) The vesicle tethers to a 
target compartment. (e) SNARE proteins mediate vesicle fusion to the target 
compartment. Throughout transport, the vesicle associated Rab protein is found in the 
GTP-bound active form and is membrane associated. Upon GTPase activating protein 
(GAP)-induced GTP hydrolysis, the inactive Rab-GDP binds a GDP-dissociation 
inhibitor (GDI). The resulting complex is cytosolic. The Rab activity cycle resumes when 
a GDI displacement factor (GDF) and a Rab guanine exchange factor (GEF) act to 
promote release of GDP and loading of GTP onto the Rab, returning it to a membrane-
bound active state. Figure adapted by permission from Macmillan Publishers Ltd: Nature 
Rev. Mol. Cell. Biol. (Stenmark, 2009) ©2009. 
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Transport carrier formation is followed by its movement towards and fusion to a 
target compartment (Figure 1.3c-d). This process is regulated by the Rab family of small 
Rab GTPases (Hutagalung and Novick, 2011; Stenmark, 2009; Takai et al., 2001). Their 
functional cycle will be described in greater detail in the next section. It is sufficient to 
note here that an active, GTP-loaded Rab protein becomes associated with the budding or 
budded transport carrier. The active Rab protein will then recruit various types of effector 
molecules that directly influence vesicle behavior. For example, Rabs may recruit motor 
proteins of the dynein, kinesin, or myosin families (Hutagalung and Novick, 2011), 
which will determine whether the transport carriers utilize actin fibers or microtubules for 
their movement, and whether this movement is directed towards the (+) end or (-) end of 
microtubules. Similarly, Rabs may recruit tethering and vesicle fusion factors, which will 
recognize the appropriate target compartment, tether the transport carrier to that 
compartment, and mediate the fusion of the two membranes and delivery of the cargo 
(Figure 1.3d-e). For example, Rab1 on ER-to-Golgi transport vesicles recruits p115 
(Allan et al., 2000), which tethers anterograde transport vesicles to the Golgi, while Rab8 
recruits the exocyst complex to post-Golgi vesicles (Mazelova et al., 2009b). Various 
SNARE systems control vesicle fusion at various subcellular locations (Martens and 
McMahon, 2008; Rizo and Rosenmund, 2008; Rizo and Xu, 2015; Wickner and 







1.5. The Rab GTPases 
While the major regulators of transport carrier formation at the donor 
compartment are the Sar/Arf GTPases, the major regulators of transport carrier behavior 
are the Rab GTPases (Hutagalung and Novick, 2011; Stenmark, 2009). They form the 
largest family of small GTPase in eukaryotes, with over 60 encoded by the human 
genome (Diekmann et al., 2011; Gurkan et al., 2005). They are somewhat specifically 
associated with discrete steps of vesicular trafficking (Figure 1.4). Rab1, for example, 
regulates early anterograde traffic, from the ER to the Golgi (Plutner et al., 1991), while 
Rab5 regulates the initial steps of endocytic traffic (Bucci et al., 1992; Gorvel et al., 
1991). Several Rabs may act together within a given pathway, such as Rab11 and Rab8 in 
post-Golgi transport to the primary cilium (Knodler et al., 2010; Westlake et al., 2011), 
while several isoforms may be differentially expressed in various tissues and regulate 





Figure 1.4. Subcellular localization of Rab GTPase functions. The major organelles of 
a polarized eukaryotic cells are depicted, together with vesicular traffic pathways that 
connect them. The many Rab GTPases are depicted at their site of function or 
localization. Figure adapted by permission from Macmillan Publishers Ltd: Nature Rev. 
Mol. Cell. Biol. (Stenmark, 2009) ©2009. For detailed references, please see the original 
review article (Stenmark, 2009). 
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The Rabs amino-terminal domain is the best conserved and contains the GTPase 
domain. This domain is related to the GTPase domains of other small GTPases of the 
Rho, Rac and Sar/Arf families (Takai et al., 2001; Wittinghofer and Vetter, 2011), and is 
involved in GTP or GDP binding and GTP hydrolysis. Sequences connected to the 
GTPase domain change conformation depending on the nucleotide load of the GTPase 
and are involved in effector molecule recognition and binding (Takai et al., 2001). The 
carboxyl-terminal domain of the Rabs has a more divergent primary sequence and may 
be involved in the localization of the Rab to a given organelle or vesicle (Chavrier et al., 
1991). Lastly, conserved cysteines at or very near to the carboxyl-terminus of the Rabs 
are prenylated with prenyl (usually geranylgeranyl) lipid tails (Khosravi-Far et al., 1991; 
Leung et al., 2006). These lipid tails mediate the association of the Rabs with target 
membranes and are essential for function (Khosravi-Far et al., 1991; Nuoffer et al., 
1994).  
The Rab nucleotide exchange and hydrolysis cycle (Figures 1.3 and 1.5) is similar 
to that of other small GTPases (Hutagalung and Novick, 2011; Stenmark, 2009; Takai et 
al., 2001). The active form is the GTP-bound form; active Rab-GTP complexes are 
membrane bound and mediate effector recruitment (Figure 1.3a-d). Intrinsic Rab GTPase 
activities are generally slow (Ingmundson et al., 2007), ensuring that inactivation of the 
Rabs does not occur prematurely. When Rab function needs to cease, however, a Rab 
GTPase activating protein, or GAP, will bind to the active Rab and stimulate its GTPase 
activity (Barr and Lambright, 2010). The resulting Rab GDP is inactive, and it detaches 
from the membrane, creating a cytosolic, inactive, GDP-bound pool of Rab molecules. A 
GDP dissociation inhibitor, or GDI, accelerates the extraction of prenylated, GDP-loaded, 
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inactive Rabs from the membrane (Gavriljuk et al., 2013), and, in the process, shields the 
hydrophobic Rab prenyl moiety in the otherwise hydrophilic cytoplasm (Pylypenko et al., 
2006; Rak et al., 2003). The Rabs are returned to their active by exchange of the GDP for 
a GTP. This is facilitated by proteins called guanine nucleotide exchange factors, or 
GEFs, which may also ensure recruitment and activation of a given Rab at the 
appropriate membrane compartment (Barr and Lambright, 2010; Blumer et al., 2013). 
The Rabs are thus recycled back into a new round of activity. 
 
 
Figure 1.5. The Rab GDP-GTP cycle. An inactive GDP-bound Rab releases GDP and 
binds GTP, a process promoted by a GEF. The active Rab-GTP is membrane bound and 
recruits effector molecules. Upon stimulation by a GAP, GTP hydrolysis occurs and the 
Rab returns to the inactive GDP-bound state. Figure adapted by permission from 
Macmillan Publishers Ltd: Nature Rev. Mol. Cell. Biol. (Stenmark, 2009) ©2009. 
 
An ongoing debate focuses on which factors determine membrane identity. It is 
clear by now that the Rabs, due to their somewhat specific association with discrete 
subcellular compartments, are obvious membrane identity marker candidates, but they are 
not the only ones (Barr, 2013; Pfeffer, 2013). Other factors that establish membrane 
identity include the lipid and protein composition of an organelle and vesicle. As traffic is 
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by necessity continuously dynamic, it is likely that membrane identity is too. Indeed, one 
Rab may direct the recruitment of another Rab's GEF, which in turn activates the latter 
onto the membrane and therefore changes membrane identity (Blumer et al., 2013). Rabs 
may also recruit phosphoinositide kinases or phosphatases, which modify the lipid head 
groups on a membrane and therefore change the nature of that membrane (Shin et al., 
2005). Regardless of the spatio-temporally, morphologically and compositionally 
dynamic nature of vesicular transport networks, the generally specific functional 
association between a given Rab and a given organelle or transport carrier render the 
Rabs obvious targets during investigations aimed at defining a specific cargo's transport 
pathway(s). 
1.6. Selected methods to study Rab function 
Study of Rab GTPase involvement in vesicular transport is facilitated by the 
availability of several well-established experimental approaches. These include, but are 
not limited to, expression of DN Rab mutants, expression of fluorescent protein-tagged 
Rab constructs, and overexpression of Rab GAPs and GEFs, including bacterial effectors 
that have evolved to target specific Rabs. 
Introducing any one of several mutations into the Rab protein sequence can 
abrogate the Rab functional cycle. This is most commonly done using mutations that 
interfere with the guanine nucleotide exchange and hydrolysis cycle. Shown in Table 1.1 
below are these three major mutant classes, along with references to publications where 
the noted Rab1 mutations have been characterized in greater detail. The amino acids 
mutated are indicated on a crystal structure of Rab1b in Figure 1.6. The mutations mirror 





Figure 1.6. Rab1b crystal structure. Crystal structure of Rab1b at 1.7 Å resolution 
(Protein Data Bank structure 3NKV). Structure initially published in (Muller et al., 2010). 
Shown is the Rab1b backbone (in gray), together with several features highlighted. The 
GTP analog GppNHp (guanosine 5’-β,γ-imidotriphosphate, is in cyan. The guanine ring 
is at the right, and the alpha, beta and gamma phosphates are indicated at the left. The 
Gln67 residue involved in GTP hydrolysis is in red. The Ser22 residue involved in Mg2+ 
coordination is in green, while the Mg2+ ion is in orange. The Asn121 residue involved in 
guanine ring binding is in blue. Original structure was processed using PyMOL. 
 
A conserved asparagine residue in the guanine ring binding site of the Rab 
proteins (Figure 1.6, equivalent to H-RasN116) may be mutated and replaced with the 
bulkier and hydrophobic isoleucine residue. This change prevents the resulting mutant 
protein from stably binding GDP or GTP (Pind et al., 1994; Walter et al., 1986). Indeed, 
it is thought that this mutant may exchange GDP and GTP too rapidly and in an 
unregulated manner (Pind et al., 1994; Walter et al., 1986). This mutation may induce 
unregulated recruitment of GTPase effectors, possibly at ectopic locations, thus affecting 
their dynamics and function. Expression of this nucleotide-binding Rab1 mutant affected 
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the dynamics of Rab1 effector (p115, GBF1) association with membranes (Alvarez et al., 
2003; Brandon et al., 2006; Garcia-Mata et al., 2003; Monetta et al., 2007).  
A conserved serine or threonine residue of the nucleotide binding pocket is 
located close to the β- and γ-phosphates of GTP (Figure 1.6) and is involved in Mg2+ 
coordination in H-Ras (Farnsworth and Feig, 1991). Replacement of the equivalent Rab 
residue, for example Rab1aS25, with an asparagine residue does not allow GTP binding, 
but permits GDP binding (Nuoffer et al., 1994). As such, this GTP-binding mutant is 
locked in the inactive GDP-bound form. Rab1aS25N (or Rab1bS22N) has been proposed to 
compete with the WT Rab1a or Rab1b for binding of either a Rab1 GEF or a Rab1 GDI 
(Nuoffer et al., 1994), in a model mirroring that proposed to explain H-RasS17N activity 
(Farnsworth and Feig, 1991). This mutant may be interchangeably referred to either as a 
GTP-binding or as a GDP-restricted mutant; throughout this work, I will refer to it as a 
GDP-restricted mutant. Both it, and the above-mentioned nucleotide-binding mutant, are 
widely referred to in the literature as DN mutants.  
A third, well conserved glutamine residue also close to the γ-phosphate of GTP 
(Figure 1.6) performs intrinsic GTPase activity of the Rabs, and at times also the 
stimulated GTPase activity (Gavriljuk et al., 2012; Mihai Gazdag et al., 2013; Mishra et 
al., 2013; Yu et al., 2013). Its mutation to a leucine (or another hydrophobic residue) 
abrogates intrinsic Rab GTPase activity, resulting in a mutant that becomes locked in the 
GTP-bound, active form (Mishra et al., 2013). This GTP-restricted/GTPase mutant is at 
times referred to as dominant active mutant. Since the expression of these mutants may 
result in abrogation of the normal Rab function, albeit at a different stage within the GTP 
cycle, I will refer to the GTPase mutants as DN mutants as well.  
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Activity Rab1(a or b) 
mutation 
Reference 








Nucleotide-free Inactive Rab1aN124I 
Rab1bN121I 
(Pind et al., 
1994) 
GTP-binding GDP-restricted Inactive Rab1aS25N 
Rab1bS22N 









The general effectiveness of these mutants in inhibiting Rab function in transport 
is in part due to their ability to interfere with the normal dynamics of the Rab functional 
GTP/GDP exchange and hydrolysis cycle. The Rab regulators GEF and GAP also 
interfere with the dynamics of this cycle by skewing the Rab-GDP/Rab-GTP ratio 
towards the active form (the Rab GEFs) or the inactive form (the Rab GAPs). 
Overexpression of either has been successfully used to modulate and investigate Rab 
function (Fuchs et al., 2007; Udayar et al., 2013; Yoshimura et al., 2010). Proteins with 
GEF or GAP activity have also evolved in some bacterial pathogens that replicate 
intracellularly, in vesicles derived from the cellular organelles (Hicks and Galan, 2013). 
Legionella pneumophila is an extensively studied example, and has been shown to inject 
into the host cell cytoplasm several proteins that modulate Rab1 function (Hardiman et 
al., 2012). Other examples of bacteria that have evolved capabilities to control 
intracellular vesicular transport include Coxiella burnetii (Campoy et al., 2011; Hardiman 
et al., 2012), Salmonella typhi (Spano and Galan, 2012), Shigella flexneri and 
Escherichia coli (Dong et al., 2012). That the activities of these bacterial effectors have 
been fine-tuned over many cycles of evolution informs both their specificity and their 
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efficacy, and recommends them for use in experiments aimed at modulating Rab 
function. 
Lastly, Rab proteins have generally been proven to tolerate fluorescent protein-
tagging very well. Many fluorescent protein-Rab fusions have been shown to retain the 
localization patterns of the parental Rab, as well as its function (Chen and Wandinger-
Ness, 2001; Feng et al., 2001; Moyer et al., 2001b; Peranen and Furuhjelm, 2001). This is 
however not true across the board, since examples exist where attachment of even a small 
epitope tag has resulted in a non-functional Rab chimera (Tisdale and Balch, 1996). 
However, the general usefulness of such fusions remains uncontested, since the many 
functional fusions allow detailed spatial and temporal analyses of Rab involvement in 
traffic (Huang et al., 2010; Rzomp et al., 2003; Sonnichsen et al., 2000), as well as a 
means for monitoring expression levels. 
1.7. A case study in complex transport regulation: the hepatocyte 
This work specifically focuses on analyzing the secretion pathways utilized by 
hepatic lipoproteins and HCV, a hepatotropic virus. In order to properly contextualize 
any experimental findings regarding the regulation of transport of these cargoes, one 
must consider the function and architecture of the hepatocyte. I therefore introduce here a 
few notions regarding liver function, architecture and how the hepatocyte functional and 
structural polarization relate to these. 
1.8. Liver function and architecture 
The liver carries out a number of complex and often essential functions in the 
animal body (Strain and Neuberger, 2002; Treyer and Musch, 2013). Among these are 
energy storage, excretion, drug processing, and the synthesis of numerous serum 
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components, such as albumin, alpha-1-antitrypsin, complement, coagulation factors, and 
lipoproteins. The convergence of these functions in one organ is informed by the liver's 
complex architecture (Figure 1.7). Blood enters the organ through the portal vein, which 
collects nutrient-rich venous blood from most of the intestine, and through the hepatic 
artery, which brings in oxygenated blood from the heart. The blood intake supply divides 
and bathes the liver cells in a system of sinusoids, then reunites to exit the organ through 
the hepatic vein, and thus re-enters into the general circulation. As such, the liver serves 
as one of several filters of the circulatory system: it takes up components from the 
afferent blood supply and releases its own products into efferent blood. The other major 
liver function, excretion, is achieved through the bile canaliculi system, which converges 
into the bile ducts and transports the bile (which includes digestive aids and waste 
products) to the proximal intestine (Boyer, 2013). The function of the organ is predicated 
on the separation of the blood-related functions of the liver from its excretory function, 
resulting in an architecture of inter-weaved biliary duct tree branches and afferent and 





Figure 1.7. Liver architecture. Schematic of liver structural organization. Shown at the 
top in blue and red are the blood vessels. Blood flows from branches of the portal vein 
and the hepatic artery, into the hepatic sinusoids, and then into the central veins, which 
return the blood into general circulation. Shown in green is the bile duct system, which 
collects bile from the bile canaliculi. The hepatocytes (in purple) separate the biliary 
(apical) compartment and the sinusoidal (basolateral) compartment. Other liver-resident 
cell types (endothelial, Kupffer and stellate cells) are indicated, but discussion of their 
function is beyond the scope of this work. Figure adapted from (Bhatia et al., 2014). 
Reprinted with permission from AAAS. 
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1.9. Hepatocyte organization 
The separation between the blood-related and bile-related functions of the liver 
occurs at the level of the hepatocyte (Figure 1.8), which is the functional unit of this 
organ. Hepatocytes are polarized cells with apical (biliary) and basolateral (sinusoid) 
surfaces (Gissen and Arias, 2015; Musch, 2014; Treyer and Musch, 2013). While this 
structural and functional division of the hepatocyte is related to the organization of the 
cells of simpler, columnar epithelia, such as those of the lung or of the intestine 
(Marchiando et al., 2010; Rodriguez-Boulan and Macara, 2014), the hepatic cells display 
a more complex architecture. Thus, at contact sites between hepatocytes, rows of tight 
junctions delineate narrow apical intercellular lumens, called bile canaliculi (Gissen and 
Arias, 2015; Musch, 2014; Treyer and Musch, 2013). These canals converge to form the 
bile duct system and transport the bile, which contains the excretory and digestive 
products of the hepatocytes (Boyer, 2013). Several canaliculi may flank a given 
hepatocyte, while the rest of the hepatocyte surface, outside the tight junctions which 
delineate the bile canaliculi, forms basolateral surfaces oriented towards other 
hepatocytes or towards the sinusoidal space (Gissen and Arias, 2015; Musch, 2014; 
Ogawa et al., 1979; Treyer and Musch, 2013). Given the cell's essential role in so many 
aspects of animal life, it is important to understand how hepatocytes regulate secretion in 











Figure 1.8. Hepatocyte polarity. (A) Three-dimensional schematic of spatial 
relationships between hepatocytes, bile canaliculi, and hepatic sinusoids. The narrow 
apical (biliary) domains, in green, are sequestered between adjacent hepatocytes and form 
a complex network of canaliculi, while the basolateral domains encompass the remaining 
hepatocyte surfaces. Figure from (Gissen and Arias, 2015), DOI 
10.1016/j.jhep.2015.06.015, reproduced under the Creative Commons Attribution 
License (CC BY, http://creativecommons.org/licenses/by/4.0/, accessed on February 10, 
2016). (B) Simplified depiction of a sheet of hepatocytes surrounded by apical 
canalicular domains (in green) sequestered between adjacent cells. Top and bottom 
surfaces are formed by basolateral domains. (C) Schematic section, perpendicular on the 
apical lumen, through a hepatocyte-like polarity system. The apical lumen (red) is found 
between adjacent cells, while basolateral domains (top and bottom) sandwich the cells. 
(B) and (C) images adapted from (Treyer and Musch, 2013), with the permission from 








1.10. Hepatic secretory cargoes of interest 
My interest has long been in studying biological phenomena related to disease. In 
the context of hepatic secretion, the lipoproteins and HCV have stood out as ideal study 
candidates. I have also included albumin in this analysis, since its physico-chemical 
properties diverge from those of the lipoproteins and of HCV. This work therefore 
focuses on identifying the transport pathways involved in the secretion of a model 
monomeric protein, albumin, and of the larger and more complex macromolecular 
assemblies that are the lipoproteins and the HCV particles. I now describe some relevant 
known features of these cargoes.  
1.11. Albumin 
I selected serum albumin as a model for the secretion of small, monomeric 
proteinaceous cargo. Albumin is the most abundant protein in plasma, where it helps 
maintain homeostasis of the circulatory system while also binding to and transporting 
various small molecules throughout the body (Ha and Bhagavan, 2013; Quinlan et al., 
2005; Rothschild et al., 1988; Yamasaki et al., 2013). The albumin mRNA is translated 
by ER-associated ribosomes. The amino-terminal signal peptide directs translocation of 
the nascent protein into the lumen of the ER, resulting in a form termed proalbumin 
(Judah et al., 1973; Quinn et al., 1975), which is then transported by the vesicular 
secretory system. During transport, proalbumin is further proteolytically processed into 
the mature form, albumin (Bathurst et al., 1987; Brennan and Peach, 1988). No 
glycosylation sites are predicted in the primary amino-acid sequence of albumin; it is 




1.12. Hepatic lipoproteins 
Definition, general features and metabolic functions. Lipoproteins are large, 
complex, macromolecular assemblies that employ the lipid-binding and amphipathic 
properties of their protein components, the apolipoproteins, to solubilize and transport 
otherwise poorly soluble lipids, such as triglycerides, sphingolipids, cholesterol and 
cholesterol esters (Mahley et al., 1984). The major lipoproteins produced in the body are 
the chylomicrons, the very low-density lipoproteins (VLDL) and the high-density 
lipoproteins (HDL). Chylomicrons are produced by enterocytes and transport dietary 
lipids from the intestine to the rest of the body. They are the largest of the lipoproteins 
produced in the body, with diameters over 100 nm (Mahley et al., 1984). As they become 
depleted of their lipid cargo, they become denser and are termed (chylomicron) remnants. 
The VLDL fulfill similar lipid transport functions as the chylomicrons, but are produced 
by hepatocytes. They have densities below 1.006 g/mL and are the largest among the 
non-chylomicron lipoproteins, with diameters in the range of 30 to 90 nm (Mahley et al., 
1984). As VLDL deliver their lipid cargo to cells throughout the body, they too become 
gradually denser and are therefore termed intermediate-density lipoproteins (IDL, with 
densities in the range of 1.006 to 1.019 g/mL), or low-density lipoproteins (LDL, with 
densities between 1.019 and 1.063 g/mL). Lipid loss by VLDL is accompanied by a 
reduction in particle size, down to LDL diameters of about 20 nm (Mahley et al., 1984). 
Lastly, HDL are the smallest (8-12 nm in diameter) and densest (densities in the range of 
1.063 g/mL to 1.21 g/mL) of the plasma lipoproteins. HDL particles fulfill a major role in 
a process termed reverse cholesterol transport, which consists of the shuttling of 
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cholesterol from cells throughout the body to the liver, where cholesterol processing and 
excretion occurs (Zannis et al., 2015).  
The lipid transport function of the lipoproteins is facilitated by their structural 
organization. At the core of the particle are neutral lipids such as triglycerides and 
cholesterol esters. This hydrophobic core is similar to that of intracellular lipid droplets 
(Welte, 2015; Wilfling et al., 2014), in which the hydrophobic fats are also segregated 
from the aqueous cellular environment with which the neutral lipids are immiscible. The 
lipid core is surrounded by a polar lipid monolayer, organized similarly to a single leaflet 
of a membrane that has been wrapped around the neutral lipid center. Apolipoproteins 
can also on the surface of lipoprotein particles (Mahley et al., 1984). These proteinaceous 
components utilize lipid-binding domains, most commonly amphipathic helices (Segrest 
et al., 1992), to associate with the lipid particle. Apolipoproteins are involved both in 
lipoprotein formation and in their functional processing throughout the body.  
Apolipoproteins and their disease associations. Serum lipoproteins contain 
several proteins components, termed apolipoproteins. ApoB100 is expressed in 
hepatocytes and is essential for VLDL formation, serving as its defining structural 
component. It is a very large protein of over 4500 amino acids and contains hydrophobic 
β-sheet domains involved in lipid binding (Chen et al., 1986; Cladaras et al., 1986; Law 
et al., 1986; Yang et al., 1986). Apolipoprotein B48 (ApoB48) synthesis results from 
citidine deamination of the ApoB100 mRNA by Apobec-1, which creates a premature 
STOP codon in the sequence (Teng et al., 1993; Tennyson et al., 1989). ApoB48 is 
produced in enterocytes in humans, and in both enterocytes and hepatocytes in rodents 
(Davidson and Shelness, 2000). Enterocyte-made ApoB48 is involved in chylomicron 
 
28 
biogenesis, while hepatic ApoB100 drives VLDL particle formation (Mansbach and 
Siddiqi, 2010; Olofsson and Boren, 2005). Other apolipoproteins include those belonging 
to the A, C and E classes (Kohan, 2015; Kohan et al., 2015; Mahley, 1988; Mahley et al., 
1984; Maiga et al., 2014; Norata et al., 2015; Phillips, 2014; Sacks, 2015; Sundaram and 
Yao, 2012; Zannis et al., 2015). Some of these may undergo cycles of association with 
and dissociation from the surface of the large ApoB-containing lipoproteins: the 
chylomicrons, the VLDL and the LDL, and are therefore referred to as exchangeable 
apolipoproteins. They may also participate in the formation of HDL particles (Zannis et 
al., 2015). They have been shown to regulate, at least in part, ApoB-containing 
lipoprotein biogenesis, receptor binding of the lipoproteins, and lipolysis (Kohan, 2015; 
Kohan et al., 2015; Mahley, 1988; Mahley et al., 1984; Maiga et al., 2014; Norata et al., 
2015; Phillips, 2014; Sacks, 2015; Sundaram and Yao, 2012; Zannis et al., 2015).  
Among the most extensively investigated apolipoproteins, and components of 
both VLDL and HCV particles, are ApoB100 and ApoE. Since the work I present here 
deals exclusively with these two lipoprotein components, I restrict myself to providing 
detailed background information regarding only these two. The investigation principles 
that I present throughout this work are nonetheless transferable to the analysis of the 
secretion of other exchangeable apolipoproteins. 
In humans, VLDL obligatorily contains ApoB100, a component that likely has a 
structural function. VLDL also contains ApoE and other exchangeable apolipoprotein 
components (Utermann, 1975). Proper regulation of VLDL formation (assembly), 
secretion, and metabolism are tightly controlled; defects in these processes have been 
associated with numerous metabolic disease syndromes. Such conditions include 
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abetalipoproteinemia (Berriot-Varoqueaux et al., 2000; Wetterau et al., 1992), which 
results from a defect in the lipidation of ApoB100, and hypobetalipoproteinemia 
(Schonfeld, 2003; Schonfeld et al., 2005; Young et al., 1989), which results from 
missense mutations in the ApoB100 sequence. These and other types of primary 
lipoproteinemias may cause atherosclerosis and coronary artery disease (Lusis et al., 
2004). 
ApoE, the other apolipoprotein I investigate here, occurs in humans as several 
major isoforms, termed ApoE2, ApoE3 and ApoE4, respectively (Utermann et al., 1977; 
Weisgraber et al., 1981). While ApoE3 is the most common isoform and is considered 
"neutral" with respect to disease association, ApoE2 is associated with type III 
hyperlipoproteinemia and ApoE4 is associated with type V hyperlipoproteinemia 
(Ghiselli et al., 1982a; Ghiselli et al., 1982b; Utermann et al., 1977). Furthermore, the 
minor isoform ApoE3-Leiden is a dominant predictor of type III hyperlipoproteinemia 
(Havekes et al., 1986). Type III disease association is correlated with low clearance rate 
of ApoE-containing lipoproteins due to defects in LDL receptor (LDLR) binding (Gregg 
et al., 1981); indeed, ApoE contains a well defined LDLR-binding domain (Wilson et al., 
1991).  The absence of ApoE expression, or expression of LDLR-binding defective ApoE 
isoforms, results in accumulation of VLDL, triglycerides, and cholesterol in plasma 
(Mahley et al., 1999; Plump et al., 1992; Zhang et al., 1992), and increases the likelihood 
of developing atherosclerosis and coronary artery disease. In these conditions, large 
amounts of plasma LDL, including its oxidized forms, are deposited in arterial walls. The 
arterial wall thus accumulates plaque, loses elasticity, and the arterial lumen narrows, 
eventually leading to cardiovascular morbidity (Breslow, 2000, 2001). 
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Besides its role in cholesterol transport and metabolism, ApoE has many other 
functions. Some of these functions are related to its expression by a wide variety of cells 
in many tissues. For example, macrophages express ApoE and may use it to deliver 
necessary lipids at sites of nerve regeneration (Ignatius et al., 1986; Snipes et al., 1986). 
Similarly, astrocytes express ApoE (Murakami et al., 1988; Pitas et al., 1987), which may 
be involved in sustaining proper neuronal physiology. Indeed, ApoE has been implicated 
in neurodegenerative disease conditions (Corder et al., 1994; Corder et al., 1993; 
Greenberg et al., 1995; Martinez et al., 2005; Vance and Hayashi, 2010), with ApoE4 
being associated with higher risk of developing late onset Alzheimer's disease, while 
ApoE2 protecting against the same condition (Corder et al., 1994; Corder et al., 1993). 
ApoE has also been shown to modulate cell activation and migration (Ali et al., 2005; 
Kelly et al., 1994; Kothapalli et al., 2004; van den Elzen et al., 2005), and just recently, 
increased ApoE expression by melanoma cells was shown to increase aggressive tumor 
behavior and metastatic potential (Pencheva et al., 2012). ApoE-dependent modulation of 
cell activation may be achieved through direct transcriptional control (Theendakara et al., 
2016) or through cell-surface receptor-mediated signaling (Pencheva et al., 2012).   
1.13. Lipoprotein assembly and secretion 
VLDL assembly and secretion. VLDL assembly commences with the translation 
of the ApoB100 mRNA and the concurrent translocation of the resulting protein (Chen et 
al., 1986; Cladaras et al., 1986; Law et al., 1986; Yang et al., 1986) into the lumen of the 
ER. Efficient translocation requires concomitant loading of lipids onto the nascent 
polypeptide; this lipidation process is catalyzed by the microsomal triglyceride transport 
protein (Boren et al., 1992; Wetterau et al., 1992). From the ER, ApoB100-containing 
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VLDL transits the Golgi system (Ehrenreich et al., 1973) en route to the basolateral 
plasma membrane, where it is secreted. The complex processes of assembly and 
maturation of the VLDL particle that occur during its journey through the secretory 
pathway may include further lipidation, association with exchangeable apolipoproteins, 
including ApoE, and various post-translational modifications (Olofsson and Boren, 2005; 
Sundaram and Yao, 2010, 2012; Tiwari and Siddiqi, 2012). VLDL progression through 
the secretory pathway is also controlled by at least two degradative processes (Ginsberg 
and Fisher, 2009; Rutledge et al., 2010). When lipid sources are insufficient to achieve 
proper initial lipidation or if the microsomal triglyceride transport protein activity is 
reduced or abolished, ApoB100 translocation stalls. The nascent polypeptide then 
becomes exposed to the cytoplasm and is ubiquitinylated and targeted for proteasome-
mediated ER-associated degradation (Benoist and Grand-Perret, 1997; Fisher et al., 2011; 
Fisher et al., 1997; Zhou et al., 1998). When pre-VLDL formation is completed, but the 
nascent lipoprotein becomes exposed to poly-unsaturated fatty acids or is oxidized, then 
the particle is targeted for degradation by the autophagosome (Pan et al., 2008a). Only 
VLDL molecules that survive this strict quality control process are secreted. 
ApoE secretion in the presence or absence of VLDL. Secreted VLDL particles 
also contain ApoE, a 299-amino-acid, O-glycosylated exchangeable apolipoprotein (Rall 
et al., 1982; Utermann, 1975; Wernette-Hammond et al., 1989; Zanni et al., 1989). ApoE 
can be secreted on its own from many cell types, including hepatocytes (Dashti et al., 
1980), macrophages (Basu et al., 1981), and astrocytes (Pitas et al., 1987), and can form 
HDL particles involved in cholesterol transport. Indeed, a major function of lipoprotein-
associated ApoE is to tightly bind LDLR family receptors and to promote clearance of 
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cholesterol-rich lipoprotein particles from circulation (Mahley, 1988; Plump et al., 1992; 
Zhang et al., 1992). ApoE isoforms or mutants with low LDLR-binding affinity are 
associated with type III hyperlipoproteinemia and coronary artery disease (Breslow, 
2000; Mahley et al., 1999). ApoE is synthesized on ER-associated ribosomes, is 
translocated into the lumen of the ER, and is transported through the Golgi to the cell 
surface in secretory vesicles that travel along microtubules (Kockx et al., 2007). A 
fraction of newly-synthesized ApoE is degraded intracellularly in a post-ER compartment 
(Deng et al., 1995; Ye et al., 1993). Once secreted, ApoE may associate with the cell 
surface (Lilly-Stauderman et al., 1993), and may become re-internalized and recycled 
(Heeren et al., 2003; Laatsch et al., 2012). Lastly, beyond simply being associated with 
VLDL particles, ApoE was also shown to promote their secretion (Kuipers et al., 1997; 
Mensenkamp et al., 2001). Various lipoprotein components thus display a complex 
functional interplay during the assembly and egress of VLDL, with major implications 
for human disease. 
1.14. Hepatitis C virus 
Another known cargo of the secretory pathway in hepatocytes is HCV. Infection 
with HCV may be the cause of several very serious disease conditions, and it was, until 
recently, very difficult to cure (Thomas, 2013). Furthermore, HCV is peculiar in that it 
very closely associates with host lipoproteins, including ApoE and ApoB100 
(Lindenbach, 2013; Lindenbach and Rice, 2013). HCV has thus become an obvious 
target in our investigation into how hepatocytes regulate cargo secretion. I provide here a 
summary of relevant aspects of the HCV life cycle that I hope will inform the 
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understanding of the investigations I have commenced into the regulation of HCV 
particle secretion. 
1.15. Hepatitis C  
Hepatitis - the inflammation of the liver - can have widely varied etiologies, with 
viral infections being a major cause (Protzer et al., 2012). Several hepatotropic viruses 
have been identified and shown to be etiologic agents of viral hepatitis. Hepatitis A virus 
(Matheny and Kingery, 2012) and hepatitis E virus (Khuroo and Khuroo, 2016; Perez-
Gracia et al., 2014; Sayed et al., 2015) generally cause self-limiting acute hepatitis, while 
hepatitis B virus, HCV and the hepatitis B virus-dependent hepatitis delta virus, in turn, 
often establish chronic infections that may remain active over several decades 
(MacLachlan and Cowie, 2015; MacLachlan et al., 2015; Rizzetto, 2015; Thomas, 2013). 
The usual progression of HCV infection is depicted in Figure 1.9. While some patients 
clear HCV infections spontaneously, the virus often causes chronic infection, which may 
further progress through the following stages: liver fibrosis, liver cirrhosis, and 
hepatocellular carcinoma (Hoofnagle, 1997; Thomas, 2000). Liver failure secondary to 
advanced chronic viral hepatitis remains a major indication for liver transplantation 
(Neuberger, 2016). Given the severity of HCV-dependent pathologies, HCV infection 
remains a major health burden worldwide, with over 185 million people (or almost 3% of 
the world population) thought to be chronically infected with the virus (Mohd Hanafiah 
et al., 2013). This problem is exacerbated by the failure to develop a protective anti-HCV 
vaccine (Honegger et al., 2014; Walker and Grakoui, 2015), and by the high costs of 
effective and well tolerated treatments that have only recently become available (Ayoub 





Figure 1.9. HCV disease progression. Symptoms associated with the successive stages 
of HCV infection. ALT, alanine aminotransferase plasma levels; HCC, hepatocellular 
carcinoma. Figure adapted by permission from Macmillan Publishers Ltd: Nature Med. 
(Thomas, 2013) ©2013. 
 
1.16. The HCV virion: structure and composition 
HCV is an enveloped virus and has a single-stranded, positive-sense RNA 
genome; it belongs to the genus Hepacivirus within the Flaviviridae family 
(Bartenschlager et al., 2011; Moradpour et al., 2007; Scheel and Rice, 2013). Notable 
related viruses include the recently identified hepaciviruses (Kapoor et al., 2011; Kapoor 
et al., 2013; Pybus and Theze, 2015), as well as the more distantly related flaviviruses, 
pestiviruses, and pegiviruses (Knipe and Howley, 2013). 
The HCV particle contains the positive polarity RNA genome, virus-encoded 
proteins, namely the capsid protein Core and the glycoproteins E1 and E2, and host cell 
derived proteins and lipid membranes (Bartenschlager et al., 2011; Lindenbach, 2013; 
Lindenbach and Rice, 2013; Scheel and Rice, 2013). Of the host-cell derived viral 
particle protein components, most notable are ApoE and ApoB100. The virus association 
with hepatocyte-derived lipoproteins confers it light, lipoprotein-like densities, 
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particularly in vivo (Andre et al., 2002; Lindenbach, 2013; Lindenbach et al., 2006; 
Lindenbach and Rice, 2013; Nielsen et al., 2006). The HCV-lipoprotein chimeric entity is 
called a lipoviroparticle (Andre et al., 2002).  
Unlike the more highly and uniformly organized flavivirus particles (Kuhn et al., 
2002; Mukhopadhyay et al., 2003; Mukhopadhyay et al., 2005; Zhang et al., 2003a; 
Zhang et al., 2003b), HCV presents a more amorphous structure, not easily resolved by 
conventional structural techniques (Catanese et al., 2013). This may be due in part to 
lipoprotein association, the nature of which has not been unambiguously described as of 
yet (Lindenbach, 2013; Lindenbach and Rice, 2013). Highly purified infectious particles 
are about 70 nm (40-100 nm range) in diameter (Catanese et al., 2013), although earlier 
reports have described a significantly more heterogeneous (both in size and shape) 
particle population found in more crude viral preparations (Gastaminza et al., 2010; Merz 
et al., 2011; Yu et al., 2007).  
1.17. HCV life cycle 
The HCV life cycle follows the classical paradigm of virus propagation, as 
depicted in Figure 1.10. At a cellular level, the infectious HCV particle enters a host cell, 
primarily the human hepatocyte, where the virus replicates its genome, and assembles 
and releases new infectious particles that further propagate the cycle (Scheel and Rice, 
2013). To survive inside the host, the virus has developed mechanisms to counteract the 
host's antiviral defenses, both innate and adaptive (Dustin et al., 2014; Dustin and Rice, 
2007; Horner and Gale, 2013). Lastly, to spread within the human population, the virus 
must be able to infect new hosts. A major driving force for the ongoing epidemic was 
transmission through non-sterile medical procedures and the lack of screening blood for 
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transfusion, organs for transplant, and similar other human donor-derived biomedical 
products (Thomas, 2000, 2013). More recently, injection drug habits in conjunction with 
use of non-sterile paraphernalia has constituted a major cause of new transmissions 
(Thomas, 2013), and reports have emerged linking HCV transmission with unsafe sexual 
practices in at-risk populations (Danta et al., 2007; Schmidt et al., 2011; Thomas, 2013; 
Urbanus et al., 2009; van de Laar et al., 2009; van de Laar et al., 2010; van de Laar et al., 
2007). The mode of HCV transmission prior to the modern medicine-facilitated and 











Figure 1.10. The HCV life cycle. The cycle of cellular infection by HCV: (1) The 
lipoprotein-associated virus binds a series of co-receptors, then undergoes receptor-
mediated endocytosis (2), to mediate entry into the target cells. Acid mediated fusion of 
the viral and host cell membrane within an endosomal compartment leads to release of 
the viral capsid into the cytosol and uncoating of the genome (3). The genome is 
translated on ER-associated ribosomes (4), then undergoes replication (5) via a (-) strand 
RNA intermediate. Virion morphogenesis (6) occurs in an ER-related compartment. The 
newly formed viruses mature (7) as they are secreted by the host cell vesicular transport 
system (8), to be released into the extracellular space. LDLR, LDL receptor; GAG, 
glucosaminoglycans; SCARB1, scavenger receptor B1, CLDN1, claudin1; OCLN, 
occludin. Figure adapted by permission from (Ploss and Rice, 2009), ©2009 European 






HCV Entry. The virus enters the target hepatocytes via receptor-mediated 
endocytosis, followed by acid-mediated fusion of viral and cellular membranes 
(Lindenbach and Rice, 2013; Scheel and Rice, 2013). Binding to hepatocytes is mediated 
by several cell-surface co-receptors and may involve a cascade of binding and transport 
events before the virus is internalized (Lindenbach and Rice, 2013; Scheel and Rice, 
2013). Ligands on the surface of the viral particles include the E2 envelope glycoprotein 
and potentially the associated host lipoproteins, while the cellular receptors include: 
glucosaminoglycans, LDLR (Andre et al., 2002; Monazahian et al., 1999), the tetraspanin 
membrane proteins CD81 (Pileri et al., 1998), and scavenger receptor B1 (Bartosch et al., 
2003), the tight junction proteins claudin-1 (Evans et al., 2007) and occludin (Ploss et al., 
2009), the epidermal growth factor receptor and the ephrin type-A receptor 2 (Lupberger 
et al., 2011), and the Niemann-Pick C1-like 1 cholesterol absorption receptor (Sainz et 
al., 2012). Following receptor-mediated endocytosis, acidification of virus-containing 
endosomal compartments is thought to mediate conformational changes within the viral 
glycoproteins, which mediate virus-host membrane fusion (Takikawa et al., 2000), 
leading to release of the RNA genome into the target cell’s cytoplasm, thus initiating 
HCV infection. 
Translation and polyprotein processing. The HCV protein is encoded by the 
positive sense viral genome, in which the protein-coding region is flanked by highly 
structured 5'- and 3'- end untranslated regions, or UTRs (Figure 1.11A). The HCV 
genome is translated on ER-associated ribosomes (Hijikata et al., 1991), which recognize 
the 5'-UTR-contained HCV internal ribosome entry site (IRES) structure (Tsukiyama-
Kohara et al., 1992). Translation of the viral RNA results in the synthesis of a single 
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precursor polyprotein (Figure 1.11B). This HCV polyprotein contains, in order of 
translation, the following viral proteins (Figure 1.11B-C): the capsid protein Core, the 
envelope glycoproteins E1 and E2, the viroporin p7, and the nonstructural proteins (NS) 
2, 3, 4A, 4B, 5A and 5B (Grakoui et al., 1993c; Lin et al., 1994). These 10 mature HCV 
proteins are released from the precursor polyprotein by four proteases (Figure 1.11B), 
two expressed by the host cell and two by the virus. The host cell proteases involved in 
HCV polyprotein processing are the signal peptidase, which cleaves the viral polyprotein 
at the junctions between Core and E1, between E1 and E2, between E2 and p7, and 
between p7 and NS2 (Hijikata et al., 1991; Lin et al., 1994; Mizushima et al., 1994a; 
Mizushima et al., 1994b), and the signal peptide peptidase, which removes the E1 signal 
peptide from the carboxyl terminus of the Core protein (McLauchlan et al., 2002). The 
virus encodes the remaining protease activities required for the processing of its 
polyprotein, namely a cysteine protease formed by NS2 and the amino terminus of NS3 
(Grakoui et al., 1993b; Hijikata et al., 1993a; Lorenz et al., 2006), and a serine protease 
formed by NS3 and its cofactor NS4A (Bartenschlager et al., 1995; Hijikata et al., 1993a; 
Kim et al., 1996; Lin et al., 1995; Love et al., 1996; Tomei et al., 1993). The NS2-3 
cysteine protease cleaves the NS2/3 junction (Grakoui et al., 1993b; Hijikata et al., 
1993a), while the NS3-4A serine protease cleaves the NS3/4A, 4A/4B, 4B/5A and 5A/5B 
junctions (Bartenschlager et al., 1993; Grakoui et al., 1993a; Hijikata et al., 1993a; 
Hijikata et al., 1993b; Tomei et al., 1993). The resulting mature HCV proteins are then 
involved in viral genome replication, virion assembly, and release of assembled progeny 






Figure 1.11. The HCV genome and the encoded proteins. (A) Depiction of the HCV 
RNA genome. The open reading frame is flanked by 5’ and 3’ UTRs. The 5’UTR 
contains an IRES. (B) IRES-mediated translation results in the synthesis of a large 
polyprotein, which undergoes proteolytic processing. Arrows indicate the sites of 
cleavage by the two viral proteases. Filled diamonds indicate the sites of cleavage by the 
host signal peptidase, while the empty diamond indicates the site of cleavage by the host 
signal peptide peptidase. (C) The 10 major HCV proteins are shown. Known selected 
functions are listed under each protein. Figure adapted by permission from Macmillan 
Publishers Ltd: Nature Rev. Microbiol. (Moradpour et al., 2007) ©2007. 
 
The replication organelle and genome replication. A characteristic of many 
cytoplasm-replicating RNA viruses is that they reorganize host cell membranes to create 
new functional entities dedicated to the replication of the viral genome (Romero-Brey 
and Bartenschlager, 2014). This adaptation may serve several purposes. For example, by 
concentrating the enzymatic activities in a small volume or on a small surface, the 
efficiency of the genome replication process would also be increased. Since many of 
these viruses are enveloped viruses, the final stages of particle assembly, namely the 
envelopment of the capsid and the concurrent loading of the envelope glycoproteins, 
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would also benefit from the spatial coupling of genome replication with the membrane-
dependent particle envelopment step on an organelle of the vesicular secretory pathway. 
Lastly, by segregating, to some extent, the viral replication process from the rest of the 
cytoplasm, the viruses may have achieved a spatial separation of the genome and its 
replication intermediates - both potent activators of cytoplasmic innate immune signaling 
pathways - and the cytosolic innate immune sensor molecules, such as those belonging to 
the RIG-I family of cytoplasmic innate immune receptors. The creation of a specialized 
membranous organelle to perform viral genome replication would thus shield the virus 
and the virus-infected cell from the immediate and long-term anti-viral effects of an 
activated innate immune system.  
HCV, like other flaviviruses, replicates its genome on an ER-derived membranous 
formation, which has been described as a network of small, interconnected vesicular 
structures, also called a membranous web (Egger et al., 2002; Romero-Brey and 
Bartenschlager, 2014; Romero-Brey et al., 2012). The replication activities occurring 
within it require the non-structural proteins NS3 through NS5B, the 5' and 3' viral 
genome UTRs, as well as some RNA secondary structure-forming sequences present 
within the HCV ORF (Lohmann, 2013). The NS3-5B proteins are the viral proteins both 
necessary and sufficient for genome replication (Egger et al., 2002; Lohmann et al., 1999; 
Moradpour et al., 2004; Moradpour et al., 2003). The NS3/4A dimer cleaves the 
polyprotein and releases the other individual NS proteins such that they can perform their 
respective functions (Kim et al., 1996; Love et al., 1996). NS3 also contains a helicase 
domain, likely involved in RNA unwinding (Raney et al., 2010). NS4A targets NS3 to 
membranes due to its amphipathic helix (Wolk et al., 2000). NS4B has a major function 
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in organizing host membranes into the replication complex (Egger et al., 2002; Romero-
Brey et al., 2012). NS5A has RNA binding properties and is essential for both replication 
and assembly of the viral particle, but does not possess a known enzymatic activity 
(Appel et al., 2008; Love et al., 2009; Tellinghuisen et al., 2008; Tellinghuisen et al., 
2004; Tellinghuisen et al., 2005). Lastly, NS5B is the RNA-dependent RNA polymerase 
that replicates the viral genome (Behrens et al., 1996; Lesburg et al., 1999). This process 
involves the synthesis of a complementary, negative sense copy of the viral genome, 
which then serves as a template for the production of more copies of the positive sense 
RNA genome. A major requirement for genome replication is the involvement of the host 
cell microRNA miR-122, a tropism determinant that is also utilized by the virus to 
modulate host cell gene expression (Jopling et al., 2005; Luna et al., 2015). 
HCV assembly and lipoprotein association. Assembly of HCV particles is 
currently believed to occur at or near cytoplasmic lipid droplets or on ER-derived 
membranes (Bartenschlager et al., 2011; Lindenbach, 2013; Lindenbach and Rice, 2013). 
This model is based on several observations. The HCV Core protein, which is required 
for the formation of the HCV virion (Miyanari et al., 2007; Murray et al., 2007), localizes 
onto lipid droplets and ER membranes (Boson et al., 2011; Miyanari et al., 2007; Murray 
et al., 2007). The ability of Core to associate with the cytoplasmic surfaces of the lipid 
droplets and of the ER membrane is required for viral particle assembly (Boulant et al., 
2007; Targett-Adams et al., 2008). Second, in pulse-chase time course experiments, 
fluorescently labeled Core molecules were observed to relocate from their site of 
synthesis (ER-bound ribosomes) to the surface of lipid droplets and then back to the ER 
(Counihan et al., 2011). Furthermore, the E1/E2 glycoprotein heterodimer, required for 
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particle production and entry, localizes specifically within the ER (Cocquerel et al., 1999; 
Cocquerel et al., 1998), where it is presumably loaded onto the nascent viral particles 
during particle envelopment. Particle assembly involves tight coordination of the 
structural viral particle components (Core, E1 and E2) and some nonstructural HCV 
proteins (p7, NS2, NS3, NS5A), as evidenced by their colocalization and interaction 
networks, the later revealed both biochemically and genetically (Appel et al., 2008; 
Gentzsch et al., 2013; Jirasko et al., 2010; Jones et al., 2011; Kim et al., 2011; 
Lindenbach, 2013; Lindenbach and Rice, 2013; Ma et al., 2008; Masaki et al., 2008; 
Miyanari et al., 2007; Murray et al., 2008; Popescu et al., 2011).  
Production of infectious HCV also requires that cells express apolipoproteins, 
such as ApoE and/or ApoB100 (Chang et al., 2007; Fukuhara et al., 2014; Gastaminza et 
al., 2008; Hishiki et al., 2010; Huang et al., 2007; Hueging et al., 2014; Lee et al., 2014; 
Long et al., 2011; Vogt et al., 2013). These apolipoproteins are incorporated into the 
virus particles (Andre et al., 2002; Catanese et al., 2013; Chang et al., 2007; Nielsen et 
al., 2006) and confer them lipoprotein-like properties, such as a light density (Andre et 
al., 2002; Gastaminza et al., 2008; Gastaminza et al., 2006; Lindenbach et al., 2006; 
Nielsen et al., 2006), resulting in the formation of lipoviroparticles (Andre et al., 2002). 
Knockdown of ApoE or ApoB100, or inhibition of their lipidation, impairs HCV particle 
production (Chang et al., 2007; Gastaminza et al., 2008; Jiang and Luo, 2009), and Core 
punctate signals were shown to colocalize with ApoE punctate signals in infected cells 
(Coller et al., 2012). Additionally, the E2 transmembrane domain was shown to interact 
with ApoE (Lee et al., 2014). Association of ApoE and ApoB100 with HCV may serve 
several functions in the viral life cycle: they may help prevent intracellular degradation of 
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newly assembled HCV particles (Gastaminza et al., 2008), mediate transport of HCV 
through the secretory pathway (Hishiki et al., 2010), and facilitate entry into target cells 
through interactions with viral co-receptors, including  LDLR (Agnello et al., 1999; 
Monazahian et al., 1999), glucosaminoglycans (Germi et al., 2002) and scavenger 
receptor B1 (Scarselli et al., 2002). Overall, the uniquely tight associations between HCV 
and the liver-derived apolipoproteins ApoE and ApoB100, as well as the complex nature 
of VLDL and HCV particle assembly and secretion from hepatocytes, invites the inquiry 
of how the secretion routes of these entities are molecularly regulated. 
1.18. Regulation of HCV and lipoprotein release 
HCV and lipoprotein secretion has been characterized in broad terms, but 
molecular details of the regulation of these processes remain somewhat sparse. Both 
VLDL and HCV transit through the Golgi as they are being secreted, as both ApoB100 
and HCV glycoproteins acquire glycan chain modifications that require Golgi-resident 
enzyme activity (Tran et al., 2002; Vieyres et al., 2010). Furthermore, VLDL particles, 
HCV and ApoE have each been colocalized or co-isolated with the Golgi (Coller et al., 
2012; Ehrenreich et al., 1973; Kockx et al., 2007). Brefeldin A, a potent and widely used 
inhibitor of ER to Golgi traffic, has been shown to impair the secretion of HCV, ApoE 
and ApoB100 (Deng et al., 1995; Gastaminza et al., 2008; Rustaeus et al., 1995; Ye et al., 
1992; Ye et al., 1993). Lastly, transport of ApoE and of HCV appears to occur along 
microtubules, since the movement of fluorescently labeled HCV (Coller et al., 2012) or 




Investigation into how HCV and lipoproteins are transported from the ER to the 
Golgi remains an area of continued interest. Experiments in several systems have 
documented that both HCV (Coller et al., 2012) and lipoprotein (Gusarova et al., 2003; 
Jones et al., 2003; Siddiqi et al., 2003) transport depend on the activity of Sar1 GTPases. 
This is consistent with the particles - at least initially - being transported by a COPII 
membrane carrier, since Sar1 is the GTPase that specifically recruits COPII at the site of 
vesicle formation at ER exit sites (Kuge et al., 1994; Nakano and Muramatsu, 1989). 
There, VLDL may be loaded into a specialized transport vesicle, the VLDL transport 
vesicle, which was found to be larger than a regular protein transport vesicle, and of a 
lighter density (Siddiqi, 2008). Albumin has been shown to be transported by such 
protein transport vesicles, and it was absent from the VLDL transport vesicle (Siddiqi, 
2008). It is unclear at the moment whether exclusion of regular proteins from the VLDL 
transport vesicle is due to passive phenomena (i.e. once a VLDL is sorted there is not 
much room left in the nascent VLDL transport vesicle to package more cargo) or active 
processes (i.e. the VLDL is actively concentrated into VLDL transport vesicles while the 
regular proteins are actively excluded from VLDL transport vesicles and/or actively and 
specifically concentrated into protein transport vesicles). Also intriguing is the finding 
that ApoB100 and ApoE segregated into distinct subpopulations of in vitro-made ER-
derived vesicles, but were found in the same Golgi-derived vesicle population (Gusarova 
et al., 2007). Since at least a fraction of the hepatic ApoE may be secreted as part of 
VLDL particles (Dolphin, 1981; Reardon et al., 1998; Vance et al., 1984; Wilcox and 
Heimberg, 1987), these findings suggest that ApoE-VLDL association occurs in the 
Golgi, and that their transport from the ER to the Golgi occurs in separate carriers. 
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Less is known about these cargoes' post-Golgi routes of secretion. They have been 
shown to be partly degraded intracellularly in a post-Golgi compartment, since 
degradation was sensitive to inactivation of ER to Golgi transport by brefeldin A 
treatment (Deng et al., 1995; Gastaminza et al., 2008; Ye et al., 1993). Furthermore, this 
post-ER degradation has been shown to be inhibited by treatment with protease inhibitors 
that target endosomal cathepsin and calpain proteases (Deng et al., 1995; Gastaminza et 
al., 2008; Hiwasa et al., 1990; Ye et al., 1993). It may be the case that some of these 
cargoes are targeted for endolysosomal degradation, which may be reduced in the 
presence of said protease inhibitors. It may also be the case that the secretion pathway(s) 
of these cargoes passes through an endosomal compartment, where some cargo becomes 
degraded. Indeed, release of HCV particles has been shown to be reduced when Rab11a 
expression was impaired (Coller et al., 2012). Rab11a is a defining marker of recycling 
endosomes (Ullrich et al., 1996), as I will more fully explain in Chapter 4. HCV secretion 
was also reduced when Rab3d expression was knocked down (Coller et al., 2012). Rab3d 
(also known as Rab16) is known to function at late exocytic steps (Fukuda, 2008) and 
may thus regulate the final transport steps of HCV secretion. Differences nevertheless do 
appear to exist between post-Golgi HCV and VLDL transport, since HCV transport was 
impaired when expression of the γ-1 subunit of the clathrin adaptor protein complex AP-
1 was knocked down, while VLDL secretion was unaffected (Benedicto et al., 2015).  
Characterization in greater detail of the molecular basis of post-Golgi transport of 
HCV and of lipoprotein particles is in order. Such work also needs to account for other 
known aspects of intracellular transport of HCV and of lipoprotein components. A major 
concern is the need to distinguish, particularly in imaging experiments, between secretory 
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behavior of newly synthesized cargo and endocytic recycling of cargo up-taken from the 
extracellular space. ApoE, for example, was shown to be a recycled cargo, although 
ApoB was not, but was instead targeted for lysosomal degradation (Heeren et al., 2003; 
Laatsch et al., 2012). HCV, in turn, enters cells through receptor mediated endocytosis 
(Coller et al., 2009). It is unclear to what extent newly endocytosed particles may reach a 
compartment that may also function in secretion, such as the recycling endosome (Coller 
et al., 2012), and how transport of endocytosed infectious viruses differs, if at all, from 
transport of endocytosed non-infectious viruses, which form the majority of the particles 
even in some of the most enriched infectious virus preparations (Catanese et al., 2013; 
Gastaminza et al., 2010).  
Any interpretation of experimental findings documenting the involvement of one 
pathway or the other in HCV or lipoprotein secretion must also account for the possibility 
that one single pathway may not be exclusively or even primarily responsible for cargo 
release.  
1.19. Significance 
As repeatedly emphasized above, the hepatic cargoes that are the focus of the 
studies I present here serve essential functions in the human body. Maintenance of 
circulatory system homeostasis and lipid transport are the most obvious of these functions 
(Ha and Bhagavan, 2013; Olofsson and Boren, 2005; Yamasaki et al., 2013; Zannis et al., 
2015). The disease association of these cargoes is extensive. Atherosclerotic 
cardiovascular disease is a leading cause of morbidity and mortality worldwide (Barquera 
et al., 2015). The pathologies associated with HCV infection are also numerous and can 
severely affect human life (Hoofnagle, 1997; Thomas, 2013). Understanding the 
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processes involved in the production of these bioparticles is thus necessary, and may, in 
the long run, provide avenues for therapeutic intervention.  
From a cell biological perspective, this topic is of interest because it deals with a 
particularly challenging question: how are large cargoes, such as VLDL or HCV 
particles, transported by the secretory pathway, given that documented sizes of transport 
vesicles appear to be insufficient to allow for packaging of these large cargoes (Miller 
and Schekman, 2013)? Indeed, intensive recent research efforts have dealt with how such 
cargoes are packaged into COPII-dependent ER-derived vesicles (Jin et al., 2012; 
Mansbach and Siddiqi, 2010). While my work does not address the sorting of large 
cargoes into the transport carriers per se, it nevertheless touches on the question of 
whether there are any differences between the transport regulation of carriers that shuttle 
regularly-sized proteins, such as albumin, and those that transport the large lipoprotein 
and viral particles. This body of work also lays the groundwork for addressing the 
question of how polarized transport of lipoproteins and of HCV is regulated by the 
hepatocyte. 
Lastly, the analysis of HCV and lipoprotein secretion must be undertaken while 
considering the evolutionary history of the virus. That HCV has evolved to be so closely 
associated with the hepatic lipoproteins is a testimony to how well the virus has "learned" 
the cell biology of the hepatocyte (Lindenbach, 2013; Lindenbach and Rice, 2013; Scheel 
and Rice, 2013). Delineating which transport pathways are common for HCV and 
lipoproteins, and which are distinct, may well advance the understanding of both host and 
pathogen cell biology. This line of inquiry conceptually mirrors the study of the exocytic 
transport of the vesicular stomatitis virus glycoprotein (VSVg), which has helped define 
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major features of secretory vesicular traffic (Bergmann, 1989), or the study of viral and 
bacterial toxin entry, which have facilitated the investigation of important endocytic 
processes (Pelkmans, 2005; Schiavo and van der Goot, 2001).  
1.20. Aims 
Given the biomedical importance of the lipoproteins and HCV alike, and given 
the complex and interconnected cell biology that is involved in the production of these 
cargoes by hepatocytes, I set out to define and characterize molecular, spatial and 
temporal aspects of lipoprotein and HCV egress. My work aimed to: (i) identify the 
transport regulators of HCV and lipoprotein particle secretion by means of performing a 
screen using DN mutants of the Rab GTPases; (ii) confirm and describe the involvement 
of specified members of the Rab family in these secretory processes,; and (iii) validate 
fluorescent protein-tagged versions of the Rab GTPases and of cargoes as useful tools in 
live-cell imaging analyses of hepatic cargo secretion. I now compile the work I have 
performed to date, and describe some avenues of investigation that I believe future work 
could successfully pursue. This thesis will thus describe at length the methodology used 
to advance this project. I will then present the design and the results of the DN Rab 
GTPase screen that I used to unbiasedly identify regulators of hepatic cargo secretion. I 
will describe ongoing investigations into how Rab11 and Rab8 GTPases may control 
lipoprotein and HCV secretion, and the characterization of Rab1 involvement in the same 
processes. I will also describe the tests I performed to determine whether fluorescent 
protein-tagged ApoE might be used in the study of hepatic lipoprotein and HCV 
secretion. Throughout the pages, I will also discuss how the approaches and the assays 
that I have utilized may be improved and adapted to other lines of investigation.  
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Chapter 2.  
Materials and Methods. 
 
2.1. DNA manipulations 
Standard molecular biology protocols were used to construct or modify the 
plasmids used in this work, as described below. Polymerase chain reaction (PCR) using 
Platinum PCR Supermix (Life Technologies) or Takara polymerase (Clontech) was 
performed to amplify DNA fragments, which were then digested using New England 
Biolabs restriction endonucleases and ligated (Quick Ligase, New England Biolabs) into 
target vectors. Alternatively, the In-Fusion HD kit (Clontech) was employed, according 
to the manufacturer's instructions, to insert DNA fragments into target vectors. Site-
directed mutagenesis (SDM) was performed using the Quick Change Lightning Site 
Directed Mutagenesis kit (Agilent) according to the manufacturer's instructions. Plasmids 
were transformed and grown in the DH5α E. coli strain at 30°C (retroviral and lentiviral 
vectors) or at 37°C (all other vectors) in LB medium or terrific broth (Difco). Ampicillin 
was used at 100 μg/mL and kanamycin was used at 50 μg/mL for selection. DNA was 
isolated using Purelink Quick Plasmid Miniprep, Quick Gel Extraction or HiPure Plasmid 
Maxiprep kits (Life Technologies). Plasmids and some of their relevant features are listed 
in Table 2.1, while the text below also describes the steps undertaken to make these 
constructs. Table 2.1 also includes a series of plasmids that were used as templates for 
amplification of various DNA sequences, or as vector backbones. The references or 
commercial sources for the various plasmids used in this work are also listed in Table 
2.1. For the Rab-encoding plasmids that I used in the DN Rab screen part of this work, I 
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also list in Table 2.1 the NCBI reference sequence number of the respective WT human 
Rab proteins. The nucleotide sequences of the DNA primers employed during the 
plasmid construction process are listed in Table 2.2, and the primers are referred to in the 
text by their names. They were chemically synthesized by IDT. The nucleotide sequences 
of the relevant features of both intermediate and final constructs were confirmed using 
DNA sequencing by Genewiz or Macrogen. 
Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
Non-viral plasmids 
pCR3.1 SynGag HIV-1 Gag  (Graf et al., 
2000) 




pVSVg VSVg Pseudotyping 
vectors 
Clontech 
pHCMV-VSVg VSVg (Beyer et 
al., 2002) 




pmEGFP-N1 PCMV MCS-mEGFP EGFPA206K Lab plasmid 
pmCherry-N1 PCMV MCS-mCherry  Clontech 




pCMV-XL5 Rab10 Rab10  
Origene pCMV-XL5 Rab12 Rab12  
pCMV-XL5 Calnexin Calnexin  






pCMV-SPORT6 Rab1b Rab1b  
pCMV-SPORT6 Rab1c/35 Rab1c/35  
pCMV-SPORT6 Rab3d/16 Rab3d/16  
pCMV-SPORT6 Rab5b Rab5b  
pCMV-SPORT6 Rab5c Rab5c  
pCMV-SPORT6 Rab13 Rab13  
pCMV-SPORT6 Rab21 Rab21  
pCMV-SPORT6 Rab22a Rab22a  
pCMV-SPORT6 Rab23 Rab23  
pCMV-SPORT6 Rab27a Rab27a  
pCMV-SPORT6 Rab27b Rab27b  
pCMV-SPORT6 Rab38 Rab38  
pOTB7-Rab2a Rab2a  
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
pOTB7-Rab3b Rab3b  
pOTB7-Rab4b Rab4b  
pOTB7-Rab6a Rab6a  
pOTB7-Rab7a Rab7a  
pOTB7-Rab8a Rab8a  
pOTB7-Rab11c/25 Rab11c/25  
pOTB7-Rab22b/31 Rab22b/31  
pOTB7-Rab24 Rab24  
pOTB7-Rab33a Rab33a  
pOTB7-Rab43 Rab43  
pDNR-LIB-Rab2b Rab2b  
pDNR-LIB-Rab8b Rab8b  
pDNR-LIB-Rab32 Rab32  
pBlueScriptR-Rab15 Rab15  
pBlueScriptR-Rab33b Rab33b  
pCR-TOPO-Rab11b Rab11b  
pCR-TOPO-Rab36 Rab36  
pCDNA5 Flag3-Rab5a Rab5a 
Obtained from 
Addgene 
(Sun et al., 
2010a) 
pEGFP-Rab11aWT Rab11a (Choudhury 
et al., 2002) 
pEGFP-Rab18 Rab18  Lab plasmid 
HCV plasmids 
pFL J6/JFH1 PT7 HCV J6/JFH1 
cDNA 
For in vitro 
transcription 
(Lindenbach 
et al., 2005) 
Lentiviral plasmids 






pLX304 Rab3a Rab3a  
(Yang et al., 
2011) 
pLX304 Rab3c Rab3c  
pLX304 Rab4a Rab4a  
pLX304 Rab6b Rab6b  
pLX304 Rab6c Rab6c  
pLX304 Rab7b Rab7b  
pLX304 Rab9a Rab9a  
pLX304 Rab9b Rab9b  
pLX304 Rab14 Rab14  
pLX304 Rab17 Rab17  
pLX304 Rab19b Rab19b  
pLX304 Rab20 Rab20  
pLX304 Rab26 Rab26  
pLX304 Rab7L1/29 Rab7L1/29  
pLX304 Rab30 Rab30  
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
pLX304 Rab34 Rab34  
pLX304 Rab37 Rab37  
pLX304 Rab39a Rab39a  
pLX304 Rab39b Rab39b  
pLX304 Rab40a Rab40a  
pLX304 Rab40al Rab40al  
pLX304 Rab40b Rab40b  
pLX304 Rab40c Rab40c  
pLX304 Rab41 Rab41  
pLVX Puro PCMV MCS;  
PPGK PuroR 
 Clontech 
pLenti4/V5-Dest ZeoR  Invitrogen 








pLVX Hhi3 PCMV MCS; 
PPGK HygroR 
This study 
pLVX Nhi3 PCMV MCS; PPGK 
NeoR 
This study 
pLVX Phi3 PCMV MCS; 
PPGK PuroR 
This study 
pLVX Zhi3 PCMV MCS; PPGK 
ZeoR 
This study 





pLVX Hhi3 ApoE3 PCMV ApoE3 ApoE3 engineered 













pLVX Phi3 mCherry PCMV mCherry mCherry control 
expression vector 
This study 
pLVX Phi3 FLuc PCMV FLuc  This study 
pLVX Bhi3 FLuc   This study 




 This study 




 This study 




 This study 




 This study 
OL177 pLVX Che-hi3 
Rab1b 
PCMV hab1b NP_112243.1 This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL178 pLVX Che-hi3 
Rab1bN121I 
PCMV Rab1bN121I  This study 
OL249 pLVX Che-hi3 
Rab1bQ67L 
PCMV Rab1bQ67L  This study 
OL250 pLVX Che-hi3 
Rab1bS22N 
PCMV Rab1bS22N  This study 
OL 175 pLVX Che-hi3 
Rab1a 
PCMV Rab1a NP_004152.1 This study 
OL 176 pLVX Che-hi3 
Rab1aN124I 
PCMV Rab1aN124I  This study 
OL179 pLVX Che-hi3 
Rab1c/35 
PCMV Rab1c/35 NP_006852.1 This study 
OL180 pLVX Che-hi3 
Rab1c/35N120I 
PCMV Rab1c/35N120I  This study 
OL181 pLVX Che-hi3 
Rab2a 
PCMV Rab2a NP_002856.1 This study 
OL182 pLVX Che-hi3 
Rab2aN119I 
PCMV Rab2aN119I  This study 
OL183 pLVX Che-hi3 
Rab3a 
PCMV Rab3a NP_002857.1 This study 
OL184 pLVX Che-hi3 
Rab3aN135I 
PCMV Rab3aN135I  This study 
OL185 pLVX Che-hi3 
Rab3b 
PCMV Rab3b NP_002858.2 This study 
OL186 pLVX Che-hi3 
Rab3bN135I 
PCMV Rab3bN135I  This study 
OL187 pLVX Che-hi3 
Rab3c 
PCMV Rab3c NP_612462.1 This study 
OL188 pLVX Che-hi3 
Rab3cN143I 
PCMV Rab3cN143I  This study 
OL189 pLVX Che-hi3 
Rab3d/16 
PCMV Rab3d/16 NP_004274.1 This study 
OL190 pLVX Che-hi3 
Rab3d/16N135I 
PCMV Rab3d/16N135I  This study 
OL191 pLVX Che-hi3 
Rab4a 
PCMV Rab4a NP_004569.2 This study 
OL192 pLVX Che-hi3 
Rab4aN126I 
PCMV Rab4aN126I  This study 
OL193 pLVX Che-hi3 
Rab5a 
PCMV Rab5a NP_004153.2 This study 
OL194 pLVX Che-hi3 
Rab5aN133I 
PCMV Rab5aN133I  This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL195 pLVX Che-hi3 
Rab6a 
PCMV Rab6a NP_002860.2 This study 
OL196 pLVX Che-hi3 
Rab6aN126I 
PCMV Rab6aN126I  This study 
OL197 pLVX Che-hi3 
Rab7b 
PCMV Rab7b NP_796377.3 This study 
OL198 pLVX Che-hi3 
Rab7bN124I 
PCMV Rab7bN124I  This study 
OL199 pLVX Che-hi3 
Rab8a 
PCMV Rab8a NP_005361.2 This study 
OL200 pLVX Che-hi3 
Rab8aN121I 
PCMV Rab8aN121I  This study 
OL319 pLVX Che-hi3 
Rab8aQ67L 
PCMV Rab8aQ67L  This study 
OL320 pLVX Che-hi3 
Rab8aT22N 
PCMV Rab8aT22N  This study 
OL201 pLVX Che-hi3 
Rab8b 
PCMV Rab8b NP_057614.1 This study 
OL202 pLVX Che-hi3 
Rab8bN121I 
PCMV Rab8bN121I  This study 
OL321 pLVX Che-hi3 
Rab8bQ67L 
PCMV Rab8bQ67L  This study 
OL322 pLVX Che-hi3 
Rab8bT22N 
PCMV Rab8bT22N  This study 
OL203 pLVX Che-hi3 
Rab9a 
PCMV Rab9a NP_004242.1 This study 
OL204 pLVX Che-hi3 
Rab9aN124I 
PCMV Rab9aN124I  This study 
OL205 pLVX Che-hi3 
Rab10 
PCMV Rab10 NP_057215.3 This study 
OL206 pLVX Che-hi3 
Rab10N122I 
PCMV Rab10N122I  This study 
OL207 pLVX Che-hi3 
Rab11a 
PCMV Rab11a NP_004654.1 This study 
OL208 pLVX Che-hi3 
Rab11aN124I 
PCMV Rab11aN124I  This study 
OL313 pLVX Che-hi3 
Rab11aQ70L 
PCMV Rab11aQ70L  This study 
OL314 pLVX Che-hi3 
Rab11aS25N 
PCMV Rab11aS25N  This study 
OL209 pLVX Che-hi3 
Rab11b 
PCMV Rab11b NP_004209.2 This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL210 pLVX Che-hi3 
Rab11bN124I 
PCMV Rab11bN124I  This study 
OL315 pLVX Che-hi3 
Rab11bQ70L 
PCMV Rab11bQ70L  This study 
OL316 pLVX Che-hi3 
Rab11bS25N 
PCMV Rab11bS25N  This study 
OL211 pLVX Che-hi3 
Rab11c/25 
PCMV Rab11c/25 NP_065120.2 This study 
OL212 pLVX Che-hi3 
Rab11c/25N125I 
PCMV Rab11c/25N125I  This study 
OL213 pLVX Che-hi3 
Rab12 
PCMV Rab12 NP_001020471.2 This study 
OL214 pLVX Che-hi3 
Rab12N155I 
PCMV Rab12N155I  This study 
OL215 pLVX Che-hi3 
Rab13 
PCMV Rab13 NP_002861.1 This study 
OL216 pLVX Che-hi3 
Rab13N121I 
PCMV Rab13N121I  This study 
OL217 pLVX Che-hi3 
Rab14 
PCMV Rab14 NP_057406.2 This study 
OL218 pLVX Che-hi3 
Rab14N124I 
PCMV Rab14N124I  This study 
OL219 pLVX Che-hi3 
Rab18 
PCMV Rab18 NP_067075.1 This study 
OL220 pLVX Che-hi3 
Rab18N122I 
PCMV Rab18N122I  This study 
OL221 pLVX Che-hi3 
Rab19b 
PCMV Rab19b NP_001008749.2 This study 
OL222 pLVX Che-hi3 
Rab19bN130I 
PCMV Rab19bN130I  This study 
OL223 pLVX Che-hi3 
Rab22b/31 
PCMV Rab22b/31 NP_006859.2 This study 
OL224 pLVX Che-hi3 
Rab22b/31N119I 
PCMV Rab22b/31N119I  This study 
OL225 pLVX Che-hi3 
Rab23 
PCMV Rab23 NP_057361.3 This study 
OL226 pLVX Che-hi3 
Rab23N121I 
PCMV Rab23N121I  This study 
OL227 pLVX Che-hi3 
Rab26 
PCMV Rab26 NP_055168.2 This study 
OL228 pLVX Che-hi3 
Rab26N177I 
PCMV Rab26N177I  This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL229 pLVX Che-hi3 
Rab27a 
PCMV Rab27a NP_004571.2 This study 
OL230 pLVX Che-hi3 
Rab27aN133I 
PCMV Rab27aN133I  This study 
OL231 pLVX Che-hi3 
Rab27b 
PCMV Rab27b NP_004154.2 This study 
OL232 pLVX Che-hi3 
Rab27bN133I 
PCMV Rab27bN133I  This study 
OL233 pLVX Che-hi3 
Rab32 
PCMV Rab32 NP_006825.1 This study 
OL234 pLVX Che-hi3 
Rab32N143I 
PCMV Rab32N143I  This study 
OL235 pLVX Che-hi3 
Rab33a 
PCMV Rab33a NP_004785.1 This study 
OL236 pLVX Che-hi3 
Rab33aN151I 
PCMV Rab33aN151I  This study 
OL237 pLVX Che-hi3 
Rab39a 
PCMV Rab39a NP_059986.1 This study 
OL238 pLVX Che-hi3 
Rab39aH127I 
PCMV Rab39aH127I  This study 
OL239 pLVX Che-hi3 
Rab40a 
PCMV Rab40a NP_543155.2 This study 
OL240 pLVX Che-hi3 
Rab40aN126I 
PCMV Rab40aN126I  This study 
OL251 pLVX Che-hi3 
Rab2b 
PCMV Rab2b NP_116235.2 This study 
OL252 pLVX Che-hi3 
Rab2bN119I 
PCMV Rab2bN119I  This study 
OL253 pLVX Che-hi3 
Rab4b 
PCMV Rab4b NP_057238.3 This study 
OL254 pLVX Che-hi3 
Rab4bN121I 
PCMV Rab4bN121I  This study 
OL255 pLVX Che-hi3 
Rab5b 
PCMV Rab5b NP_002859.1 This study 
OL256 pLVX Che-hi3 
Rab5bN133I 
PCMV Rab5bN133I  This study 
OL257 pLVX Che-hi3 
Rab5c 
PCMV Rab5c NP_004574.2 This study 
OL258 pLVX Che-hi3 
Rab5cN134I 
PCMV Rab5cN134I  This study 
OL259 pLVX Che-hi3 
Rab6b 
PCMV Rab6b NP_057661.3 This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL260 pLVX Che-hi3 
Rab6bN126I 
PCMV Rab6bN126I  This study 
OL261 pLVX Che-hi3 
Rab6c 
PCMV Rab6c NP_115520.2 This study 
OL262 pLVX Che-hi3 
Rab6cN126I 
PCMV Rab6cN126I  This study 
OL263 pLVX Che-hi3 
Rab7a 
PCMV Rab7a NP_004628.4 This study 
OL264 pLVX Che-hi3 
Rab7aN125I 
PCMV Rab7aN125I  This study 
OL265 pLVX Che-hi3 
Rab9b 
PCMV Rab9b NP_057454.1 This study 
OL266 pLVX Che-hi3 
Rab9bN124I 
PCMV Rab9bN124I  This study 
OL267 pLVX Che-hi3 
Rab15 
PCMV Rab15 NP_941959.1 This study 
OL268 pLVX Che-hi3 
Rab15T22N 
PCMV Rab15T22N  This study 
OL269 pLVX Che-hi3 
Rab17 
PCMV Rab17 NP_071894.1 This study 
OL270 pLVX Che-hi3 
Rab17N132I 
PCMV Rab17N132I  This study 
OL271 pLVX Che-hi3 
Rab20 
PCMV Rab20 NP_060287.1 This study 
OL272 pLVX Che-hi3 
Rab20N113I 
PCMV Rab20N113I  This study 
OL274 pLVX Che-hi3 
Rab21 
PCMV Rab21 NP_055814.1 This study 
OL274 pLVX Che-hi3 
Rab21N132I 
PCMV Rab21N132I  This study 
OL275 pLVX Che-hi3 
Rab22a 
PCMV Rab22a NP_065724.1 This study 
OL276 pLVX Che-hi3 
Rab22aN118I 
PCMV Rab22aN118I  This study 
OL277 pLVX Che-hi3 
Rab24 
PCMV Rab24 NP_570137.2 This study 
OL278 pLVX Che-hi3 
Rab24T120I 
PCMV Rab24T120I  This study 
OL279 pLVX Che-hi3 
Rab28 
PCMV Rab28 NP_004240.2 This study 
OL280 pLVX Che-hi3 
Rab28N129I 
PCMV Rab28N129I  This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL281 pLVX Che-hi3 
Rab29/7L1 
PCMV Rab29/7L1 NP_003920.1 This study 
OL282 pLVX Che-hi3 
Rab29/7L1N125I 
PCMV Rab29/7L1N125I  This study 
OL283 pLVX Che-hi3 
Rab30 
PCMV Rab30 NP_055303.2 This study 
OL284 pLVX Che-hi3 
Rab30N122I 
PCMV Rab30N122I  This study 
OL285 pLVX Che-hi3 
Rab33b 
PCMV Rab33b NP_112586.1 This study 
OL286 pLVX Che-hi3 
Rab33bN148I 
PCMV Rab33bN148I  This study 
OL287 pLVX Che-hi3 
Rab34 
PCMV Rab34 NP_114140.4 This study 
OL288 pLVX Che-hi3 
Rab34S166I 
PCMV Rab34S166I  This study 
OL289 pLVX Che-hi3 
Rab36 
PCMV Rab36 NP_004905.2 This study 
OL290 pLVX Che-hi3 
Rab36T237I 
PCMV Rab36T237I  This study 
OL291 pLVX Che-hi3 
Rab37 
PCMV Rab37 NP_001006639.1 This study 
OL292 pLVX Che-hi3 
Rab37N143I 
PCMV Rab37N143I  This study 
OL293 pLVX Che-hi3 
Rab38 
PCMV Rab38 NP_071732.1 This study 
OL294 pLVX Che-hi3 
Rab38N127I 
PCMV Rab38N127I  This study 
OL295 pLVX Che-hi3 
Rab39b 
PCMV Rab39b NP_741995.1 This study 
OL296 pLVX Che-hi3 
Rab39bH123I 
PCMV Rab39bH123I  This study 
OL297 pLVX Che-hi3 
Rab40al 
PCMV Rab40al NP_001027004.1 This study 
OL298 pLVX Che-hi3 
Rab40alN126I 
PCMV Rab40alN126I  This study 
OL299 pLVX Che-hi3 
Rab40b 
PCMV Rab40b NP_006813.1 This study 
OL300 pLVX Che-hi3 
Rab40bN126I 
PCMV Rab40bN126I  This study 
OL301 pLVX Che-hi3 
Rab40c 
PCMV Rab40c NP_066991.3 This study 
 
60 
Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 
OL302 pLVX Che-hi3 
Rab40cN126I 
PCMV Rab40cN126I  This study 
OL303 pLVX Che-hi3 
Rab41 
PCMV Rab41 NP_001027898.2 This study 
OL304 pLVX Che-hi3 
Rab41N143I 
PCMV Rab41N143I  This study 
OL305 pLVX Che-hi3 
Rab42 
PCMV Rab42 NP_001180461.1 This study 
OL306 pLVX Che-hi3 
Rab42H129I 
PCMV Rab42H129I  This study 
OL307 pLVX Che-hi3 
Rab43 
PCMV Rab43 NP_940892.1 This study 
OL308 pLVX Che-hi3 
Rab43N131I 
PCMV Rab43N131I  This study 
Lentiviral shRNA plasmids 
pLKO.1   Dharmacon 






Retroviral plasmids    
LMNI IRES-BlastR  (Jouvenet et 
al., 2009) 
pLHCX HygroR  Clontech 
pLNCX2 NeoR  Clontech 




pRetroX TRE3G PTRE3G-MCS For Dox-inducible 
expression 
Clontech 
pRetroX TRE3G-FLuc PTRE3G-FLuc  Clontech 
pRetroX TRE3G-mCherry PTRE3G mCherry  This study 




 This study 




 This study 




 This study 




 This study 
OR366 pRetroX TRE3G 
mEGFP 
PTRE3G mEGFP  This study 




 This study 
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Table 2.1. Plasmids 
Construct Relevant Features Notes Source or 
Reference 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 




 This study 
Abbreviations: MLV, murine leukemia virus; HIV-1, human immunodeficiency virus 1; 
PCMV, cytomegalovirus (CMV) promoter; PPGK, phosphoglycerate kinase (PGK) 
promoter; PTRE3G, third generation tetracycline response element (TRE) promoter; MCS, 
multicloning site; SP, signal peptide; FLuc, firefly luciferase; BlastR, blasticidin 
resistance gene, blasticidin S deaminase, bsd; HygroR, hygromycin resistance gene, 
hygromycin B phosphotransferase, hph; NeoR, neomycin/kanamycin resistance gene, 
neomycin phosphotransferase, npt; PuroR, puromycin resistance gene, puromycin N-






2.2. Modified lentivirus expression vectors  
To allow for versatile expression of multiple constructs in the same cell, a palette 
of lentiviral expression vectors was constructed. The vectors are listed in Table 2.1 and 
some of their relevant features are depicted in Figure 2.1. These vectors were derived 
from pLVX Puro, and were engineered to carry antibiotic resistance markers that allowed 
transduced cells to be selected with one of the following antibiotics: puromycin (P), 
blasticidin (B), hygromycin (H), neomycin or its substitute, G418, (N) , zeocin (Z) or the 
fluorescent protein reporter mCherry (Che). The multicloning site (MCS) was also 
expanded in steps. The name of each vector includes all the relevant information about 
the vector. For example, in the case of pLVX Phi3: pLVX signifies that the backbone of 
the vector was derived from Clontech's pLVX Puro; P in Phi3 signifies that the 
resistance/reporter gene is the puromycin resistance gene; hi in Phi3 signifies that gene 
expression from the MCS is controlled by the high expression cytomegalovirus (CMV) 
promoter; and, lastly, 3, in Phi3 signifies that the 3rd generation of expanded MCS can 
be found in this vector. Since all these vectors contain the same MCS, transfer of genes 
among them can be easily achieved by a simple "cut/paste" reaction: cutting the insert 
from the donor vector with suitable restriction enzymes followed by ligation between the 
same sites in the target vector. Here follow the cloning steps that I used to make these 
vectors. I thank Brenna Flatley and Rachel Belote for performing some of these steps.  
pLVX Phi3. An improved MCS DNA, containing sequences cleaved, in order, by 
the following restriction endonucleases: 5'-ClaI-BlpI-BclI-AgeI-AfeI-HindIII-BglII-
XhoI-EcoRI-NotI-BspEI-MluI-SalI-MfeI-PspOMI-ApaI-NsiI-SphI-AvrII-NgoMIV-
NaeI-HpaI-AsiSI-SbFI-BamHI-ClaI-3', was custom synthesized into the pUC57-Amp 
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vector (Genewiz). The improved MCS was excised as a ~100 base-pair (bp) AfeI/BamHI 
fragment from pUC57-Amp-MCS and ligated into the AfeI/BamHI backbone of pLVX 
Puro to form pLVX Phi. A modified pSL1180 cloning vector, named pSL1180.1, was 
obtained by digesting pSL1180 with AfeI and SmaI followed by re-ligation of the 
purified vector backbone. The ~1.9 kbp XbaI/KpnI fragment of pLVX Puro was ligated 
into XbaI/KpnI-cut pSL1180.1. In this vector, the BsiWI site within the PuroR gene was 
mutated by SDM using primers NT430 and NT431. The mutation is silent. The resulting 
XbaI/KpnI fragment was reinserted into the XbaI/KpnI sites of pLVX Phi. Primers 
NT454 and NT455 were annealed to each other and then ligated into the XbaI/BamHI 
sites of the vector to further improve the MCS. 
 
 
Figure 2.1. Organization of lentiviral and retroviral vectors. (A) pLVX-based vectors 
expressing an antibiotic selection marker; (B) pLVX Che-hi3 vector expressing an 
mCherry fluorescent protein reporter in lieu of the antibiotic resistance; (C and D) 
retroviral vectors used to make inducible expression cell lines. (C) pRetroX Tet3G vector 
used to generate Huh-7.5 TetON clonal cell lines. It constitutively expresses a TetON3G 
reverse transactivator. (D) pRetroX TRE3G-based vectors used to transduce the Huh-7.5 
TetON clonal cell lines.  The TetON3G reverse transactivator binds to the Tetracycline 
Response Element TRE3G in the presence of doxycycline and induces gene expression. 
LTR, long terminal repeat; ψ, packaging signal; PCMV, CMV promoter; MCS, 
multicloning site; GOI, gene of interest; PPGK, phosphoglycerate kinase promoter; AbR, 
antibiotic resistance marker; IRES, internal ribosome entry site; NeoR, neomycin 
resistance; PTRE3GV, virus-adapted TRE3G promoter; PuroR, puromycin resistance. 
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pLVX Bhi3. The PGK promoter sequence of pLVX Puro was amplified using 
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence was 
PCR amplified from pLVX Puro using primers NT189 and NT190, then digested with 
AbsI and KpnI. The Blasticidin resistance gene BlastR was PCR amplified from LMNI 
using primers NT197 and NT198, then digested with AbsI and XmaI. These three 
fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to form PPGK-
BlastR-WPRE. In this construct, the XhoI site at the 5’ end of BlastR was mutated by 
SDM using primers NT438 and NT439, and the XmaI site at the 3’ end of BlastR was 
mutated by SDM using primers NT440 and NT441. The resulting ~1.7 kilobase-pair 
(kbp) XbaI/KpnI fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX 
Phi. Primers NT454 and NT455 were annealed to each other and then ligated into the 
XbaI/BamHI sites of the vector to further improve the MCS. 
pLVX Hhi3. The PGK promoter sequence of pLVX Puro was amplified using 
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE 
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then 
digested with AbsI and KpnI. The Hygromycin resistance gene HygroR was PCR 
amplified from pLHCX using primers NT195 and NT196, then digested with AbsI and 
XmaI. These three fragments were assembled between the XbaI and KpnI sites of 
pSL1180.1 to form PPGK-HygroR-WPRE. The EcoRI site within the HygroR gene was 
mutated by SDM using primers NT432 and NT433. The AsiSI site within the HygroR 
gene was mutated by SDM using primers NT434 and NT435. The mutations are silent. 
The XhoI site at the 5’ end of the HygroR gene was mutated by SDM using primers 
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NT442 and NT443. The XmaI site at the 3’ end of the HygroR gene of was mutated by 
SDM using primers NT444 and NT445. The resulting ~2.3 kbp XbaI/KpnI fragment was 
ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi. Primers NT454 and NT455 
were annealed to each other and then ligated into the XbaI/BamHI sites of the vector to 
further improve the MCS. 
pLVX Nhi3 The PGK promoter sequence of pLVX Puro was amplified using 
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE 
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then 
digested with AbsI and KpnI. The Neomycin resistance gene NeoR was PCR amplified 
from pLNCX2 using primers NT193 and NT194 and digested with AbsI and XmaI. 
These three fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to 
form PPGK-NeoR-WPRE. The XhoI site at the 5’ end of the NeoR gene of was mutated 
by SDM using primers NT446 and NT447. The XmaI site at the 3’ end of the NeoR gene 
was mutated by SDM using primers NT448 and NT449. The resulting ~2.1 kbp 
XbaI/KpnI fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi. 
Primers NT454 and NT455 were annealed to each other and then ligated into the 
XbaI/BamHI sites of the vector to further expand the MCS. 
pLVX Zhi3. The PGK promoter sequence of pLVX Puro was amplified using 
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE 
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then 
digested with AbsI and KpnI.  The Zeocin resistance gene ZeoR of pLenti4/V5-Dest was 
PCR amplified using primers NT321 and NT322, then digested with AbsI and AgeI. 
These three fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to 
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form PPGK-ZeoR-WPRE. The XmaI site within the ZeoR gene was mutated by SDM 
using primers NT436 and NT437. The mutation is silent. The XhoI site at the 5’ end of 
the ZeoR gene was mutated by SDM using primers NT452 and NT453. The resulting 
~1.6 kbp XbaI/KpnI fragment of pSL1180 PPGK -ZeoR-WPRE was ligated into the ~6.3 
kbp XbaI/KpnI backbone of pLVX Phi. Primers NT454 and NT455 were annealed to 
each other and then ligated into the XbaI/BamHI sites of the vector to further expand the 
MCS. 
pLVX Che-hi3. The PGK promoter sequence of pLVX Puro was amplified using 
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE 
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then 
digested with AbsI and KpnI.  The two fragments were assembled between the XbaI and 
KpnI sites of pSL1180.1 to form PPGK-WPRE. Next mCherry was amplified from 
pmCherry-N1 using primers Inf-For and Inf-Rev and inserted into the XmaI-digested site 
of the PPGK-WPRE fragment using an InFusion reaction. The ~2.0 kbp XbaI/KpnI 
resulting fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi3. 
Table 2.2 DNA oligonucleotide primer sequences 
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2.3. Lentiviral constructs for constitutive expression  
I wish to acknowledge the help that I received in making some of these 
constructs, primarily from Caroline Gleason, but also from Colin Belanger. Some of the 
lentiviral vectors listed below and in Table 2.1 were given an identifier starting with the 
letters "OL". These two letters stand for "Organelle Lentivirus" and signify that these 
vectors need to be packaged into lentiviral particles using a human immunodeficiency 
virus 1 (HIV-1)-based packaging system.  
pLVX Phi3 FLuc and pLVX Bhi3 FLuc The firefly (Photinus pyralis) luciferin 
4-monooxygenase (FLuc) was amplified using primers NT775 and NT776 from pRetroX 
TRE3G-Luc, digested with MluI and BamHI and ligated into the MluI/BamHI sites of 
pLVX Phi3 or pLVX Bhi3, respectively. 
pLVX Phi3 mCherry. The ~0.7 kbp EcoRI/NotI fragment from pmCherry-N1 
was ligated into the EcoRI/NotI sites of pLVX Phi3. 
OL135 pLVX Phi3 mCherry-Rab1b. Rab1b cDNA was amplified from pCMV-
SPORT6 Rab1b using primers NT472 and NT473 and digested with AvrII and BamHI; 
mCherry was amplified from pmCherry-N1 using primers NT358 and NT693 and 
digested with MluI and AvrII). The fragments were assembled within the MluI/BamHI 
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sites of pLVX Phi3. OL115 pLVX Phi3 mCherry-Rab1bQ67L. Primers NT653 and 
NT654 were used to introduce the Q67L mutation into the Rab1b sequence by SDM. 
OL142 pLVX Phi3 mCherry-Rab1bS22N. Primers NT700 and NT701 were used to 
introduce the S22N mutation into the Rab1b sequence by SDM. OL143 pLVX Phi3 
mCherry-Rab1bN121I. Primers NT702 and NT703 were used to introduce the N121I 
mutation into the Rab1b sequence by SDM.  
pLVX Hhi3 ApoE3. A DNA sequence encoding an shRNA-resistant version of 
ApoE3 was chemically synthesized, PCR-amplified using NT628 and NT636, digested 
with MluI and BamHI and inserted into the MluI/BamHI sites of pLVX Hhi3. The silent 
mutations present in this ApoE3 cDNA created a mismatch with the shRNA sequence 
encoded by pLKO.1 shApoE (Clone ID TRCN0000010913, Broad Institute's Genetic 
Perturbation Platform).  
pLVX Hhi3 ApoE3-mEGFP. ApoE3 (shRNAres) was amplified with NT117 
and NT637, digested with KpnI and BamHI and inserted into the KpnI/BamHI sites of 
pmEGFP-N1. ApoE3-mEGFP was then amplified using NT628 and NT644, digested 
with MluI and XbaI and cloned into the MluI/XbaI sites of pLVX Hhi3.  
pLVX Phi3 mEGFP-ApoE3. The following fragments were assembled into the 
cloning vector pSL1180: a sequence encoding amino acids 1-22 of calnexin (its signal 
peptide) was amplified using NT356  and NT357 from pCMV6-XL5 Calnexin and 
digested with MluI and EagI; mEGFP (monomeric enhanced green fluorescent protein) 
was amplified from pmEGFP-N1 using primers NT344 and NT358 and digested with 
EagI and AvrII; mature ApoE3 coding sequence (amino acids 1 through 299) was 
amplified with NT635 and NT636 and digested with AvrII and BamHI. The resulting 
 
75 
signal peptide-mEGFP-ApoE3 was excised using MluI and BamHI and inserted into the 
MluI/BamHI sites of pLVX Phi3.  
OL175 pLVX Che-hi3 Rab1a. Rab1a sequence (obtained from pCMV-Sport6 
Rab1a) was PCR amplified using primers NT487 and NT781, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL 176 pLVX Che-hi3 
Rab1aN124I. SDM was performed on OL175 using primers NT698 and NT699. 
OL177 pLVX Che-hi3 Rab1b. Rab1b was amplified from OL135 using primers 
NT473 and NT782, digested with MluI and BamHI and ligated into the MluI/BamHI 
sites of pLVX Che-hi3. OL178 pLVX Che-hi3 Rab1bN121I. Rab1bN121I was amplified 
from OL143 using primers NT473 and NT782, digested with MluI and BamHI and 
ligated into the MluI/BamHI sites of pLVX Che-hi3. OL249 pLVX Che-hi3 Rab1bQ67L. 
Rab1bQ67L was amplified from OL115 using primers NT473 and NT782, digested with 
MluI and BamHI and ligated into the MluI/BamHI sites of pLVX Che-hi3. OL250 
pLVX Che-hi3 Rab1bS22N. Rab1bS22N was amplified from OL142 using primers NT473 
and NT782, digested with MluI and BamHI and ligated into the MluI/BamHI sites of 
pLVX Che-hi3.  
OL179 pLVX Che-hi3 Rab1c/35. Rab1c sequence was PCR amplified from 
pCMV-Sport6/Rab1c/35 using primers NT783 and NT784, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL180 pLVX Che-hi3 
Rab1c/35N120I. SDM was performed on OL179 using primers NT832 and NT833. 
OL181 pLVX Che-hi3 Rab2A. Rab2a sequence (obtained from pOTB7-Rab2a) 
was PCR amplified using primers NT465 and NT785, digested with MluI and BamHI 
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and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL182 pLVX Che-hi3 
Rab2aN119I. SDM was performed on OL181 using primers NT834 and NT835. 
OL183 pLVX Che-hi3 Rab3a. Rab3a sequence was PCR amplified from 
pLX304 Rab3a using primers NT786 and NT787, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL184 pLVX Che-hi3 Rab3aN135I. 
SDM was performed on OL183 using primers NT836 and NT837. 
OL185 pLVX Che-hi3 Rab3b. Rab3b sequence was PCR amplified from 
pOTB7-Rab3b using primers NT788 and NT789, digested with EcoRI and BamHI and 
cloned into the EcoRI/BamHI sites of pLVX Che-hi3. OL186 pLVX Che-hi3 
Rab3bN135I. SDM was performed on OL185 using primers NT838 and NT839. 
OL187 pLVX Che-hi3 Rab3c. Rab3c sequence was PCR amplified from 
pLX304 Rab3c  using primers NT790 and NT791, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL188 pLVX Che-hi3 Rab3cN143I. 
SDM was performed on OL187 using primers NT840 and NT841. 
OL189 pLVX Che-hi3 Rab3d/16. Rab3d/16 sequence (from pCMV-Sport6 
Rab3d) was PCR amplified using primers NT567 and NT792, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL190 pLVX Che-hi3 
Rab3d/16N135I. SDM was performed on OL189 with primers NT842 and NT843. 
OL191 pLVX Che-hi3 Rab4a. Rab4a sequence was PCR amplified from 
pLX304 Rab4a  using primers NT793 and NT794, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL192 pLVX Che-hi3 Rab4aN126I. 
SDM was performed on OL191 using primers NT844 and NT845. 
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OL193 pLVX Che-hi3 Rab5a. Rab5a sequence (obtained from pCDNA5 Flag3-
Rab5a) was PCR amplified using primers NT483 and NT795, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL194 pLVX Che-hi3 
Rab5aN133I. SDM was performed on OL193 using primers NT755 and NT756. 
OL195 pLVX Che-hi3 Rab6a. Rab6a sequence was PCR amplified from 
pOTB7-Rab6a using primers NT796 and NT797, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL196 pLVX Che-hi3 Rab6aN126I. 
SDM was performed on OL195 using primers NT846 and NT847. 
OL197 pLVX Che-hi3 Rab7b. Rab7b sequence was PCR amplified from 
pLX304 Rab7b using primers NT798 and NT799, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL198 pLVX Che-hi3 Rab7bN124I. 
SDM was performed on OL197 using primers NT848 and NT849. 
OL199 pLVX Che-hi3 Rab8a. Rab8a sequence was PCR amplified from 
pOTB7-Rab8a using primers NT800 and NT801, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL200 pLVX Che-hi3 Rab8aN121I. 
SDM was performed on OL199 using primers NT850 and NT851. OL319 pLVX Che-
hi3 Rab8aQ67L. SDM was performed on OL199 using primers NT978 and NT979. 
OL320 pLVX Che-hi3 Rab8aT22N. SDM was performed on OL199 using primers 
NT980 and NT981. 
OL201 pLVX Che-hi3 Rab8b. Rab8b sequence (obtained from pDNR-LIB-
Rab8b) was PCR amplified using primers NT459 and NT802, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL202 pLVX Che-hi3 
Rab8bN121I. SDM was performed on OL201 using primers NT852 and NT853. OL321 
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pLVX Che-hi3 Rab8bQ67L. SDM was performed on OL201 using primers NT667 and 
NT668. OL322 pLVX Che-hi3 Rab8bT22N. SDM was performed on OL201 using 
primers NT982 and NT983. 
OL203 pLVX Che-hi3 Rab9a. Rab9a sequence was PCR amplified from 
pLX304 Rab9a  using primers NT803 and NT804, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL204 pLVX Che-hi3 Rab9aN124I. 
SDM was performed on OL203 using primers NT854 and NT855. 
OL205 pLVX Che-hi3 Rab10. Rab10 sequence was PCR amplified from 
pCMV-XL5/Rab10 using primers NT805 and NT806, digested with MluI and BamHI 
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL206 pLVX Che-hi3 
Rab10N122I. SDM was performed on OL205 using primers NT856 and NT857.  
OL207 pLVX Che-hi3 Rab11a. Rab11a sequence (obtained from pEGFP-
Rab11aWT) was PCR amplified using primers NT485 and NT807, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL208 pLVX 
Che-hi3 Rab11aN124I. SDM was performed on OL207 using primers NT858 and NT859. 
OL313 pLVX Che-hi3 Rab11aQ70L. SDM was performed on OL207 using primers 
NT669 and NT670. OL314 pLVX Che-hi3 Rab11aS25N. SDM was performed on OL207 
using primers NT972 and NT973.  
OL209 pLVX Che-hi3 Rab11b. Rab11b sequence (obtained from pCR-BluntII-
Topo/Rab11b) was PCR amplified using primers NT479 and NT808, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL210 pLVX 
Che-hi3 Rab11bN124I. SDM was performed on OL209 using primers NT860 and NT861. 
OL315 pLVX Che-hi3 Rab11bQ70L. SDM was performed on OL209 using primers 
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NT671 and NT672. OL316 pLVX Che-hi3 Rab11bS25N. SDM was performed on OL209 
using primers NT974 and NT975. 
OL211 pLVX Che-hi3 Rab11c/25. Rab11c/25 sequence (from pOTB7 
Rab11c/25) was amplified using primers NT491 and NT809, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL212 pLVX Che-hi3 
Rab11c/25N125I. SDM was performed on OL211 with primers NT862 and NT863. 
OL213 pLVX Che-hi3 Rab12. Rab12 sequence was PCR amplified from 
pCMV-XL5/Rab12 using primers NT829 and NT830, digested with EcoRI and AvrII and 
cloned into the EcoRI/AvrII sites of pLVX Che-hi3. OL214 pLVX Che-hi3 Rab12N155I. 
SDM was performed on OL213 using primers NT866 and NT867. 
OL215 pLVX Che-hi3 Rab13. Rab13 sequence (obtained from pCMV-
Sport6/Rab13) was PCR amplified using primers NT477 and NT810, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL216 pLVX 
Che-hi3 Rab13N121I. SDM was performed on OL215 using primers NT868 and NT869. 
OL217 pLVX Che-hi3 Rab14. Rab14 sequence was PCR amplified from 
pLX304 Rab14  using primers NT811 and NT812, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL218 pLVX Che-hi3 Rab14N124I. 
SDM was performed on OL217 using primers NT870 and NT871. 
OL219 pLVX Che-hi3 Rab18. Rab18 sequence was PCR amplified from 
pEGFP-Rab18 using primers NT813 and NT814, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL220 pLVX Che-hi3 Rab18N122I. 
SDM was performed on OL219 using primers NT872 and NT873. 
 
80 
OL221 pLVX Che-hi3 Rab19b. Rab19b sequence was PCR amplified from 
pLX304 Rab19b  using primers NT815 and NT816, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. The E12STOP mutation from the 
template was reverted by SDM using primers NT894 and NT895. OL222 pLVX Che-
hi3 Rab19bN130I. SDM was performed on OL221 using primers NT874 and NT875. 
OL223 pLVX Che-hi3 Rab22b/31. Rab22b/31 sequence (obtained from pOTB7-
Rab22b/31) was amplified using primers NT493 and NT817, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL224 pLVX Che-hi3 
Rab22b/31N119I. SDM was performed on OL223 with primers NT876 and NT877. 
OL225 pLVX Che-hi3 Rab23. Rab23 sequence (obtained from pCMV-Sport6 
Rab23) was PCR amplified using primers NT468 and NT469, digested with AvrII and 
SalI and cloned into the AvrII/SalI sites of pSL1180. The BamHI site within the Rab23 
coding sequence was mutagenized using primers NT516 and NT517. The resulting 
mutation is silent. The product was amplified with NT469 and NT818, digested with 
MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL226 pLVX 
Che-hi3 Rab23N121I. SDM was performed on OL225 with primers NT878 and NT879. 
OL227 pLVX Che-hi3 Rab26. Rab26 sequence was PCR amplified from 
pLX304 Rab26 using primers NT819 and NT820, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL228 pLVX Che-hi3 Rab26N177I. 
SDM was performed on OL227 using primers NT880 and NT881. 
OL229 pLVX Che-hi3 Rab27a. Rab27a sequence (obtained from pCMV-
Sport6/Rab27a) was PCR amplified using primers NT471 and NT821, digested with 
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MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL230 pLVX 
Che-hi3 Rab27aN133I. SDM was performed on OL229 using primers NT882 and NT883. 
OL231 pLVX Che-hi3 Rab27b. Rab27b sequence (obtained from pCMV-
Sport6/Rab27b) was PCR amplified using primers NT495 and NT822, digested with 
MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL232 pLVX 
Che-hi3 Rab27bN133I. SDM was performed on OL231 using primers NT884 and NT885. 
OL233 pLVX Che-hi3 Rab32. Rab32 sequence (obtained from pDNR-
LIB/Rab32) was PCR amplified using primers NT461 and NT823, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL234 pLVX 
Che-hi3 Rab32N143I. SDM was performed on OL233 using primers NT886 and NT887. 
OL235 pLVX Che-hi3 Rab33a. Rab33a sequence (from pOTB7-Rab33a) was 
PCR amplified using primers NT466 and NT467, digested with AvrII and EcoRI and 
cloned into the AvrII/EcoRI sites of pSL1180. The BamHI site within the Rab33a coding 
sequence was mutagenized using primers NT514 and NT515. The resulting mutation is 
silent. The product was amplified using NT467 and NT824, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL236 pLVX Che-hi3 
Rab33aN151I. SDM was performed on OL235 with primers NT888 and NT889. 
OL237 pLVX Che-hi3 Rab39a. Rab39a sequence was PCR amplified from 
pLX304 Rab39a using primers NT825 and NT826, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL238 pLVX Che-hi3 
Rab39aH127I. SDM was performed on OL237 using primers NT890 and NT891. 
OL239 pLVX Che-hi3 Rab40a. Rab40a sequence was PCR amplified from 
pLX304 Rab40a using primers NT827 and NT828, digested with MluI and BamHI and 
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cloned into the MluI/BamHI sites of pLVX Che-hi3. OL240 pLVX Che-hi3 
Rab40aN126I. SDM was performed on OL239 using primers NT892 and NT893. 
OL251 pLVX Che-hi3 Rab2b. Rab2b sequence (obtained from pDNR-
LIB/Rab2b) was PCR amplified using primers NT489 and NT899, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL252 pLVX 
Che-hi3 Rab2bN119I. SDM was performed on OL251 using primers NT996 and NT997. 
OL253 pLVX Che-hi3 Rab4b. Rab4b sequence (obtained from pOTB7-Rab4b) 
was PCR amplified using primers NT903 and NT904, digested with AvrII and EcoRI and 
cloned into the AvrII/EcoRI sites of pLVX Che-hi3. OL254 pLVX Che-hi3 Rab4bN121I. 
SDM was performed on OL253 using primers NT998 and NT999. 
OL255 pLVX Che-hi3 Rab5b. Rab5b sequence (obtained from pCMV-
Sport6/Rab5b) was PCR amplified using primers NT481 and NT900, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL256 pLVX 
Che-hi3 Rab5bN133I. SDM was performed on OL255 with primers NT1000 and NT1001. 
OL257 pLVX Che-hi3 Rab5c. Rab5c sequence (obtained from pCMV-
Sport6/Rab5c) was PCR amplified using primers NT475 and NT901, digested with MluI 
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL258 pLVX 
Che-hi3 Rab5cN134I. SDM was performed on OL257 with primers NT1002 and NT1003. 
OL259 pLVX Che-hi3 Rab6b. Rab6b sequence was PCR amplified from 
pLX304 Rab6b  using primers NT905 and NT906, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL260 pLVX Che-hi3 Rab6bN126I. 
SDM was performed on OL259 using primers NT1004 and NT1005. 
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OL261 pLVX Che-hi3 Rab6c. Rab6c sequence was PCR amplified from 
pLX304 Rab6c using primers NT907 and NT908, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. The A159T mutation from the 
template was reverted by SDM using primers NT964 and NT965. OL262 pLVX Che-
hi3 Rab6cN126I. SDM was performed on OL261 using primers NT1006 and NT1007. 
OL263 pLVX Che-hi3 Rab7a. Rab7a sequence was PCR amplified from 
pOTB7-Rab7a using primers NT909 and NT910, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL264 pLVX Che-hi3 Rab7aN125I. 
SDM was performed on OL263 using primers NT1008 and NT1009. 
OL265 pLVX Che-hi3 Rab9b. Rab9b sequence was PCR amplified from 
pLX304 Rab9b using primers NT911 and NT912, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL266 pLVX Che-hi3 Rab9bN124I. 
SDM was performed on OL265 using primers NT1010 and NT1011. 
OL267 pLVX Che-hi3 Rab15. Rab15 sequence was PCR amplified from 
pBlueScriptR-Rab15 using primers NT913 and NT914, digested with EcoRI and BamHI 
and cloned into the EcoRI/BamHI sites of pLVX Che-hi3. OL268 pLVX Che-hi3 
Rab15T22N. SDM was performed on OL267 using primers NT1012 and NT1013. 
OL269 pLVX Che-hi3 Rab17. Rab17 sequence was PCR amplified from 
pLX304 Rab17 using primers NT915 and NT916, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL270 pLVX Che-hi3 Rab17N132I. 
SDM was performed on OL269 using primers NT1014 and NT1015. 
OL271 pLVX Che-hi3 Rab20. Rab20 sequence was PCR amplified from 
pLX304 Rab20 using primers NT917 and NT918, digested with MluI and BamHI and 
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cloned into the MluI/BamHI sites of pLVX Che-hi3. OL272 pLVX Che-hi3 Rab20N113I. 
SDM was performed on OL271 using primers NT1016 and NT1017. 
OL273 pLVX Che-hi3 Rab21. Rab21 sequence was PCR amplified from 
pCMV-Sport6/Rab21 using primers NT919 and NT920, digested with MluI and BamHI 
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL274 pLVX Che-hi3 
Rab21N132I. SDM was performed on OL273 using primers NT1018 and NT1019. 
OL275 pLVX Che-hi3 Rab22a. Rab22a sequence was PCR amplified from 
pCMV-Sport6/Rab22a using primers NT921 and NT922, digested with MluI and BamHI 
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL276 pLVX Che-hi3 
Rab22aN118I. SDM was performed on OL275 using primers NT1020 and NT1021. 
OL277 pLVX Che-hi3 Rab24. Rab24 sequence was PCR amplified from 
pOTB7-Rab24 using primers NT923 and NT924, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL278 pLVX Che-hi3 Rab24T120I. 
SDM was performed on OL277 using primers NT1022 and NT1023. 
OL279 pLVX Che-hi3 Rab28. Rab28-coding sequence was synthesized 
(Genewiz) in the pUC-Kan vector. Rab28 was excised using MluI and BamHI and cloned 
into the MluI/BamHI sites of pLVX Che-hi3. OL280 pLVX Che-hi3 Rab28N129I. SDM 
was performed on OL279 using primers NT1024 and NT1025. 
OL281 pLVX Che-hi3 Rab29/7L1. Rab29/7L1 sequence was PCR amplified 
from pLX304 Rab7L1 using primers NT927 and NT928, digested with MluI and BamHI 
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL282 pLVX Che-hi3 
Rab29/7L1N125I. SDM was performed on OL281 using primers NT1026 and NT1027. 
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OL283 pLVX Che-hi3 Rab30. Rab30 sequence was PCR amplified from 
pLX304 Rab30 using primers NT929 and NT930, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL284 pLVX Che-hi3 Rab30N122I. 
SDM was performed on OL283 using primers NT1028 and NT1029. 
OL285 pLVX Che-hi3 Rab33b. Rab33b sequence (obtained from pBlueScriptR-
Rab33b) was PCR amplified using primers NT463 and NT902, digested with MluI and 
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL286 pLVX Che-hi3 
Rab33bN148I. SDM was performed on OL285 using primers NT1030 and NT1031. 
OL287 pLVX Che-hi3 Rab34. Rab34 sequence was PCR amplified from 
pLX304 Rab34  using primers NT931 and NT932, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. The S244N mutation from the 
template was reverted by SDM using primers NT1054 and NT1055. OL288 pLVX Che-
hi3 Rab34S166I. SDM was performed on OL287 using primers NT1032 and NT1033. 
OL289 pLVX Che-hi3 Rab36. Rab36 sequence was PCR amplified from pCR-
TOPO/Rab36 using primers NT933 and NT934, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL290 pLVX Che-hi3 Rab36T237I. 
SDM was performed on OL289 using primers NT1034 and NT1035. 
OL291 pLVX Che-hi3 Rab37. Rab37 sequence was PCR amplified from 
pLX304 Rab37 using primers NT935 and NT936, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL292 pLVX Che-hi3 Rab37N143I. 
SDM was performed on OL291 using primers NT1036 and NT1037. 
OL293 pLVX Che-hi3 Rab38. Rab38 sequence was PCR amplified from 
pCMV-Sport6/Rab38 using primers NT937 and NT938, digested with MluI and BamHI 
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and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL294 pLVX Che-hi3 
Rab38N127I. SDM was performed on OL293 using primers NT1038 and NT1039. 
OL295 pLVX Che-hi3 Rab39b. Rab39b sequence was PCR amplified from 
pLX304 Rab39b using primers NT939 and NT940, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL296 pLVX Che-hi3 
Rab39bH123I. SDM was performed on OL295 using primers NT1040 and NT1041. 
OL297 pLVX Che-hi3 Rab40al. Rab40al sequence was PCR amplified from 
pLX304 Rab40al using primers NT941 and NT942, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL298 pLVX Che-hi3 
Rab40alN126I. SDM was performed on OL297 using primers NT1042 and NT1043. 
OL299 pLVX Che-hi3 Rab40b. Rab40b sequence was PCR amplified from 
pLX304 Rab40b using primers NT943 and NT944, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. The P42T mutation from the 
template was reverted by SDM using primers NT966 and NT967. OL300 pLVX Che-
hi3 Rab40bN126I. SDM was performed on OL299 using primers NT1044 and NT1045. 
OL301 pLVX Che-hi3 Rab40c. Rab40c sequence was PCR amplified from 
pLX304 Rab40c using primers NT945 and NT946, digested with EcoRI and AvrII and 
cloned into the EcoRI/AvrII sites of pLVX Che-hi3. The K64R mutation from the 
template was reverted by SDM using primers NT968 and NT969. OL302 pLVX Che-
hi3 Rab40cN126I. SDM was performed on OL301 using primers NT1046 and NT1047. 
OL303 pLVX Che-hi3 Rab41. Rab41 sequence was PCR amplified from 
pLX304 Rab41 using primers NT947 and NT948, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. The S193P mutation from the 
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template was reverted by SDM using primers NT960 and NT961. OL304 pLVX Che-
hi3 Rab41N143I. SDM was performed on OL303 using primers NT1048 and NT1049. 
OL305 pLVX Che-hi3 Rab42. Rab42-coding sequence was synthesized 
(Genewiz) in the pUC-Kan vector. Rab42 was excised using MluI and BamHI and cloned 
into the MluI/BamHI sites of pLVX Che-hi3. OL306 pLVX Che-hi3 Rab42H129I. SDM 
was performed on OL305 using primers NT1050 and NT1051. 
OL307 pLVX Che-hi3 Rab43. Rab43 sequence was PCR amplified from 
pOTB7-Rab43 using primers NT951 and NT952, digested with MluI and BamHI and 
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL308 pLVX Che-hi3 Rab43N131I. 
SDM was performed on OL307 using primers NT1052 and NT1053. 
2.4. Retroviral constructs for inducible expression 
Some of the retroviral vectors listed below and in Table 2.1 were given an 
identifier starting with the letters "OR". These two letters stand for "Organelle 
Retrovirus" and signify that these vectors need to be packaged into retroviral particles 
using a murine leukemia virus (MLV)-based packaging system. 
pRetroX TRE3G-mCherry. The ~0.7 kbp BamHI/NotI fragment from 
pmCherry-N1 was ligated into the BamHI/NotI sites of pRetroX TRE3G (Clontech). 
OR366 pRetroX TRE3G-mEGFP. The ~0.7 kbp BamHI/NotI fragment from pmEGFP-
N1 was ligated into the BamHI/NotI sites of pRetroX TRE3G. 
OR161 pRetroX TRE3G-mCherry-Rab1b. mCherry-Rab1b was amplified 
from OL135 with primers NT729 and NT731, digested with BamHI/NotI, and ligated 
into the BamHI/NotI sites of pRetroX TRE3G. OR162 pRetroX TRE3G-mCherry-
Rab1bQ67L. mCherry-Rab1bQ67L was amplified from OL115 with primers NT729 and 
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NT731, digested with BamHI/NotI, and ligated into the BamHI/NotI sites of pRetroX 
TRE3G. OR163 pRetroX TRE3G-mCherry-Rab1bS22N. mCherry-Rab1bS22N was 
amplified from OL142 with primers NT729 and NT731, digested with BamHI/NotI, and 
ligated into the BamHI/NotI sites of pRetroX TRE3G. OR164 pRetroX TRE3G-
mCherry-Rab1bN121I. mCherry-Rab1bN121I was amplified from OL143 with primers 
NT729 and NT731, digested with BamHI/NotI, and ligated into the BamHI/NotI sites of 
pRetroX TRE3G.  
OR332 pRetroX TRE3G mCherry-Rab11a. OR333 pRetroX TRE3G 
mCherry-Rab11aN124I. OR334 pRetroX TRE3G mCherry-Rab11aQ70L. OR336 
pRetroX TRE3G mCherry-Rab11aS25N. mCherry was amplified from pmCherry-N1 
using NT358 and NT729 and digested with BamHI and AvrII. Rab11a (WT and mutant) 
sequences were amplified from OL207, OL208, OL313 or OL314 using NT484 and 
NT1123, and digested with AvrII and NotI. The resulting mCherry and Rab11a fragments 
were assembled into the BamHI/NotI sites of pRetroX TRE3G. 
OR337 pRetroX TRE3G mCherry-Rab11b. OR338 pRetroX TRE3G 
mCherry-Rab11bN124I. OR340 pRetroX TRE3G mCherry-Rab11bQ70L. OR341 
pRetroX TRE3G mCherry-Rab11bS25N. mCherry was amplified from pmCherry-N1 
using NT358 and NT729 and digested with BamHI and AvrII. Rab11b (WT and mutant) 
sequences were amplified from OL209, OL210, OL315 or OL316 using NT478 and 
NT1124, and digested with AvrII and NotI. The resulting mCherry and Rab11b 
fragments were assembled into the BamHI/NotI sites of pRetroX TRE3G. 
OR342 pRetroX TRE3G mCherry-Rab8a. OR344 pRetroX TRE3G 
mCherry-Rab8aN121I. OR345 pRetroX TRE3G mCherry-Rab8aQ67L. OR346 
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pRetroX TRE3G mCherry-Rab8aT22N. mCherry was amplified from pmCherry-N1 
using NT358 and NT729 and digested with BamHI and AvrII. Rab8a (WT and mutant) 
sequences were amplified from OL199, OL200, OL319 or OL320 using NT991 and 
NT1125, and digested with AvrII and NotI. The resulting mCherry and Rab8a fragments 
were assembled into the BamHI/NotI sites of pRetroX TRE3G. 
OR348 pRetroX TRE3G mCherry-Rab8b. OR349 pRetroX TRE3G 
mCherry-Rab8bN121I. OR350 pRetroX TRE3G mCherry-Rab8bQ67L. OR356 
pRetroX TRE3G mCherry-Rab8bT22N. mCherry was amplified from pmCherry-N1 
using NT358 and NT729 and digested with BamHI and AvrII. Rab8b (WT and mutant) 
sequences were amplified from OL201, OL202, OL321 or OL322 using NT458 and 
NT1126, and digested with AvrII and NotI. The resulting mCherry and Rab8b fragments 
were assembled into the BamHI/NotI sites of pRetroX TRE3G. 
OR367 pRetroX TRE3G-GFP-DrrA61-647. L. pneumophila GFP-DrrA61-647 was 
amplified from pGFP-DrrA61-647 using NT729 and NT1069, digested with BamHI/EcoRI 
and ligated into the BamHI/EcoRI sites of pRetroX TRE3G.  
2.5. Mammalian cell lines: derivation, selection and growth 
The cell lines used in this work, the retroviral and lentiviral vectors used for their 
construction and their antibiotic resistances are listed in Table 2.3. Briefly, human 
hepatocellular carcinoma Huh-7.5 cells (Blight et al., 2002), Huh-7.5-derived cells, 
human epithelial adenocarcinoma HeLa cells, and human embryonic kidney HEK293T 
cells were grown in Dulbecco's Modified Eagle's Medium (DMEM, Gibco), 
supplemented with L-glutamine, sodium pyruvate, 0.1 mM non-essential amino-acids 
(from here-on referred to as DMEM+) and 10% fetal bovine serum (FBS, Sigma or 
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HyClone) in humidified incubators at 37°C and in a 5% CO2 atmosphere. Antibiotic 
selection of transduced Huh-7.5-derived cell lines employed puromycin (2 μg/mL), 
G418/geneticin (500 μg/mL), hygromycin (150 μg/mL) or blasticidin (6 μg/mL). HeLa 
cells were selected using puromycin (1 μg/mL) or hygromycin (250 μg/mL). The 
antibiotics were from Sigma or Invivogen. Selection was started two days after 
transduction and was maintained throughout subsequent growth. I wish to thank Caroline 
Gleason and Jenna Lobby for their help in determining the antibiotic selection conditions 
employed throughout this work. 
Table 2.3. Cell lines 
Cell line Parental 
Cell Line 






HEK293T N/A N/A G418 P. 
Bieniasz 
Huh-7.5 N/A N/A none (Blight et 
al., 2002) 
Huh-7.5 FLuc Huh-7.5 pLVX Phi3 FLuc Puro This Study 
Huh-7.5 TetON 
(Clone 9, Cl9) 
Huh-7.5 pRetroX Tet3G G418 (Luna et 
al., 2015) 
Huh-7.5 TetON 
(Clone 1, Cl1) 
Huh-7.5 pRetroX Tet3G G418 This Study 
Huh-7.5 TetON 
(Clone 2, Cl2) 
Huh-7.5 pRetroX Tet3G G418 This Study 
Huh-7.5 TetON 
(Clone 4, Cl4) 
Huh-7.5 pRetroX Tet3G G418 This Study 
Huh-7.5 TetON 
(Clone 12, Cl12) 
Huh-7.5 pRetroX Tet3G G418 This Study 
Cl9 FLuc Cl9 pLVX Bhi3 FLuc Blast; 
G418 
This Study 
Cl9 OR161 Cl9 OR161 pRetroX TRE3G-
mCherry-Rab1B 
Puro; G418 This Study 
Cl9 OR161 FLuc Cl9 
OR161 




Cl9 OR162 Cl9 OR162 pRetroX TRE3G-
mCherry-Rab1BQ67L 
Puro; G418 This Study 
Cl9 OR162 FLuc Cl9 
OR162 






Table 2.3. Cell lines 
Cell line Parental 
Cell Line 






Cl9 OR163 Cl9 OR163 pRetroX TRE3G-
mCherry-Rab1BS22N 
Puro; G418 This Study 
Cl9 OR163 FLuc Cl9 
OR163 




Cl9 OR164 Cl9 OR164 pRetroX TRE3G-
mCherry-Rab1BN121I 
Puro; G418 This Study 
Cl9 OR164 FLuc Cl9 
OR164 
















Cl9 OR332 Cl9 OR332 pRetroX TRE3G 
mCherry-Rab11a 
Puro; G418 This Study 
Cl9 OR333 Cl9 OR333 pRetroX TRE3G 
mCherry-Rab11aN124I 
Puro; G418 This Study 
Cl9 OR334 Cl9 OR334 pRetroX TRE3G 
mCherry-Rab11aQ70L 
Puro; G418 This Study 
Cl9 OR336 Cl9 OR336 pRetroX TRE3G 
mCherry-Rab11aS25N 
Puro; G418 This Study 
Cl9 OR337 Cl9 OR337 pRetroX TRE3G 
mCherry-Rab11b 
Puro; G418 This Study 
Cl9 OR338 Cl9 OR338 pRetroX TRE3G 
mCherry-Rab11bN124I 
Puro; G418 This Study 
Cl9 OR340 Cl9 OR340 pRetroX TRE3G 
mCherry-Rab11bQ70L 
Puro; G418 This Study 
Cl9 OR341 Cl9 OR341 pRetroX TRE3G 
mCherry-Rab11bS25N 
Puro; G418 This Study 
Cl9 OR342 Cl9 OR342 pRetroX TRE3G 
mCherry-Rab8a 
Puro; G418 This Study 
Cl9 OR344 Cl9 OR344 pRetroX TRE3G 
mCherry-Rab8aN121I 
Puro; G418 This Study 
Cl9 OR345 Cl9 OR345 pRetroX TRE3G 
mCherry-Rab8aQ67L 
Puro; G418 This Study 
Cl9 OR346 Cl9 OR346 pRetroX TRE3G 
mCherry-Rab8aT22N 
Puro; G418 This Study 
Cl9 OR348 Cl9 OR348 pRetroX TRE3G 
mCherry-Rab8b 
Puro; G418 This Study 
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Table 2.3. Cell lines 
Cell line Parental 
Cell Line 






Cl9 OR349 Cl9 OR349 pRetroX TRE3G 
mCherry-Rab8bN121I 
Puro; G418 This Study 
Cl9 OR350 Cl9 OR350 pRetroX TRE3G 
mCherry-Rab8bQ67L 
Puro; G418 This Study 
Cl9 OR356 Cl9 OR356 pRetroX TRE3G 
mCherry-Rab8bT22N 
Puro; G418 This Study 
Huh-7.5/EV 
Hygro 
Huh-7.5 pLVX Hhi3 Hygro This Study 
Huh-7.5/ApoE-
GFP 
Huh-7.5 pLVX Hhi3 ApoE3-
mEGFP 
Hygro This Study 
EVKD Huh-7.5 pLKO.1 (EV) Puro M. Scull 










EKD1 Huh-7.5 pLKO.1 shApoE Puro M. Scull 
EKD1/EV Hygro EKD1 pLVX Hhi3 Puro; 
Hygro 
This Study 
EKD1/ApoE EKD1 pLVX Hhi3 ApoE3 Puro; 
Hygro 
This Study 





EKD2 Huh-7.5 pLKO.1 shApoE Puro M. Scull 
EKD2/EV Hygro EKD2 pLVX Hhi3 Puro; 
Hygro 
This Study 
EKD2/ApoE EKD2 pLVX Hhi3 ApoE3 Puro; 
Hygro 
This Study 





HeLa N/A N/A None P. 
Bieniasz 
HeLa/ApoE-GFP HeLa pLVX Hhi3 ApoE3-
mEGFP 
Hygro This Study 
HeLa/GFP-ApoE HeLa pLVX Phi3 mEGFP-
ApoE3 
Puro This Study 









Huh-7.5 TetON clonal cell lines. HCV-permissive Huh-7.5-derived clonal cell 
lines were engineered to constitutively express the TetON3G transactivator protein via 
transduction with retroviral particles generated using pRetroX Tet3G.  Transduced cells 
were selected with G418, then clonal cell lines were obtained by plating the selected 
population in 96-well plates at 0.5-0.8 cells/well. Six weeks later, 12 Huh-7.5 TetON 
single-clone-containing wells were expanded and characterized. The Huh-7.5 TetON 
clones were tested for permissivity to HCV infection and spread using the reporter virus 
Jc1 378-1-TagRFP (Christopher Jones). This HCV reporter is similar to Jc1 378-1-YPet 
(Horwitz et al., 2013), but expresses a NS5A-TagRFP fusion instead of a NS5A-YPet 
fusion. TagRFP is a red fluorescent protein (RFP) variant (Merzlyak et al., 2007), while 
YPet is a yellow fluorescent protein variant (Nguyen and Daugherty, 2005). The clones, 
alongside the parental Huh-7.5 cells, were infected with the RFP reporter HCV at a 
multiplicity of infection (MOI) of 0.1 tissue culture infectious dose 50 (TCID50) per cell. 
The cells were harvested at 30 h or at 72 h post infection, fixed, and the percentage of 
infected (RFP-positive) cells was determined by flow cytometry. Clones 1, 2, 4, 9 and 12 
were infected at levels comparable to the parental Huh-7.5 at both time points and were 
chosen for further characterization. To determine expression induction properties, each 
clone was transduced with retroviral particles made using pRetroX TRE3G-mCherry. 
Transduced populations were selected with G418 and Puromycin.  To determine a dose-
response induction curve for each TRE3G-mCherry-transduced TetON clone, decreasing 
3-fold serial dilutions of doxycycline (Clontech) were used, starting from a high dose of 
10 μg/mL. The cells were treated for 48 h then the mCherry fluorescence was quantified 
by flow cytometry (Figure 2.2A). Since induction of mCherry expression in all the clones 
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was found to near a plateau at about 3 μg/mL, this dose was used in all subsequent 
experiments. To determine the time-course of induction, the reporter-transduced clones 
were incubated with 3 μg/mL doxycycline for 0, 6, 12, 24, 36 or 48 h, and then the 
mCherry fluorescence was quantified by flow cytometry (Figure 2.2A-B). Growth rates 
were quantified using CyQuant NF Cell Proliferation Assay (Molecular Probes) for 
several days after plating 15,000 or 5,000 cells/well in 96-well plates. All clones had 
indistinguishable growth rates compared to the parental Huh-7.5, except for Clone 4, 
which had a 30% lower growth rate as measured at 96 h after plating. Based on these 
tests, Clone 9 was deemed to have the best properties in terms of permissivity to HCV 
infection, tightness and magnitude of induction in response to doxycycline, was therefore 









Figure 2.2. Characterization of Huh-7.5 TetON clonal cell lines. The Huh-7.5 TetON 
clones were transduced with a retrovirus expressing a doxycycline-inducible mCherry 
fluorescent protein reporter and the induction of gene expression was characterized by 
flow cytometry. (A) Doxycycline dose-response curve. Median fluorescence intensity 
values of populations of cells treated for 48 h with the indicated concentrations of 
doxycycline. A.U., arbitrary units. (B and C). Time course of induction. The cells were 
treated with 3 μg/mL doxycycline for the indicated amounts of time, then the mCherry 
fluorescence levels were quantified in single live cells by flow cytometry. (B) Data points 
represent the median single-cell mCherry fluorescence intensity levels in each sample. 
(C) Histograms of single cell mCherry fluorescence levels corresponding to the data 
points from panel B. 
 
Huh-7.5 ApoE knockdown cell clones. Stable clonal control knockdown and 
ApoE knockdown Huh-7.5 cell lines were generated by Dr. Margaret A. Scull. I am 
grateful to her for allowing me to use these cell lines. Huh-7.5 cells were transduced with 
lentivirus particles generated using empty vector pLKO.1, or pLKO.1 shApoE, which 
expresses an ApoE-targeting shRNA (clone ID=TRCN0000010913, Broad Institute's 
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Genetic Perturbation Platform).  The cells were selected using puromycin before 
undergoing single cell sorting into 96-well plates on a BD Aria2 Sorter at the Rockefeller 
University Flow Cytometry Core Facility.  Individual cell clones were expanded in 
DMEM+ supplemented with 10% FBS and 10 units/mL penicillin and 10 μg/mL 
streptomycin (Gibco) and screened for HCV pseudoparticle entry and HCV replication 
competence as well as ApoE knockdown by quantitative reverse transcription PCR (qRT-
PCR) and Western blotting. The empty vector-transduced clone was designated Huh-7.5 
EV KD, while the two ApoE knockdown clones were designated Huh-7.5 EKD1 and 
Huh-7.5 EKD2, respectively.  
2.6. Plasmid transfections 
Plasmid transfection of HEK293T cells was done by quickly vortexing plasmid 
DNA and polyethyleneimine (Polysciences Inc, stock at 1 mg/mL in water) at a ratio of 
1:4 in Optimem-I (Gibco, 10% of total media volume in the plate). The transfection mix 
was kept at room temperature for 10 min, then the media on the cells was changed to 
fresh media and the transfection mix was added. The media was again changed at 4-6 h. 
Huh-7.5 cells were transfected with Lipofectamine-3000 (Invitrogen) according to the 
manufacturer's instructions.  
2.7. Lentivirus and retrovirus particle production 
Low-passage HEK293T cells (60-80% confluent) were co-transfected using 
polyethyleneimine and a 5:5:1 ratio of a retroviral or lentiviral plasmid, a suitable GagPol 
plasmid, and a VSVg plasmid, respectively. To obtain virus for routine transductions, 11 
μg of total DNA were used to transfect a 100-mm dish, in a total of 10 mL of media. To 
produce high titer virus stocks, 88 μg of total DNA were used to transfect a 150-mm dish 
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in a total of 20 mL of media. Virus-producing HEK293Ts were maintained in DMEM+ 
supplemented with 3% FBS. Virus-containing media was collected at 24 h, (and 48 h and 
72 h, as needed) post transfection, filtered through a 0.45 μm filter, and used to transduce 
target cells immediately, after short storage at 4°C, or frozen at -80°C with added 20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  (HEPES, Gibco) and 4 μg/mL 
Polybrene (Millipore). Fresh media was added to cells after each harvest, if further 
collections were needed. For virus concentration, pooled virus-containing media was 
mixed at a ratio of 3:1 with LentiX Concentrator (Clontech), cooled at 4°C, then 
centrifuged for 45 min at 4°C and 1,500 x g. The viral pellet was resuspended into 
DMEM+ supplemented with 3% FBS, 20 mM HEPES and 4 μg/mL Polybrene, to 
achieve a 50 to 100-fold concentration, then aliquoted and stored at -80°C until used. 
Infections of Huh-7.5-derived cell lines were done in DMEM+ supplemented with 3% 
FBS, and 4 μg/mL Polybrene, for between 6 and 16 h, after which the media was changed 
to DMEM+ containing 10% FBS. 
2.8. Lentivirus titer determinations 
Titers of lentiviruses expressing fluorescent protein (FP) markers were 
determined using a flow cytometry-based assay as previously described (Sastry et al., 
2002). Briefly, Huh-7.5 cells were plated in 12-well plates at 105 cells/well. The 
following morning, serial dilutions of lentivirus stocks were made in DMEM+ 
(supplemented with 3% FBS and 4 μg/mL Polybrene) and 1 mL of each dilution was 
used to infect individual wells. The media was changed at 6-8 h to 1 mL DMEM+ 
supplemented with 10% FBS. At 48 h post infection, the cells were processed and 
analyzed live by flow cytometry. Mock-transduced Huh-7.5 cells were used for gating. 
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The percent of fluorescent protein-positive, single live cells was recorded. Dilutions 
yielding a percent of fluorescent protein-positive cells between 1 and 20% were used to 
calculate the titer of the original stock using the formula:  
	
	 	 %	 	 	
	 	
 
2.9. Flow cytometry 
Cells were washed with phosphate-buffered saline (PBS) and trypsinized; trypsin 
was inactivated using cold DMEM+ containing 10% FBS. The cells were then pelleted 
for 2-3 min at 1,500 x g and 4°C, washed once with cold FACS buffer (PBS, 25 mM 
HEPES, pH 7.4, 1% bovine serum albumin), resuspended in FACS buffer containing 50 
ng/mL 4',6-diamidino-2-phenylindole (DAPI, Molecular Probes), and kept on ice until 
analyzed on a BD-LSRII flow cytometer equipped with 405, 488, 561 and 640 nm lasers. 
Gating and analysis was performed using BD FACSDiva and FlowJo software. 
2.10. HCV 
RNA transcripts of the infectious HCV clone J6/JFH1 were generated from 
plasmids as previously described (Lindenbach et al., 2005). Briefly, plasmid DNA was 
linearized by digestion with XbaI, templates were purified by Minelute column (Qiagen), 
and 1 µg DNA was transcribed using the T7 RiboMAX™ Express Large Scale RNA 
Production System (Promega). Template DNA was removed by digestion with 1 U 
DNase I and RNA was cleaned up by RNeasy kit (Qiagen) with an additional on-column 
DNase I digestion step (Qiagen). RNA was quantified by absorbance at 260 nm, its 




HCV RNA was transfected into Huh-7.5 cells by electroporation as described 
previously (Lindenbach et al., 2005). Briefly, Huh-7.5 cells were trypsinized, washed 
twice with ice-cold Hanks' Balanced Salt Solution (HBSS, Ca2+/Mg2+-free, Gibco), and 
resuspended to 1.5 x 107 cells/mL in cold PBS. For each electroporation, 5 µg of HCV 
RNA were mixed with 6 x 106 cells and immediately pulsed using an ElectroSquare 
Porator ECM 830 (BTX, Holliston, MA; 860 V, 99 µsec, five pulses). Electroporated 
cells were diluted in 30 mL of DMEM+ supplemented with 10% FBS, and plated in 24-
well plates. Media was changed at 4-6 h, when a set of wells was further washed in cold 
PBS and harvested in RLT buffer (Qiagen) containing 0.14 M 2-mercaptoethanol for 
quantification of HCV RNA by qRT-PCR. When needed, cell supernatants were 
harvested, clarified through a 0.45 µm filter and frozen at -80°C for assay of infectious 
virus production by limiting dilution assay and tissue culture infectious dose 50 
calculation by the method of Reed and Muench, as previously described (Lindenbach et 
al., 2005). For quantification of intracellular infectious virus levels (Gastaminza et al., 
2006), the cells were trypsinized and pelleted at 1,500 x g for 3 min. Pellets were washed 
and resuspended in DMEM+ supplemented with 10% FBS. The cells were lysed by four 
freeze-thaw cycles, and the debris pelleted by twice centrifuging at 1,500 x g for 5 min. 
The supernatant was collected and viral infectivity was quantified as described above. 
2.11. Luciferase assay 
For luciferase activity measurements in the cell lysates, cells expressing the firefly 
luciferase were washed once in cold PBS, then 1 x Cell culture lysis reagent (Promega) 
was added. The plates were immediately sealed with adhesive aluminum foil, and stored 
at -80°C. On the day of the assay, the plates were thawed at 4°C and the cell lysates were 
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transferred to 96-well plates. Protein concentration in the samples was determined when 
needed using the Microplate BCA Protein Assay Kit, Reducing Agent Compatible 
(Thermo Scientific). Activity (luminescence) in 20 μL of lysate was measured 
immediately following injection of 50 μL of firefly luciferase assay buffer + substrate 
(Promega) using a Synergy Neo plate reader (Bio-Tek). 
2.12. Microscopy 
Cells were imaged live in growth medium or in cell imaging media (Hanks' 
balanced salts [Sigma], supplemented with 5% FBS, 0.1 mM non-essential amino acids, 
10 mM HEPES, pH 7.5) or after fixation with 4% paraformaldehyde (Electron 
Microscopy Sciences) solution in PBS and further PBS washes. Images were acquired on 
the following systems: Olympus IX70/IX81 inverted microscopes equipped with 10X 
UplanFL 0.3 numerical aperture air or 60X UPlanApo 1.2 numerical aperture water 
objectives and Hamamatsu ORCA-ER cameras and Metamorph software (Molecular 
Devices), or a Deltavision system (Applied Precision) equipped with a 60X 1.42 
numerical aperture oil objective and SoftWoRx software (Applied Precision). 
Deconvolution of fluorescence images using measured point-spread function was done in 
the SoftWoRx software, Pearson's coefficient measurements were done in Imaris 
(Bitplane), and final images were processed using FiJi (Schindelin et al., 2012) or 
Metamorph software. 
2.13. Transferrin uptake 
 The protocol to measure the uptake of transferrin was adapted from (Fielding et 
al., 2012). Huh-7.5 cells were grown in 6-well plates. They were incubated for 1 h at 
37°C in serum-free DMEM+, then washed with PBS and incubated in CellStripper 
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(Corning) at room temperature until they became detached. The cells were immediately 
moved into microcentrifuge tubes, cooled and subsequently processed on ice. The cells 
were pelleted for 2 min at 1,500 x g and 4°C and resuspended in 250 μL cold serum-free 
DMEM+, then 250 μL serum-free DMEM+ containing 100 μg/mL transferrin-Alexa 
Fluor 647 (Molecular Probes) were added, mixed with the cells, and the entire volume 
was split into two tubes and incubated for 5 min on ice to allow binding to the cell 
surface, then pelleted as above. The cells from one set of tubes were washed twice each 
with 1 mL ice-cold acid buffer (PBS, 1% bovine serum albumin, pH 5.0), then 
resuspended in 100 μL FACS buffer, supplemented with 50 ng/mL DAPI as dead cell 
exclusion stain and analyzed by flow cytometry to quantify the amount of transferrin 
bound at 4°C. The cells from the second set of tubes were resuspended in serum-free 
DMEM+, incubated at 37°C for 10 min to allow uptake, then cooled on ice for 5 min and 
further acid-washed and analyzed as described above. 
2.14. VSVg transport assays 
VSVg transport was monitored biochemically by co-transfection of (per well of a 
6-well plate) 2 μg of pVSVgtsO45-GFP (Presley et al., 1997) and 0.5 μg of a pLVX 
plasmid expressing mCherry or mCherry-Rab1b constructs. The plates were placed in an 
incubator set at 39.5°C. The media was changed at 4-6 h and the cells were returned to 
39.5°C. At 24 h post-transfection, a plate containing one set of transfections was moved 
to a 32°C incubator for 3 h. The plates were then rapidly cooled on ice, washed once with 
cold PBS, scraped into PBS and moved into microcentrifuge tubes, on ice. The cells were 
pelleted at 1,500 x g for 3 min at 4°C. The pellet was resuspended in 100 μL RIPA buffer 
(Sigma) supplemented with Complete protease inhibitors (Roche), lysed on ice for 15 
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min, then centrifuged at 20,000 x g for 15 min at 4°C. The lysates were moved to a new 
tube and stored at -20°C. For endoglycosidase digestion, the lysates were thawed on ice 
and divided into 3 aliquots. One aliquot was digested with EndoH, one with PNGase F, 
and one was left untreated. Digestions were done for 2 h at 37°C according to New 
England Biolabs instructions, and were stopped by boiling the samples in 2X sodium 
dodecyl sulfate (SDS) sample buffer (containing protease inhibitors and 0.3 M 2-
mercaptoethanol) and followed by processing for SDS Polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting experiments.  
Huh-7.5 cells were plated in 35-mm glass-bottom MatTek dishes. The next day, 
each dish was co-transfected with 1 μg of pVSVgtsO45-GFP and 0.5 μg of pLVX Phi-
derived plasmid expressing mCherry or mCherry-Rab1b constructs. The dishes were 
immediately placed in an incubator set at 39.5°C. The media was changed at 4 h and the 
cells were returned to 39.5°C. At 24 h post-transfection, one set of dishes was moved to a 
32°C incubator for 3.5 h, while a second set was kept at 39.5°C, before all were fixed 
with 4% paraformaldehyde in PBS for 15 min at room temperature, then washed with 
PBS and imaged. 
2.15. SDS-PAGE and Western blotting 
Cells were lysed and boiled in reducing SDS sample buffer. The proteins were 
separated on 4-12% Bis-Tris SDS-PAGE gels (Invitrogen), then transferred onto 
nitrocellulose membranes using the iBlot system (Invitrogen). The membranes were 
blocked in 5% non-fat milk in Tris-buffered saline supplemented with 0.1 % Tween-20) 
for 1 h at room temperature, immunoblotted with primary antibodies (overnight at 4°C) 
and matched horseradish peroxidase-conjugated secondary antibodies (1 h at room 
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temperature), treated with chemiluminescence substrates (ECL Prime, Amersham or 
West Pico or West Femto, Pierce), before being exposed to Amersham Hyperfilm MP 
autoradiography film and developed. 
2.16. Antibodies 
The antibodies used throughout this work are listed in Table 2.4, alongside the 
dilutions they were used at in each application. For immunoprecipitation, the amounts of 
antibody used are described in the respective specific sections.   
Table 2.4 Antibodies and usage conditions 










 IP (Cristea et al., 
2006) 
N/A 
α-dsRed rabbit pAb  WB 1:1000 Clontech 632496 
α-(β)actin mouse 
mAb 
 WB 1:2000 Sigma A5316 
Clone 
AC-74 
α-ApoB goat pAb  IP Calbiochem 178467 
α-ApoB goat pAb  WB 1:1000 Millipore AB742 
α-ApoB rabbit pAb  IP Abcam 50069 
α-ApoE rabbit 
mAb 





α-ApoE goat pAb  WB 1:1000 
IP 
Millipore AB947 



























Table 2.4 Antibodies and usage conditions 
















goat pAb AF488 IF 1:1000 Molecular Probes A-11029 
α-rabbit 
IgG 
goat pAb AF594 IF 1:1000 Molecular Probes A-11037 
Abbreviations: IgG, immunoglobulin G; mAb, monoclonal antibody; pAb, polyclonal 
antibody; IP, immunoprecipitation; IF, immunofluorescence; WB, Western blotting; IHC, 
immunohistochemistry; HRP, horseradish peroxidase; AF, Alexa Fluor. 
 
2.17. Secretion assays and cargo quantification 
Cells were washed once with DMEM+ containing 1% FBS, and then were 
allowed to secrete cargo in the same media for the indicated amounts of time (usually 6 h 
for samples analyzed by ELISA, 5 h for samples subjected to lipoprotein immuno-
precipitation, and 6 or 24 h for HCV infectivity assays, respectively, or otherwise as 
indicated in the text or on the figures). For HCV secretion experiments, secretion was 
performed in media containing 10% FBS. At the end of the secretion period, media and 
cells were harvested and stored at -80°C until processed. If needed, cell lysates were 
harvested at this time for luciferase activity assays. For ELISA-based quantification of 
cell-associated cargo, cells were grown in 6-well plates, washed once in cold PBS 
supplemented with 50 mM ethylenediaminotetraacetic acid (EDTA), then scraped on ice 
in PBS supplemented with 50 mM EDTA. The cells were then pelleted and resuspended 
in 500 μL RIPA buffer supplemented with protease inhibitors and lysed on ice for 15 
min, then stored at -80°C. Cargo amounts in cell lysates and supernatants were quantified 
using human-specific ELISA kits (Abcam: ApoE, ab108813; ApoB100, ab108807; 
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albumin, ab108788). Unconditioned media containing 1% or 10% FBS contained 
undetectable amounts of human albumin, ApoE, or ApoB100. 
2.18. DN Rab GTPase screen 
Huh-7.5 FLuc cells were plated at 42,000 cells/well in 12-well plates. After 7 h, 
the cells were infected with pLVX Che-hi3-derived viruses expressing WT or DN 
untagged Rab GTPases. The viruses, previously concentrated and titrated, were diluted in 
DMEM+ supplemented with 3% FBS and 4 μg/mL Polybrene such that the final dose in 
each target well was either 25 or 100 I.U./cell, and was contained in a total volume of 300 
μL/well. The media was changed after 12 h to 500 μL/well of DMEM+ supplemented 
with 10% FBS. At 48 h post transduction, the cells were washed with 250 μL/well of 
DMEM+ containing 1% FBS, and then were incubated in the same media for 6 h at 37°C. 
Finally, the media was harvested and stored at -80°C until ELISA assays were performed. 
The cells were lysed on the plate in 100 μL/well of 1X cell culture lysis reagents, and 
stored at -80°C until a luciferase assay was performed. Transductions and secretion 
assays, ELISA assays and luciferase assays for paired WT-DN Rab samples were always 
performed on the same plate to minimize technical variations. 
2.19. Polarized induced hepatocyte-like cells 
The yet unpublished differentiation protocol for human induced hepatocyte-like 
cells (iHeps) from human embryonic stem cells has been developed by Dr. Xianfang Wu. 
The conditions in which the iHeps may be differentiated and polarized in a monolayer 
culture on trans-well filters has been developed by Dr. Wu and Dr. Viet Loan Dao Thi. 
The details of these protocols will be described by Dr. Wu and Dr. Dao Thi in an article 
currently in preparation. For the experiments presented in Chapter 4, trans-well filter-
 
106 
grown iHep monolayers were washed twice with HBM basal medium (Lonza) and 
exposed to fresh media in both the apical and basolateral chambers for 6 h. The medium 
added to the apical chamber (within the trans-well insert) was the HBM basal medium. 
The medium added to the basolateral chamber (outside the trans-well insert) was the 
same HBM medium supplemented with all the components of the HCM Bullet Kit 
(Lonza) with the exception of the epidermal growth factor, EGF. The media was also 
supplemented with 10 U/mL penicillin, 10 μg/mL streptomycin and 20 ng/mL 
Oncostatin-M. At the end of the 6 h secretion assay, the media were harvested and stored 
at -80°C. The cells were washed in cold PBS and then lysed at 4°C on the filter in 300 μL 
cold RIPA buffer supplemented with protease inhibitors. The lysate was also stored at -
80°C and the cargo amounts were measured in the media and in the lysates by ELISA 
Unconditioned media did not yield an ELISA signal for either human albumin, ApoE or 
ApoB100. 
2.20. Co-immunoprecipitation of lipoproteins 
Huh-7.5/EV Hygro or Huh-7.5/ApoE-GFP cells were washed once with DMEM+ 
containing 1% FBS, allowed to secrete cargo in the same media for 5 h, then media and 
cells were harvested. Media was cleared by a 3 min, 500 x g spin, then an aliquot of the 
media was mixed with SDS sample buffer, denatured, and stored at -20°C. 
Immunoprecipitation of 1.8 mL of cleared media was done as follows. All tubes were 
pre-coated with 1% bovine serum albumin, 0.1% Tween-20, PBS for 1 h, then washed 3 
times with PBS. Media was incubated with 29 μg of rabbit α-GFP, rabbit α-ApoB100, or 
normal rabbit IgG, overnight at 4°C. Protein G Dynabeads (50 μL, pre-washed with PBS) 
were added and incubated 1 h at room temperature, then washed 4 times with PBS, then 
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denatured in SDS sample buffer. Samples were then processed by SDS-PAGE and 
Western blotting. 
2.21. Radioactivity pulse-chases 
This procedure was adapted from a previous study (Wang et al., 1993) as follows. 
Huh-7.5/EV Hygro and Huh-7.5/ApoE-GFP cells were plated at 3 x 105 cells/well in 6-
well plates once day prior to the pulse chase assay. Clone 9 OR164 FLuc cells (inducibly 
expressing mCherry-Rab1bN121I) were plated at 2.5 x 10
5 cells/well in 6-well plates 2 
days before the pulse chase assay; the next day, half of the wells in each plate were 
induced with 3 μg/mL doxycycline, and the rest were left uninduced. On the day of the 
pulse chase assay, the cells were washed in PBS and then pulse labeled with 35S-cysteine 
and 35S-methionine (120 μCi/well) in DMEM containing no cold cysteine or methionine, 
and supplemented with 1% FBS and 0.1 mM non-essential amino acids for 20 min. The 
cells were then washed twice in PBS and chased in DMEM containing cycloheximide 
(Millipore, 50 μM) and excess of methionine (1.5 mg/mL) and cysteine (0.5 mg/mL). At 
each time point, the media was removed and the cells were washed once with PBS. The 
cells were lysed by rocking at 4°C for 30 min in 1 mL of Lysis buffer: 6.1 mM Na2HPO4, 
4.5 mM NaH2PO4, 88.4 mM NaCl, 36.58 mM LiCl, 24.1 mM sodium deoxycholate, 1% 
Triton X100, 1% SDS, pH 7.4, supplemented with 4 μL/mL phenylmethane-
sulfonylfluoride (Sigma, 0.1 M in ethanol) and Complete protease inhibitors. Total 
protein-incorporated radioactivity in the samples collected at each time point was 
determined after trichloroacetic acid precipitation, using scintillation fluid. 
Immunoprecipitation of ApoE, ApoB100 and albumin from media and cell lysates was 
performed by incubation with 5 μL each of the anti-ApoE, anti-ApoB100 and anti-
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albumin antibodies and 50 μL protein A sepharose 4B beads (Invitrogen) in 1X NET 
buffer (0.15 M NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5) supplemented with 1% Triton 
X100, overnight at 4°C. The beads were then washed 3 times in 1X NET buffer 
supplemented with 1% Triton X100 and 1% SDS, then the bound protein was eluted in 
1X NET buffer containing 1% SDS. Samples were resuspended in denaturing buffer: 125 
mM Tris-HCl, pH 6.8, 6 M urea, 1 mM EDTA, 10 mM dithiothreitol, 4% SDS, 25 mM 2-
mercaptoethanol, and separated by SDS-PAGE on 4-12% Bis-Tris gels. The gels were 
fixed for 15 min with a 50% methanol, 7% acetic acid aqueous solution, incubated with 
Autofluor (National Diagnostic) for 15 min, and exposed in a Typhon 9400 
phosphorimager. The intensity of each band was quantified and the background was 
subtracted in the Fiji software (Schindelin et al., 2012). Relative amounts of radiolabeled 
amino acid incorporation were calculated by dividing the intensity of the protein-specific 
band at the end of the pulse period by the measured total protein-contained radioactivity 
in the corresponding sample. Secretion of newly synthesized proteins was assessed by 
expressing the amount of radioactively labeled protein present in the media at a given 
time point as a percent of the total (secreted + cell-associated) radioactively labeled 
protein measured at the same time point. 
2.22. qRT-PCR 
To harvest RNA, cells were lysed in RLT buffer (350 μL/well, supplemented with 
0.14 M 2-mercaptoethanol), processed using Qiashredder (Qiagen) and the lysates stored 
at -80°C. RNA was isolated using the RNeasy kit (Qiagen) with the additional on column 
DNase I digestion, and stored again at -80°C. qRT-PCR was performed on 10 or 50 ng 
total RNA using the QuantiFast SYBR Green RT-PCR kit (Qiagen) and QuantiTect 
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Primer Assay kits (Qiagen) specific for human GAPDH (QT00079247), RAB1B 
(QT00046396), APOE (QT00087297), APOB (QT00020139) and ALB (QT00063693), 
respectively. Fold changes in mRNA expression levels were determined using the ΔΔCt 
method (Livak and Schmittgen, 2001), using GAPDH as reference housekeeping gene. 
HCV RNA levels were quantified against a standard curve using a one-step qRT-PCR 
assay (Multicode-RTx HCV RNA kit, Luminex Corp.) targeting the 3' UTR of the viral 
genome. Cycling was performed on a Roche Light Cycler 480 (Roche). Data analysis 
was performed on the Light Cycler 480 Software (Roche) and on the MultiCode-RTx 
Analysis Software (EraGen Biosciences). 
2.23. Transcript expression levels by RNA sequencing 
Huh-7.5 RNA sequencing (RNAseq) expression data for members of the Rab 
GTPase family, as well as for several other selected genes were extracted from datasets 
previously generated (Luna et al., 2015). The genes were ranked in ascending order of 
their expression levels. Genes to which no reads mapped were nonetheless assigned a 
score of -10 Log2CPM, to allow them to be included in the graph. Unpublished RNAseq 
data from human fetal liver cultures, or HFLCs (Andrus et al., 2011) was kindly provided 
by Drs. William Schneider, Joseph Luna and Linda Andrus.  
2.24. Statistical analyses  
Unpaired two-tailed Student's t-test was performed in most cases. For analysis of 
the DN Rab screen data, the unpaired two-tailed Student's t-test with Bonferroni 
correction was performed. For HCV experiments, a two-way ANOVA test was 
performed. P-values were calculated in Microsoft Excel or in GraphPad Prism. I am 
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grateful to Dr. Michelle Itano for expert advice and help on performing statistical 
analyses. 
2.25. Miscellaneous methods 
Rab protein amino acid sequences were aligned using the ClustalW function of 
the Megalign program of DNAStar Lasergene. Rab1b crystal structure, Protein Data 


























 Chapter 3  
A Dominant Negative Rab GTPase Screen  
Identifies Regulators of Hepatic Cargo Secretion 
 
3.1. The concept 
While progress has been achieved in characterizing the transport pathways 
mediating the secretion of hepatic lipoproteins (Sundaram and Yao, 2012; Tiwari and 
Siddiqi, 2012) and of HCV (Lindenbach, 2013; Lindenbach and Rice, 2013), further 
elucidation is required to improve our understanding of these processes. To investigate 
hepatic cargo secretion, I relied on the knowledge that Rab GTPases control relatively 
specific steps of intracellular vesicular transport (Hutagalung and Novick, 2011; 
Stenmark, 2009). For example, the Rab1, Rab2, and Rab6 subfamilies control traffic 
between the ER and the Golgi compartment, and within the Golgi (Chavrier et al., 1990a; 
Goud et al., 1990; Martinez et al., 1994; Plutner et al., 1991; Segev et al., 1988; Tisdale 
and Balch, 1996; Tisdale et al., 1992); the Rab3 and Rab8 subfamilies control post Golgi 
exocytosis (Fischer von Mollard et al., 1990; Fischer von Mollard et al., 1991; Huber et 
al., 1993a; Huber et al., 1993b); the Rab5 subfamily controls early steps of endocytosis 
(Bucci et al., 1992; Gorvel et al., 1991); and the Rab11 subfamily controls recycling of 
endocytosed proteins (Ren et al., 1998; Ullrich et al., 1996). Indeed, Rabs are considered 
a class - although not the only one - of identity markers that define the nature of a 
particular membrane-bound compartment (Barr, 2013; Pfeffer, 2013). I thus hypothesized 
that by inhibiting the function of individual Rab proteins and by measuring the effects 
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this inhibition had on the efficiency of cargo secretion, I may well be able to identify the 
Rabs, and therefore the vesicular transport pathways involved in the secretion of hepatic 
cargoes.  
This is not the first screen of this nature. Previous studies have utilized 
overexpression of proteins regulating the Rab functional cycle, such as GAPs and GEFs, 
and/or knockdown experiments to attain similar goals (Fuchs et al., 2007; Pilli et al., 
2012; Udayar et al., 2013; Yoshimura et al., 2010). Their success cemented my belief that 
this idea was sound. Furthermore, the wealth of knowledge accumulated over the past 
three decades of investigation of the regulation of intracellular transport by the Rab 
proteins (Hutagalung and Novick, 2011) allowed me to design an experimental approach 
whose implementation relied on the use of many previously described molecular tools. 
These include well characterized DN mutants, functional fusions of fluorescent proteins 
to the Rabs, activators and repressors of endogenous Rab function (Barr and Lambright, 
2010), and an ever-growing list of known Rab effectors (Hutagalung and Novick, 2011).  
3.2. DN Rab screen outline 
The outline of the screen is depicted in Figure 3.1. Since expression of DN Rab 
mutants is a well established method of inhibition of Rab function, I expressed a panel of 
such mutants in a liver-derived cell line (Figure 3.1A). For each DN Rab (red text and 
cartoons), I used expression of the WT Rab (blue text and cartoons) as the control 
condition (Figure 3.1B). I did so in an attempt to distinguish between effects due to mere 
overexpression of the Rabs and the effects due to functional differences between the WT 
and the DN versions of a given Rab. Following expression of WT-DN Rab pairs, I 
washed the cells to remove cargo loosely attached to the cell surface or to the plate, and 
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then performed a secretion assay. At the end of the secretion assay, I quantified the 
amount of cargo released into the media, and also estimated the cellular mass present in 
the well and thus responsible for secretion (Figure 3.1C). By dividing the secreted cargo 
amounts by the cell mass measurement (Figure 3.1D), I calculated a normalized level of 
secretion in each well. I then compared these normalized secretion values obtained in the 
presence of WT and DN Rab expression (Figure 3.1E). I interpreted significant 
differences between the two values to signify that the Rabs causing them were likely to 
be involved in regulating secretion of the tested cargo. To elucidate the fine details of the 




Figure 3.1. Outline of the DN Rab GTPase screen. Hepatic cells (A) were made to 
express WT (blue) or DN (red) Rab GTPases (B). Secretion assays were performed and 
secreted cargo amounts and cell masses were measured (C). The amounts of cargo 
secreted were divided by the corresponding well’s cell mass measurement to obtain 
normalized secretion values (D). The normalized secretion values obtained in the 
presence of DN Rab expression were compared to those obtained in the presence of the 







3.3. The experimental system 
I performed the DN Rab GTPase screen in the Huh-7.5 human hepatoma cell line 
(Blight et al., 2002). I chose this cell line since I wanted to be able to directly contrast the 
effects of inactivation of the hits of the Rab screen on lipoprotein secretion to their effects 
on HCV egress. The Huh-7.5 cells (Blight et al., 2002; Lindenbach et al., 2005) possess 
the ability to support the entire HCV lifecycle, which includes permitting high levels of 
HCV RNA genome replication and infectious HCV particle release. I remain aware that 
the parental Huh-7 cells (Meex et al., 2011), as well as the Huh-7.5 cells themselves 
(Ursula Andreo, personal communication), remain defective in secreting ApoB100 in the 
appropriate VLDL density fraction, and instead preponderantly secrete IDL/LDL-like 
ApoB100-containing particles. Confirmation that a certain Rab GTPase is involved in the 
secretion of HCV and/or lipoproteins in a more physiologic setting would require further 
testing in more informative, but also more expensive, and potentially less easily tractable 
or readily available primary cell or in vivo system(s).  
A final requirement of this experimental design was that I be able to estimate the 
mass of cells present at the time of the measurement of cargo secretion. Therefore, I 
transduced the Huh-7.5 cells with a lentivirus expressing firefly luciferase (FLuc). I 
confirmed that in the resulting Huh-7.5 FLuc cell line, the measured luciferase activity 
correlated linearly with the number of cells present in the culture (Figure 3.2A). 
Furthermore, this tight correlation, together with the simplicity of the luciferase activity 
assay, its large dynamic range and its high sensitivity made this a more suitable cell-mass 






Figure 3.2. Characterization of luciferase-expressing Huh-7.5 FLuc cells. Two-fold 
serial dilutions of Huh-7.5 FLuc cells were plated each in 4 wells of a 24-well plate and 
the cell lysates were harvested the next day. Luciferase activity (A) and total protein 
concentration (B) were measured in each sample and were plotted against the dilution 
factor. Values are means ± standard deviation (s.d.) of the values obtained in 4 replicate 
wells. RLU, relative light units; BSA, bovine serum albumin; l.o.d. limit of detection of 
the protein concentration assay. 
 
3.4. Expression of WT and DN Rab GTPase constructs 
To ensure relatively uniform construct expression in an overwhelming majority of 
the cells in culture, I utilized lentivirus transduction as the preferred method of Rab 
expression. In preliminary experiments, I had noticed that the transduction efficiencies of 
lentiviruses expressing DN Rab1 constructs were regularly lower than those of the 
lentiviruses expressing WT Rab1 or irrelevant proteins, despite the fact that the lentiviral 
vectors had been packaged into lentiviral particles in parallel, using the same protocol. 
This observation was not surprising since I pseudotyped the lentiviral particles using 
VSVg. Loading of VSVg onto the budding lentiviral particle requires transport of VSVg 
to the plasma membrane, the site of HIV-1 lentivirus assembly (Jouvenet et al., 2006). 
Since Rab expression was driven by the constitutively-active CMV promoter, DN Rabs 
expressed in the lentivirus particle-packaging HEK293T cells could interfere with 
lentivirus particle infectivity by affecting the exocytic transport of VSVg (Tisdale et al., 
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1992). It thus became important for me to ensure that equal doses of infectious WT and 
DN Rab-expressing lentiviruses were delivered to the target cells. I therefore established 
a method for relatively large-scale lentivirus production, followed by concentration of the 
virus stock and determination of its infectivity. To measure lentivirus titers, I utilized a 
flow cytometry-based protocol which used as readout the fluorescence of the mCherry 
protein expressed from the lentiviral vector pLVX Che-hi3 (Figure 2.1B) in which I 
cloned the WT and mutant Rabs. Using this protocol I routinely prepared concentrated 
Rab-expressing lentivirus stocks with titers in the range of 2x107 to 5x108 infectious units 
(I.U.)/mL, which were measured on Huh-7.5 cells, the same cell type that I used in most 
of the experiments.  
I also confirmed that the fluorescence measured in the transduced cells and used 
to determine lentivirus titers was due to infection by the viral particles themselves, and 
not by unspecific staining of the target cells by the lentivirus particle inoculum. This was 
a concern since I used a proprietary commercial reagent to concentrate the lentivirus 
stocks, and I had no information on whether the concentration protocol could also enrich 
exosomes, which are expected to be produced alongside the lentivirus particles (Cantin et 
al., 2008) and could deliver mRNAs from the lentivirus producing cells (Valadi et al., 
2007). Carryover of the DNA that had been used to launch lentivirus production could 
also, in principle, cause mCherry expression in the transduced cells. I thus produced 
lentiviral particles using an mCherry-expressing lentiviral vector, VSVg, and either the 
packaging system encoded by pCR/V1 NL GagPol (Zennou et al., 2004), or a plasmid 
encoding only HIV-1 Gag (Graf et al., 2000). Although HIV-I Gag retains the ability to 
form lentivirus-like particles (Zennou et al., 2004), it nevertheless cannot support particle 
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infectivity since it lacks essential enzymatic activities such as protease, reverse 
transcriptase and integrase, all of which are contained in HIV-1 Pol and required for 
productive infection (Freed, 2015).  Indeed, when I titrated the lentivirus stock produced 
using HIV-1 Gag, I detected roughly 100- to 1000-fold fewer positive cells in the 
transduced population than I did when I titrated the lentivirus stock produced using 
GagPol (Figure 3.3A). The positive cells obtained by transduction with HIV-1 Gag-
packaged particles also had lower fluorescence levels than the positive cells obtained by 
transduction with GagPol-packaged particles (Figure 3.3B). This difference was not due 
to production of fewer particles in the presence of HIV-1 Gag, since both virus stocks 
contained comparable amounts of material that was recognized by an α-capsid (CA) 
antibody (Figure 3.3C). Capsid is one of the domains of HIV-1 Gag (Bieniasz, 2009). As 
expected, HIV-Gag (p55) did not undergo proteolytic processing in the absence of the 
Pol-encoded protease activity (Figure 3.3C, left lane), but was cleaved in the presence of 
Pol (Figure 3.3C, right lane). This test therefore confirmed that the readout from the 









Figure 3.3. Specificity of lentivirus transduction. Concentrated lentivirus particle 
stocks were made using an mCherry-expressing lentiviral vector and either an HIV-1 
GagPol-expressing packaging plasmid (red) or a control HIV-1 Gag-expressing plasmid 
(blue). Huh-7.5 cells were transduced with serial dilutions of each of the stocks. The 
abundance of mCherry-positive cells (A) and their associated mCherry fluorescence 
amounts (B) are plotted. MFI, median fluorescence intensity. (C) lentiviral particles from 
each of the stocks were concentrated and analyzed by Western blotting using an α-HIV-1 
capsid (CA) antibody. Molecular weights (kDa) of the major bands are listed at the right. 
Cleavage of full length Gag (p55) is indicated by the appearance of the p42 and p24 
bands. 
Having established a method to produce high titer lentivirus stocks, I next tested 
the efficiency of target cell transduction using these viruses. Previous reports have 
overexpressed Rab1 constructs by infecting target cells with adenoviruses or lentiviruses 
at a MOI of 5-100 I.U./cell (Filipeanu et al., 2004; Filipeanu et al., 2006; Li et al., 2010; 
Yin et al., 2011). I tested two doses of lentivirus within this range, namely 25 and 100 
I.U./cell. Both doses were sufficient to transduce the overwhelming majority of the target 
cell population (Figure 3.4A) and to yield a fluorescent signal easily detectable by 
fluorescence microscopy (Figure 3.4B).  Therefore, I planned to express the Rab 
constructs under the control of a CMV promoter using a lentivirus vector which also 





Figure 3.4. Lentivirus transduction efficiency in Huh-7.5 cells. Cells were left 
uninfected or were infected with an mCherry-expressing lentivirus stock at a MOI of 25 
or 100 I.U./cell, and were then analyzed 48 h later by flow cytometry (A) or fluorescence 
microscopy (B). A.U., arbitrary units; BF, brightfield. Scale bar, 50 μm. 
 
3.5 The Rabs 
I chose to test the involvement of 62 human Rab GTPases in regulating hepatic 
cargo secretion (listed in the Table 2.1; the NCBI reference sequence identifiers for their 
amino acid sequences are listed in the table as well). Amino acid sequences were 
numbered by assigning position 1 to the predicted START methionine residue. 
Alignment of these sequences revealed, as expected (Diekmann et al., 2011; Gurkan et 
al., 2005; Wittinghofer and Vetter, 2011), a high degree of sequence similarity, 
particularly in the regions predicted to participate in the formation of the conserved Rab 
GTPase domain (Figure 3.5). These amino acid stretches contained two conserved 
phosphoryl binding sites and a guanine ring binding site, respectively, as identified in a 
previous study (Tisdale et al., 1992) and highlighted in blue in the consensus sequence 
listed at the top of the alignment (Figure 3.5).  
Several mutations that interfere with various aspects of the Rab functional cycle 
exist; these include mutations that target conserved residues that affect the Rab guanine 
nucleotide binding and hydrolysis cycle (Table 1.1, and highlighted in red ink Figure 3.5) 
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and have been widely used to inhibit Rab function. One mutation targets the conserved 
serine/threonine residue involved in phosphoryl binding, equivalent to Rab1aS25. This 
serine/threonine residue is conserved in all the Rab sequences in the list except for 
Rab40b and 40c, where it is replaced by glycine. Mutation of this residue to asparagine 
yields proteins that cannot stably bind GTP, and thus remains locked in the inactive 
GDP-bound form (Nuoffer et al., 1994). Another mutation targets the conserved 
glutamine residue involved in (basal or stimulated) GTP hydrolysis and equivalent to 
Rab1aQ70. Mutation of this residue may yield proteins defective in GTP-hydrolysis which 
causes them to be locked in the GTP-bound active state (Mishra et al., 2013). This 
residue is not conserved in 4 Rabs: Rab11c (replaced by leucine), Rab20 (replaced by 
arginine), Rab24 (replaced by serine) and Rab42 (replaced by histidine). A third mutation 
targets the conserved asparagine residue involved in guanine ring binding. Mutation of 
this residue to isoleucine may prevent the Rab from stably binding the GDP or GTP 
nucleotides (Pind et al., 1994). Rabs 24, 34, and 36 carry a serine or threonine at this site, 
while Rabs 39a, 39b and 42 carry a histidine. The sequence of Rab15, however, did not 





















Figure 3.5.  Alignment of Rab protein sequences (next page). The amino acid 
sequences of 62 Rab proteins were aligned to one another, and the alignment within 
selected conserved sequences is shown. The consensus sequence is listed at the top. The 
two phosphoryl binding sites and the guanine ring binding site, as defined in (Tisdale et 
al., 1992), are highlighted in blue within the consensus sequence. Conserved, functionally 
important amino acids, as defined in the text, are highlighted in red. The position of the 
first amino acid in each set of sequences is listed in purple at the left of the alignment. 










Since introduction of the GTPase inactivating mutation does not always yield a 
DN Rab (Tisdale et al., 1992), and since in preliminary experiments the nucleotide 
binding mutant Rab1bN121I caused a stronger Rab1b inactivation phenotype than the 
GDP-locked mutant Rab1bS22N, I chose to substitute isoleucine for the asparagine residue 
equivalent to Rab1b's N121 to create a panel of DN Rab mutants. The only exception was 
Rab15, for which I used the GDP-locked T22N mutant instead. Therefore, for all of the 
Rabs listed in Figure 3.5, I cloned sequences encoding the WT and the indicated mutant 
protein into the reporter lentiviral vector pLVX Che-hi3 (Figure 2.1B). I, then, used these 
constructs to make lentiviral particles, which I concentrated and whose titers I determined 
before using them in the DN Rab screen. 
3.6. DN Rab screen: technical considerations 
While the technical details involved in performing the DN Rab screen 
experiments are described in detail in Chapter 2, I wish to underline some technical 
aspects which I find informative in ensuring a proper interpretation of the results. First, 
the screen was performed in Huh-7.5 FLuc (Figure 4.2) cells which allowed me to easily 
quantify changes in the cell mass by measuring luciferase activities in the cell lysates.  
Second, I infected these cells with two doses of infectious virus, MOI 25 and 100 
I.U./cell, respectively (Figure 4.4). Since the effectiveness of the DN Rabs in inhibiting 
Rab function is likely correlated with the ratio between the expressed mutant and the 
natively expressed WT Rab (Nuoffer et al., 1994), by using two doses of Rab-expressing 
vectors I hoped to enhance the likelihood that I would express just the right amount of 
DN Rab constructs, which would then allow me to detect DN Rab-mediated changes in 
cargo secretion.  
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Third, all infections with a given WT-DN pair of Rabs were done in wells of a 
single plate to ensure that the wells were exposed to very similar environmental 
conditions and that any variations among the time lengths needed to process the samples 
belonging to each WT-DN Rab pair were small. Similarly, luciferase activity and ELISA 
assays for all paired samples for each of the Rabs were performed on a single plate.  
Fourth, the amount of each of the three cargoes tested: albumin, ApoE and 
ApoB100 was measured in each biological sample. I reasoned that this procedure would 
help minimize technical and/or biological variations which could cause cargo-related 
differences in the effects exerted by the inhibition of a given Rab.  
3.7. Effects of DN Rab expression on cellular luciferase activity 
By comparing the luciferase activities of lysates from cells transduced with DN 
Rabs with those of the lysates from cells transduced with the corresponding WT Rabs, I 
found that for most Rabs expression of the DN form did not significantly change the 
luciferase activity values (Figure 3.6A-B). For roughly one third of the comparisons 
where luciferase activity significantly differed between the WT and the DN-transduced 
conditions, the differences were within one Log2 distance from the reference value. I was 
encouraged by the lack of any larger differences in luciferase activities. I cannot, based 
on this data alone, discount the possibility that, under these experimental conditions, DN 
(or WT) Rab expression was accompanied by any number of toxic effects on cell 
physiology. However, the magnitude of the differences observed suggests that if any 
toxic effects accompanied Rab expression, they likely were of a limited nature in this 












Figure 3.6. Effects of DN Rab expression on cell mass (next page). Huh-7.5 FLuc cells 
were transduced with WT (blue) or DN (red) Rab-expressing lentiviruses at MOI of 25 
(A) or 100 (B) I.U./cell. A secretion assay was performed at 48 h. Mean luciferase 
activity values in WT Rab-transduced cells were set to 1. The resulting relative luciferase 
activities were plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel wells. 







3.8. Effects of DN Rab expression on cargo secretion 
For each WT-DN Rab pair tested, for each of the cargoes tested, namely albumin, 
ApoE and ApoB100, and for each of the two doses of lentivirus particles that I used, I 
compared the normalized secretion measured in the presence of DN Rab expression to 
the normalized secretion measured in the presence of the WT Rab expression (Figure 
3.1). The results are presented in Figure 3.7A-C for the MOI = 25 I.U./cell condition and 
in Figure 3.8A-C for the MOI = 100 I.U./cell condition. Each Rab for which I identified a 
significant difference between the secretion of cargo measured in the presence of the WT 
form and that measured in the presence of the DN form is highlighted by a gray 
background bar. In some cases, DN Rab expression caused a decrease in secretion, when 
compared to WT expression (i.e. DN Rab1c/35 at MOI 100 caused a decrease in the 
secretion of albumin, ApoE and ApoB100, although the ApoE change was not 
significant). In other cases, DN Rab expression caused an increase in secretion (i.e. DN 





















Figure 3.7. Effects of DN Rabs on cargo secretion at MOI 25 I.U./cell (next page). 
Huh-7.5 FLuc cells were transduced with WT (blue) or DN (red) Rab-expressing 
lentiviruses at MOI 25 I.U./cell. A secretion assay was performed at 48 h post 
transduction. Secreted cargo amounts were measured by ELISA and divided by the 
corresponding well’s luciferase activity. The mean secretion values of WT Rab-
transduced cells were set to 1. The relative secretion values of albumin (A), ApoE (B) 
and ApoB100 (C) are plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel 
wells. Significant changes in cargo secretion values (Student’s t-test with Bonferroni 



































Figure 3.8. Effects of DN Rabs on cargo secretion at MOI 100 I.U./cell (next page). 
Huh-7.5 FLuc cells were transduced with WT (blue) or DN (red) Rab-expressing 
lentiviruses at MOI 100 I.U./cell. A secretion assay was performed at 48 h post 
transduction. Secreted cargo amounts were measured by ELISA and divided by the 
corresponding well’s luciferase activity. The mean secretion values of WT Rab-
transduced cells were set to 1. The relative secretion values of albumin (A), ApoE (B) 
and ApoB100 (C) are plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel 
wells. Significant changes in cargo secretion values (Student’s t-test with Bonferroni 






























To more easily organize and interpret these results, I defined a DN Rab effect 
score as follows. For each Rab, every instance in which secretion of a cargo was affected 
was assigned a score of 1. Thus, the maximum score for any given Rab was 6 (2 Rab 
lentivirus doses tested x 3 cargoes). For the purposes of this analysis, I did not distinguish 
between a case when cargo secretion was increased and a case when cargo secretion was 
decreased. I only asked whether the difference between the effect on secretion of the DN 
Rab was significantly different from the effect of its WT control. Then, I ranked the Rabs 
in descending order based on their total effect scores (Figure 3.9). For the Rabs which 
had the same total score, I ranked them in descending order of the sub-score obtained 
using the higher dose of Rab-expressing lentivirus (Figure 3.9, filled bars). The hits were 
also organized by known protein function (Table 3.1), following the information 
summarized in a recent comprehensive review (Hutagalung and Novick, 2011). Of note, 
most significant effects were caused by WT-DN Rab pairs previously implicated in 
exocytic (including ER to Golgi transport, intra-Golgi transport, Golgi structure 
maintenance; post-Golgi exocytosis) or recycling processes (Table 3.1). Conversely, 
Rabs involved in endocytic trafficking had either a low effect on secretion, or none at all 
(Figure 3.9 and Table 3.1). Similarly, the Rab3 subfamily, whose major function is to 
control regulated exocytosis (Fukuda, 2008), such as that of neurotransmitters in the 
nervous system, was underrepresented among the hits of this DN Rab screen. The 
functional clustering of the hits was thus consistent with albumin and the lipoproteins 
being constitutively secreted cargoes (Dashti et al., 1980), and attests to the usefulness of 






Figure 3.9 Ranking of Rab effects on cargo secretion. To each Rab, for each cargo 
whose secretion the DN Rab expression significantly changed, an effect score of 1 was 
awarded. Scores accumulated at MOI 25 I.U./cell are marked with open bars; scores 
accumulated at MOI 100 I.U. /cell are marked with filled bars. The Rabs are ranked first 
in descending order of the total score, and then in descending order of the score obtained 
at MOI 100 I.U./cell. 
 
3.9. Rab expression profiles in hepatic cells 
I next inquired whether the Rabs that I identified as likely regulators of hepatic 
cargo secretion were expressed in the cells in which I performed the screen. If a DN 
effect was detected but the endogenous Rab was not expressed, I was concerned that the 
effect may have been unspecific. I thank Dr. Joseph Luna for providing RNAseq data 
(Luna et al., 2015) for Rab gene expression in Huh-7.5 cells (Figure 3.10A). I 
furthermore thank Drs. Joseph Luna, William Schneider and Linda Andrus for providing 
unpublished RNAseq expression data from human fetal liver cultures (HFLC, Figure 
3.10B). HFLCs represent a primary hepatocyte cell culture system (Andrus et al., 2011; 
Marukian et al., 2011). I ranked the Rabs in ascending order of their expression level in 
each of the two hepatocyte cell culture systems. I also included in this analysis several 
genes known to be ubiquitously expressed (such as those encoding β-actin and β-tubulin), 
genes expressed in hepatocytes (such as those encoding ApoE, ApoB100, albumin, and 
the tight junction proteins claudin-1 and occludin), and genes whose expression is 
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expected to be confined to other cell types (such as those encoding the T-cell receptor 
subunits α and β, and the photoreceptor rhodopsin). Unsurprisingly, the housekeeping 
genes and the hepatocyte-specific genes were amongst the highest expressed genes, while 
the non-hepatocyte genes had undetectable expression levels (I graphed these nonetheless 
by assigning them an expression level of -10 Log2CPM. Of the Rabs which I identified as 
hits in the DN screen (Figure 3.9), Rabs 40b and 40c had expression levels amongst the 
lowest of all the Rabs in the Huh-7.5 cells. Rab41, similarly, had a very low expression 
level in the Huh-7.5 cells, while its expression was not detected in HFLCs. Rab11c/25 
transcripts were not detected in the Huh-7.5 cells, and their expression level was also 
very low in HFLCs. Due to their low or even undetectable expression levels, Rabs 11c, 









Figure 3.10. Rab expression levels in hepatic cultures. Rab-specific transcript 
expression levels (Log2CPM) from RNAseq analysis of Huh-7.5 (A) and HFLC (B) 
cultures were ranked in ascending order. The Rabs are listed by their numbers. Included 
were expression levels of genes encoding the T cell receptor subunits α and β, (TCRA, 
and TCRB, respectively), rhodopsin (RHO), β-actin (ACTB), β-tubulin (TUBB), occludin 
(OCLN), claudin1 (CLDN1), albumin (ALB), ApoE (APOE) and ApoB100 (APOB). 
When no reads mapping to the transcript were detected, an artificially low -10 Log2CPM 











3.10. On the interpretability and meaning of the results 
For the remaining Rab hits, further investigation is required to confirm their 
involvement in cargo secretion. The screen only identified whether there was a difference 
between the effect that a WT Rab had on secretion and the effect of its DN mutant. The 
screen did not distinguish between an effect on secretion mediated by changes in the 
expression of cargo mRNAs, in the rate of their translation or translocation into the ER, 
or in the rate of protein transport along the secretory pathway. Furthermore, it is 
important to bear in mind that if a DN Rab caused a relative decrease in cargo secretion, 
this effect may have been mediated through inhibition of secretion by the DN Rab, 
through stimulation of secretion by the corresponding WT Rab, or through a combination 
of these two scenarios. Conversely, if a DN Rab caused a relative increase in cargo 
secretion, this may have been mediated through stimulation of secretion by the DN Rab, 
through inhibition of secretion by the corresponding WT Rab, or through a combination 
of these two scenarios. Lastly, some DN Rabs affected the secretion of more than one 
cargo. In some cases, such as those of Rab11A and Rab11B, the secretion of all cargoes 
was affected in the same direction (Figures 3.7 and 3.8). A possible explanation of such a 
phenotype is that the examined Rab controls the transport of all the cargoes whose 
secretion was affected. In other cases, a DN Rab caused a relative increase in the 
secretion of one cargo, while, in the same sample, causing a relative decrease in the 
secretion of another cargo. For example, Rab1b appeared to stimulate ApoE secretion but 
at the same time to inhibit ApoB secretion (Figure 3.8 and Chapter 5). A possible 
explanation of such a phenotype is that the Rab differentially controls the transport of the 
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several cargoes tested; which would make the Rab an interesting candidate for further 
investigation.  
3.11. Overview of the hits 
The Rabs which were determined to be expressed in the Huh-7.5 cells and in the 
HFLCs, and whose DN mutants significantly altered the secretion of one or several of the 
hepatic cargoes tested, were considered for further analysis. Ongoing efforts to elucidate 
the involvement of Rabs 11a, 11b, 8a, and 8b in hepatic cargo secretion are presented in 
greater detail in Chapter 4. The characterization of the differential control of hepatic 
cargo egress by Rab1b is presented in Chapter 5. I summarize herein some possibly 
interesting notes that I have gathered on documented functions of some of the other Rab 
hits. I also suggest potential means by which these Rabs may control cargo secretion in 
general, and secretion of the hepatic cargoes albumin, the lipoproteins, and HCV, in 
particular. Some of these functions are selectively summarized in Table 3.1. 
Rab1c (more widely known as Rab35) controls various aspects of endocytic 
recycling and endosome function, including delivery of membrane vesicles to the 
cytokinesis furrow of dividing cells (Kouranti et al., 2006). Since Rab1c/35 inactivation 
impaired the secretion of all the cargoes tested, it would be interesting to analyze the 
extent to which, if any, it mediates transport of vesicles containing these cargoes. The 
experiments would need to carefully rule out domino effects on secretion caused 
downstream of inhibition of cell division, which would be a major general concern in all 






Table 3.1. Selected known functions of the DN Rab screen hits. 
Function Rab References 












(Chavrier et al., 1990a; Tisdale and Balch, 1996; 
Tisdale et al., 1992) 
Rab6b, 
Rab6c 
(Goud et al., 1990; Martinez et al., 1994) 
Rab30 (Thomas et al., 2009) 
Rab33b (Zheng et al., 1998) 
Rab43 (Dejgaard et al., 2008; Fuchs et al., 2007; Haas et al., 
2007) 
Post-Golgi 
secretion and  
recycling 




(Fischer von Mollard et al., 1990) 
Rab8a 
Rab8b 




(Casanova et al., 1999; Ren et al., 1998; Ullrich et al., 
1996) 




(Winslow et al., 2010; Zoppino et al., 2010) 
Rab24 (Munafo and Colombo, 2002) 





Rab1c/35 (Kouranti et al., 2006) 
Rab4a (van der Sluijs et al., 1992; Van Der Sluijs et al., 
1991) 
Rab5c (Chavrier et al., 1990a) 
Rab7b (Chavrier et al., 1990a) 
Rab9a (Lombardi et al., 1993) 
Rab12 (Matsui et al., 2011) 
Rab21 (Simpson et al., 2004) 
Rab22a (Mesa et al., 2001) 
Rab23 (Eggenschwiler et al., 2001; Evans et al., 2003) 






Rab3d/16 inactivation affected albumin secretion in our assays, and Rab3d has 
previously been implicated in HCV release (Coller et al., 2012). It may well be one of the 
Rabs which controls the final stages of cargo release. From the same functional group of 
Rabs associated with regulated secretion, the Rabs 3b and 37 also exhibited phenotypes 
in our assays and may also be involved in hepatic cargo secretion (Fukuda, 2008). 
Rab12 inactivation stimulated ApoE and ApoB100 release, but not albumin 
release. A previous study has implicated Rab12 in regulating transport of cargo destined 
for degradation from a recycling compartment to an endolysosomal compartment (Matsui 
et al., 2011). Since hepatocytes control lipoprotein release by in part regulating their 
intracellular degradation, including from post-Golgi compartments (Pan et al., 2008a), 
and since Rab12 mediates such a process, then the observed selective stimulation of 
cargo secretion could be easily explained. The lipoprotein cargo that would no longer be 
targeted for degradation in the presence of DN Rab12 could instead find its way out of 
the cells. It would be interesting to evaluate if the density distribution profile of secreted 
ApoB100-containing lipoproteins changes in response to Rab12 inactivation. 
Rab13 inactivation impaired the release of all three cargoes I tested. An inquiry 
into Rab13 function could tease out whether Golgi to TGN traffic inhibition by 
expression of DN Rab13 (Nokes et al., 2008) is the only cause or the main cause of the 
observed phenotype, or whether other Rab13 secretory functions may also play a part 
(Sun et al., 2014). For experiments also focusing on HCV release, care should be taken to 
avoid inhibition of early events in the HCV life cycle by inactivation of Rab13 function 
in tight junction formation and maintenance. Such a concern is valid since HCV uses the 
tight junction proteins claudin-1 and occludin as essential entry co-receptors (Evans et al., 
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2007; Ploss et al., 2009), while the same tight junction proteins are known Rab13 cargoes 
(Marzesco et al., 2002; Morimoto et al., 2005; Terai et al., 2006; Yamamura et al., 2008; 
Zahraoui et al., 1994). Tight junction disruption could thus interfere with HCV infection 
and may skew interpretation of any HCV release experiments where the HCV was 
introduced into the cells via infection.  
Rab23 also exhibited an interesting phenotype, since its DN mutant decreased 
albumin secretion while simultaneously increasing ApoE secretion. Rab23 regulates 
Sonic hedgehog signaling and has been implicated in the developmental disease 
Carpenter syndrome (Eggenschwiler et al., 2001; Evans et al., 2003; Jenkins et al., 2007; 
Wang et al., 2006). Future experiments would need to carefully account for any change in 
the activation state of the cells that may result from interference with Rab23 function.  
Autophagy has also been implicated in the regulation of the secretion of hepatic 
lipoproteins, HCV and other viruses (Chen et al., 2015; Pan et al., 2008a; Shrivastava et 
al., 2015). That several Rabs associated with autophagosome formation, namely Rabs 1, 
24, and 33B (Itoh et al., 2008; Munafo and Colombo, 2002; Winslow et al., 2010; 
Zoppino et al., 2010) were identified as hits in the secretion screen attests to the 
importance of this process for cell physiology and potentially for the secretion or the 
quality control of these cargoes.  
Finally, several other Rabs (4a, 5c, 7b, 9a, 21, 22a and 39a) involved in endocytic 
and degradative processes were hits of the DN Rab screen, but their cumulative score was 





3.12. Discussion: On the future the DN Rab screen  
As I hope I have shown in this chapter, and as I will describe in further detail in 
the following two chapters, expression of a collection of 62 DN Rab GTPases has proven 
to be an effective and unbiased method that I used to inhibit secretion events from cells, 
and to identify transport pathways utilized by the tested secretory cargoes. The 
experiments that I described above outline a succession of inquiry steps that can be easily 
applied to other cellular systems and other cargoes. Indeed, since the Rab constructs were 
expressed using VSVg-pseudotyped lentiviruses, they could be easily and efficiently 
delivered to a great number of other cell types, including hard to transfect ones. I suspect 
that the facility with which I was able to transduce the overwhelming majority (Figure 
3.4) of the cells in culture may well have been instrumental in ensuring the success of the 
approach. While preparation of the virus stocks was not trivial, it did not necessitate large 
scale operations or specialized equipment. It was particularly advantageous that 
ultracentrifugation was not required to concentrate the virus stocks. Furthermore, the titer 
determination method was sufficiently easy and amenable to multiplexing, even though I 
did all the steps manually. All of these methods can easily be transferred to an averagely 
equipped laboratory that also had access to a flow cytometer.  
The methodology of the screen could nevertheless be further improved. For 
example, the lentiviral vectors could be modified to express Renilla luciferase from an 
IRES downstream of the Rab protein. In this setting, the efficiency of target cell 
transduction could be easily monitored biochemically, while continuing to estimate cell 
mass by the FLuc measurements (Figure 3.2). Alternatively, a cargo of interest could be 
modified by tagging it with an enzymatic reporter, such as a luciferase domain. Of 
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course, functional assays would need to be first performed to confirm that the tagged 
cargo molecule reproduced the secretory behavior of the endogenous protein, as outlined 
for ApoE-GFP in Chapter 6. If the tagged cargo proved functional, however, fast, easy 
and inexpensive enzymatic assays of the media and of the cell lysates may replace the 
somewhat cumbersome and expensive ELISA assays that I employed, and would 
therefore mitigate the effort and cost associated with developing and characterizing such 
















Ongoing Characterization of the Involvement of  
Rab11 and Rab8 in Hepatic Cargo Secretion 
The DN Rab screen (discussed in the previous chapter) identified several potential 
regulators of hepatic cargo egress. For reasons described throughout this chapter, the 
Rabs 11a, 11b, 8a, and 8b were particularly interesting hits. Efforts are underway to 
understand how are these Rabs, as well as the transport pathways that they regulate, 
involved in lipoprotein, albumin, and HCV secretion. Since this work is not yet complete, 
I present only the preliminary experiments that I have set up to advance this inquiry. I 
also outline some immediately obvious experiments that I am performing in order to gain 
a better understanding of the process that I am studying. Experiments further down the 
line will need to be decided based on results that have not yet been generated, so I shall 
not subject the reader to an exercise in long-term experimental planning. I do discuss 
however the implications of some possible findings, while being fully aware that, in the 
large scheme of scientific inquiry, experiments may provide unexpected results. 
4.1. Overview:  Rab11 and Rab8 functions in cargo secretion  
Rab11a and Rab11b were interesting hits of the DN Rab screen (Chapter 3), since 
expression of their DN mutants caused some of the largest phenotypes measured. The 
major known functions of the Rab11 subfamily members Rab11a, Rab11b and Rab11c 
(also known as Rab25), have been recently reviewed (Kelly et al., 2012; Welz et al., 
2014) and are summarized in Table 4.1. In non-polarized cells, Rab11 localizes at and 
controls the function of the recycling endosome, including recycling and secretory 
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activities associated with it. For example, Rab11 mediates transferrin recycling and post-
Golgi exocytosis of VSVg in non-polarized cells (Chen et al., 1998). In contrast, in 
polarized cells, Rab11 functions primarily at the apical pole, where it localizes at the 
apical recycling endosome (Casanova et al., 1999; Goldenring et al., 1996). There, Rab11 
primarily controls secretory and recycling activities of apical cargoes, with little or no 
involvement in basolateral secretion and recycling (Brown et al., 2000; Casanova et al., 
1999; Cresawn et al., 2007; Hoekstra et al., 2004; Leung et al., 2000; Sheff et al., 1999; 




Table 4.1 Summary of known Rab11 functions 
Rab11 cargoes or functions Reference 
Plasma membrane receptor transport or recycling 
Transferrin and the transferrin receptor in non-
polarized cells 
(Ren et al., 1998; Ullrich et al., 1996; 
Wilcke et al., 2000) 
Fc receptor FcRn (Tzaban et al., 2009; Ward et al., 
2005) 
Glucose transporter GLUT4 (Uhlig et al., 2005) 
Chemokine scavenging decoy receptor D6 (Bonecchi et al., 2008) 
Langerin and CD1α in Langerhans cells (Gidon et al., 2012; Salamero et al., 
2001; Uzan-Gafsou et al., 2007) 
Transforming growth factor-β (TGF-β) receptor (Mitchell et al., 2004) 
Fibroblast growth factor receptor 4, FGFR4  (Haugsten et al., 2014) 
Protease-activated receptor 2, PAR2  (Roosterman et al., 2003) 
CXCR2  (Fan et al., 2003; Fan et al., 2004) 
Low-affinity formyl peptide receptor FPRL1  (Ernst et al., 2004) 
Angiotensin II type 1 receptor AT1R  (Dale et al., 2004; Hunyady et al., 
2002) 
Thromboxane A2 receptor TPβ  (Hamelin et al., 2005; Theriault et al., 
2004) 
β1-adrenergic receptor β1AR  (Gardner et al., 2011) 
β2-adrenergic receptors β2AR  (Moore et al., 2004) 
M4 muscarinic acetylcholine receptor  (Volpicelli et al., 2002) 
μ-opioid receptor  (Wang et al., 2008) 
V2 vasopressin receptor  (Innamorati et al., 2001) 
E-cadherin (Lock and Stow, 2005) 
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Table 4.1 Summary of known Rab11 functions 
Rab11 cargoes or functions Reference 
Channel and transporter recycling 
H+-K+-ATPase of gastric parietal cells (Calhoun and Goldenring, 1997; 
Calhoun et al., 1998; Duman et al., 
1999; Goldenring et al., 1994) 
V-ATPase in salivary duct cells (Oehlke et al., 2011) 
Bile salt export pump, BSEP or ABCB11  (Wakabayashi et al., 2005; 
Wakabayashi et al., 2004) 
Hepatic multidrug resistance-associated protein 
2, MRP2 
(Park et al., 2014) 
Cystic fibrosis transmembrane conductance 
regulator, CFTR 
(Gentzsch et al., 2004; Silvis et al., 
2009; Swiatecka-Urban et al., 2005; 
Swiatecka-Urban et al., 2007) 
Dopamine transporter  (Furman et al., 2009) 
Various cation channels: HCN2, HCN4, 
KCNA5, KCNQ1, KCNE1, TRPV5, TRPV6, 
Cav1.2, ENaC 
(Best et al., 2011; Butterworth et al., 
2012; Hardel et al., 2008; McEwen et 
al., 2007; Seebohm et al., 2007; van 
de Graaf et al., 2006) 
Secreted cargo transport 
Insulin (Sugawara et al., 2009) 
Human growth hormone (Khvotchev et al., 2003) 
Interferon-γ and tumor necrosis factor α (Reefman et al., 2010) 
Soluble vascular endothelial growth factor (Jung et al., 2012); 
Matrix metalloproteinase secretion (Yu et al., 2014) 
Other Rab11 functions 
Ciliogenesis and transport to the primary cilium 
membrane 
(Deretic et al., 1996; Knodler et al., 
2010; Li et al., 2007; Mazelova et al., 
2009a; Satoh et al., 2005; Thuenauer 
et al., 2014; Ward et al., 2011; 
Westlake et al., 2011) 
Intestinal and hepatic apical transport defects 
associated with microvillus inclusion disease 
(Girard et al., 2014; Knowles et al., 
2014; Knowles et al., 2015) 
Exosome production and multivesicular body-
plasma membrane fusion 
(Savina et al., 2005; Savina et al., 
2002) 
β-amyloid production  (Udayar et al., 2013) 
Stretch-regulated exocytosis of discoidal-
fusiform vesicles in bladder umbrella cells  
(Khandelwal et al., 2013; Khandelwal 
et al., 2008) 
Colocalization with epidermal lamellar granules 
in keratinocytes  
(Ishida-Yamamoto et al., 2007) 
Melanin transfer between melanocytes and 
keratinocytes  
(Tarafder et al., 2014) 
Macrophage phagocytosis (Cox et al., 2000) 
Sorting activities in the renal proximal tubule  (Mattila et al., 2014) 
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Table 4.1 Summary of known Rab11 functions 
Rab11 cargoes or functions Reference 
Membrane recycling during cell migration  (Assaker et al., 2010; Jones et al., 
2006; Kessler et al., 2012; Prigozhina 
and Waterman-Storer, 2006) 
Membrane delivery during cytokinesis (Fielding et al., 2005; Neto et al., 
2013; Wilson et al., 2005) 
Neuronal dendrite and axon growth (Takano et al., 2012; Takano et al., 
2014) 
Developmental signaling  (Emery et al., 2005; Jafar-Nejad et 
al., 2005; Ossipova et al., 2015; 
Ossipova et al., 2014) 
General apical lumen formation  (Alvers et al., 2014; Bryant et al., 
2010) 
Bile canaliculus formation  (Wakabayashi et al., 2005) 
IgA transcytosis (Casanova et al., 1999; Sheff et al., 
1999; Xu et al., 2011; Xu et al., 2013) 
VSVg post-Golgi transport in non-polarized cells (Chen et al., 1998; de Graaf et al., 
2004) 
Functions in host cell-pathogen interactions 
HIV-1 Vpu function (Varthakavi et al., 2006) 
Influenza A virus particle formation (Amorim et al., 2011; Bruce et al., 
2010; Chou et al., 2013; Eisfeld et al., 
2011; Momose et al., 2011) 
Hantavirus (Andes virus) release (Rowe et al., 2008) 
HCV release (Coller et al., 2012) 
Porphyromonas gingivalis exit from recycling 
endosomes  
(Takeuchi et al., 2011) 
 
Functionally associated with Rab11 are two other hits of our screen, the Rab8 
isoforms Rab8a (Chavrier et al., 1990b; Chen et al., 1993) and Rab8b (Armstrong et al., 
1996). They localize to the cell periphery (Chen et al., 1993) and have been involved in 
cargo secretion (Huber et al., 1993a; Huber et al., 1993b), cell shape regulation (Peranen, 
2011), and primary cilium formation and function (Das and Guo, 2011; Nachury et al., 
2007). These known functions are summarized in Table 4.2. As with Rab11, Rab8 
involvement in both basolateral (Huber et al., 1993a; Huber et al., 1993b) and apical 
(Nachury et al., 2007; Sato et al., 2014; Sato et al., 2007) cargo transport has been 
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described. The functional coordination between Rab11 and Rab8 (Khandelwal et al., 
2013; Knodler et al., 2010; Wang et al., 2012; Westlake et al., 2011) is likely due to a 
well described axis of control that involves these two GTPases: GTP-loaded Rab11 
recruits Rabin8, a Rab8-specific GEF, which in turn recruits and activates Rab8 (Knodler 
et al., 2010; Westlake et al., 2011). Unsurprisingly therefore, in our assays, the phenotype 
associated with DN Rab11a or Rab11b expression, namely an increased relative 
secretion, was mirrored by that associated with DN Rab8b expression, which also caused 
a significant increase in relative cargo secretion (Figures 3.7 and 3.8). Expression of DN 
Rab8a, in contrast, impaired the relative cargo secretion (Figures 3.7 and 3.8). That 
inactivation of three Rabs that are expected to function in tandem (Rabs 11a, 11b, and 8b) 
caused similar effects on cargo secretion strongly supports the conclusion that these Rabs 
are likely involved in the same secretion pathway(s).  
Table 4.2 Summary of known Rab8 functions 
Rab8 cargoes or functions References 
VSVg (Ang et al., 2003; Ang et al., 2004; 
Huber et al., 1993b; Schuck et al., 
2007) 
Semliki Forest virus E2 glycoprotein transport (Huber et al., 1993a) 
Intestinal and hepatic apical transport defects 
associated with microvillus inclusion disease 
(Knowles et al., 2014; Sato et al., 
2014; Sato et al., 2007) 
Primary ciliogenesis and transport (Feng et al., 2012; Knodler et al., 
2010; Nachury et al., 2007; Omori et 
al., 2008; Sato et al., 2014; Westlake 
et al., 2011) (Deretic et al., 1995; 
Moritz et al., 2001; Wang et al., 
2012; Ward et al., 2011) 
Cell membrane protrusion formation and actin 
reorganization 
(Hattula et al., 2002; Hattula et al., 
2006; Huber et al., 1993a; Huber et 
al., 1995; Peranen et al., 1996; Powell 
and Temesvari, 2004; Simons et al., 
1999) 
Wnt signaling (Demir et al., 2013) 
Stretch-regulaterd exocytosis of discoidal-
fusiform vesicles in bladder umbrella cells  
(Khandelwal et al., 2013) 
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Table 4.2 Summary of known Rab8 functions 
Rab8 cargoes or functions References 
Vesicle delivery during cytokinesis (Kaplan and Reiner, 2011) 
Melanosome movement (Chabrillat et al., 2005; Chakraborty 
et al., 2003) 
Glucose transporter GLUT4 vesicle translocation (Ishikura and Klip, 2008; Randhawa 
et al., 2008; Sun et al., 2010b) 
Zymogen granule formation in pancreatic acinar 
cells 
(Faust et al., 2008) 
Cryptococcus neoformans capsular 
polysaccharide secretion 
(Yoneda and Doering, 2006) 
E-cadherin transport (Yamamura et al., 2008) 
Membrane Type-1 matrix metalloproteinase 
secretion 
(Bravo-Cordero et al., 2007) 
Adenocorticotropic hormone secretion (Chen et al., 2001) 
AMPA glutamate receptor recycling (Brown et al., 2007; Gerges et al., 
2004) 
Anti-mycobacterial autophagy (Pilli et al., 2012) 
Transferrin receptor traffic (Vaibhava et al., 2012) 
Apical lumen formation (Galvez-Santisteban et al., 2012) 
Metabotropic glutamate receptor subtype 1 
traffic 
(Esseltine et al., 2012) 
Dense granule release in platelets (Hampson et al., 2013) 
Endospanin interaction (Hirvonen et al., 2013) 
KCNN4 potassium channel trafficking (Bertuccio et al., 2014) 
Cytotoxic T-lymphocyte-associated protein 4 (Banton et al., 2014) 
α2B- and β2-Adrenergic receptors (Dong et al., 2010) 
Dengue virus 2 (Xu et al., 2009; Xu et al., 2008) 
ABCA1 function and cholesterol efflux (Linder et al., 2009; Linder et al., 
2007) 
Sucrase-isomaltase and lactase-phlorizin 
hydrolase 
(Cramm-Behrens et al., 2008) 
 
How do Rab11 and Rab8 GTPases control hepatic cargo secretion? In my hands, 
Rab11a, 11b and 8b inactivation by expression of DN mutants resulted in significant 
stimulation of the secretion of albumin, ApoE and ApoB100, while DN Rab8a expression 
inhibited cargo secretion (Figures 3.7 and 3.8). Albumin, ApoE and ApoB100 are 
expected to be secreted basolaterally, since all are secreted into the bloodstream. It is not 
surprising therefore that inactivation of a basolateral secretion factor, Rab8a (Huber et al., 
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1993a; Huber et al., 1993b), would result in decreased secretion of these cargoes. That 
inactivation of Rabs primarily involved with apical transport (Rabs 11a, 11b, and 8b) 
would result in stimulation of basolateral cargo secretion could be easily explained if 
competition existed between apical and basolateral secretion activities. Common factors 
utilized by both apical and basolateral secretion processes (recycling endosome 
membranes come to mind as obvious candidates, although Rab effectors or other 
vesicular traffic regulators may also be involved) could be limiting. In such a scenario, if 
apical secretion is stimulated (by WT Rab11 or 8b overexpression), then basolateral 
secretion is expected to become inhibited. Conversely, if apical secretion is impaired (by 
DN Rab11 or 8b overexpression), then basolateral secretion is expected to become 
stimulated. If either or both of the above scenarios is true, then the overall effect of paired 
WT-DN Rab expression would be a relative stimulation of basolateral cargo secretion, 
similar to what I observed. Of course, other plausible transport regulation scenarios could 
be invoked to explain the observed phenotype.  
The pattern of Rab11 and Rab8 potential involvement in polarized hepatic cargo 
secretion that I proposed above is corroborated by the findings of a study testing the 
function of these Rabs in the release of Andes virus, a New World hantavirus (Rowe et 
al., 2008). Several hantaviruses, the etiologic agents of the often lethal hantavirus 
pulmonary syndrome, have been shown to be released primarily at the apical side of 
polarized cell cultures (Krautkramer et al., 2012; Ravkov et al., 1997; Rowe and Pekosz, 
2006), with roughly 1,000-fold higher viral titers being shed apically compared to 
basolaterally (Ravkov et al., 1997; Rowe and Pekosz, 2006). This preference for 
polarized apical release is consistent with a predominantly respiratory mode of Andes 
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virus transmission (Padula et al., 2004). Andes virus release was severely inhibited by 
Rab11a, 11a and 11b, or 8a and 8b knockdown, but not by Rab8a knockdown alone 
(Rowe et al., 2008). While these experiments were done in sparsely-plated monolayer-
grown African green monkey kidney cells Vero E6/C1008 (Rowe et al., 2008), I wish to 
emphasize that these cells do possess the capacity to form polarized monolayers and to 
support polarized cargo transport (Srinivas et al., 1986; Zhou et al., 2011). In this context, 
the similarity between my findings and those of (Rowe et al., 2008) lie in the functional 
grouping of the Rab effects. Rab11a, 11b and 8b inhibition apparently stimulated 
basolateral cargo secretion (Figures 3.7 and 3.8), while Rab11a and 8b inhibition 
impaired apical cargo secretion (Rowe et al., 2008). In contrast Rab8a inhibition 
apparently impaired basolateral cargo secretion (figures 3.7 and 3.8), while not affecting 
(or even slightly stimulating) apical cargo secretion (Rowe et al., 2008). These correlated 
observations, therefore, together with the cumulative knowledge of Rab11 and Rab8 
involvement in polarized cargo secretion (Tables 4.1 and 4.2), identify these Rabs as 
interesting targets more in-depth investigations.  
 4.2. Experiments investigating Rab11 and Rab8 involvement in secretion 
The approach that I am using to investigate the involvement of Rab11 and Rab8 
in hepatic cargo secretion parallels to some extent the line of inquiry that I pursued to 
investigate the involvement of Rab1b in hepatic cargo secretion and which I present in 
detail in the next chapter. Briefly, the following steps are part of my immediate 
experimental plan:  
1. Repeat the experiments detailed in the DN Rab screen to confirm the 
reproducibility of the observed phenotype. Also include in this assay the GTPase-
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deficient and the GDP-restricted DN Rab mutants, besides the already used 
nucleotide-binding mutants. 
2. Quantify cargo expression levels in the presence of DN Rab expression to 
determine whether any DN Rab-associated changes in expression levels may 
need to be accounted for when interpreting the observed changes in cargo 
secretion. 
3. Inducibly express DN and WT Rab11 and Rab8 constructs and quantify cargo 
secretion. As explained in more detail below and in Chapter 5, inducible DN Rab 
expression is preferable to lentivirus-mediated transient expression, since 
potentially confounding experimental variations associated with lentivirus 
transduction may be easily avoided. 
4. Perform colocalization analyses between the Rabs and the cargo. I show in 
Chapter 6 that an ApoE-GFP fusion protein is functional with respect to 
lipoprotein egress, which will facilitate such colocalization experiments.  
5. Assess the effect of inhibition of Rab11 and Rab8 on cargo egress from a 
polarized, primary hepatocyte-like cell culture system. 
6. Assess the effects of DN Rab11 and Rab8 expression on HCV egress. 
Some of the experiments outlined above have been performed, and I present my 






4.3. Effects of expression of a panel of DN Rab11 and Rab8 mutants on 
hepatic cargo secretion 
To confirm the secretion phenotypes that I observed when I overexpressed the 
nucleotide-binding DN mutants of Rab11 and Rab8, I repeated the lentivirus infection 
experiment. This time, besides the WT and the nucleotide-binding DN Rab mutants, I 
included both the GDP-restricted and GTPase mutants of Rabs 11a, 11b, 8a, and 8b. I 
reasoned that if one of a given Rab's mutants specifically affected cargo secretion, then 
the other mutants are also likely to do so, since they likely inhibit the same process, albeit 
at a different stage. In a parallel experiment, I also quantified cargo mRNA levels in the 
transduced cells to determine whether Rab expression was associated with changes in 
cargo expression that may account, at least in part, for the secretion phenotype observed 





















Figure 4.1. Confirmation of the effects of DN Rab11 and Rab8 expression on cargo 
secretion (next page). (A) Huh-7.5 FLuc cells were transduced with 100 I.U./cell of 
lentiviruses expressing the indicated constructs. At 48 h, a secretion assay was 
performed. Secreted cargo amounts and lysate luciferase activities were measured. 
Normalized secreted cargo amounts are shown relative to the WT values, on a Log2 scale. 
(B) Huh-7.5 cells were transduced as in (A), RNA was extracted at 48 h post 
transduction, and cargo mRNA levels were measured. Shown are relative cargo 
expression levels, on a Log2 scale. (A and B). Shown are means ± s.d. from n=3 parallel 













Expression of all three Rab8a mutants caused a significant decrease in the 
secretion of all three cargoes tested (Figure 4.1A), consistent with previous observations 
(Figure 3.8). Cargo mRNA levels, however, were also decreased in the presence of DN 
Rab8a expression (Figure 4.1B), raising the possibility that some or all of the observed 
decrease in secretion could have been due to downregulation of cargo expression. Further 
tests are needed to distinguish the change in secretion levels due to downregulation of 
cargo expression and any possible direct effects of DN Rab8a construct expression on 
cargo transport.  
In contrast to Rab8a, expression of the Rab8b and Rab11a mutants resulted in 
increased secretion levels for all three cargoes tested. Expression of the nucleotide-
binding (N124I) and of the GDP-restricted (S25N) DN Rab11b also stimulated cargo 
secretion, while expression of the GTPase mutant (Q70L) of Rab11b resulted in impaired 
cargo secretion. The later result correlated with a downregulation of cargo expression 
levels by Rab11bQ70L. Similarly, increased secretion caused by Rab8bQ67L or Rab11bN124I 
partly correlated with increased cargo expression. For all the other mutants, namely 
Rab8bN121I, Rab8bT22N, Rab11aN124I, Rab11aS25N, Rab11aQ70L, and Rab11bS25N, the 
increased secretion associated with DN Rab expression did not correlate with increased 
cargo mRNA levels in the transduced cells, suggesting that the observed secretion 
phenotypes may be primarily due to effects of the DN Rabs on the vesicular transport of 
these cargoes. Nonetheless, additional experimentation is required to further parse these 





4.4. Cell lines inducibly expressing DN Rab11 and Rab8 
A drawback of using concentrated lentivirus particles to express the DN Rabs in 
the short term expression experiments described above and in Chapter 3 is that other 
material besides the lentivirus particles may be present in the virus stock. Such 
contaminants may include cell debris from the lentivirus producing HEK293T cells, 
exosomes, or the DNA transfected into these cells to make the lentivirus particles. To 
exclude confounding and likely unaccountable effects of non-lentivirus components of 
the lentivirus preparation, I created cell lines that can be induced to express mCherry-
tagged Rabs. To do so, I transduced the Huh-7.5 TetON cell line with retroviruses 
expressing the mCherry-tagged WT and mutant Rabs from a tetracycline response 
element (Figure 2.1D), then selected stably transduced cell populations. I used mCherry 
expression as a marker that allowed me to easily identify and quantify Rab construct 
expression. I preferred this inducible expression approach to long-term constitutive 
expression of the DN Rab constructs, in part because Rab11a (Sobajima et al., 2014; Yu 
et al., 2014) and Rab8a (Sato et al., 2014; Sato et al., 2007) knockouts are lethal in mice.  
These cell lines are in the process of being characterized. They robustly induced 
Rab construct expression after exposure to doxycycline (Figure 4.2A), and the mCherry-
Rab fusions were easily detected by Western blotting in the lysates of the induced cells 
(Figure 4.2B). Ongoing experiments in these inducible expression cell lines are designed 
to quantify the effects of DN Rab11 or Rab8 expression on cargo mRNA levels, and on 
cargo secretion as determined by quantifying both the cell-associated and secreted cargo 












Figure 4.2. Cell lines for inducible expression of Rab11 and Rab8 constructs (next 
page). Huh-7.5 TetON cells were transduced with retroviruses expressing the indicated 
constructs under the control of a tetracycline response element, and were then selected. 
(A) Induction of mCherry-Rab expression after 2 days of treatment with 3 μg/mL of 
doxycycline was characterized by flow cytometry. Red traces, non-induced cells; blue 
traces, induced cells. (B) Cell lysates from cells treated as in (A) were harvested and 


















4.5. A polarized, primary hepatocyte-like cell culture system 
As discussed at the beginning of this chapter, the increase in cargo secretion 
observed in the DN Rab screen and in the confirmatory experiments described above was 
puzzling, since Rab11 (and Rab8 acting downstream) have overwhelmingly been shown 
to control the secretion or recycling of apically-targeted secretory or membrane-
associated cargoes (Tables 4.1 and 4.2). Albumin, ApoE (Lee et al., 2003; Traber et al., 
1987), and ApoB (Traber et al., 1987) are basolateral secretory cargoes. Is the phenotype 
that I observed a manifestation of defective polarized transport that might occur in the 
Huh-7.5 cell line, or is it revealing of a potentially interesting regulation of hepatic 
basolateral secretion by Rab11?  
Historically, hepatocyte cell culture systems have been difficult to use for the 
study of at least some polarity-associated processes (Treyer and Musch, 2013). Even in 
cases where the cells retained a polar phenotype, this phenotype has manifested in 
formation of bile canaliculi-like structures between adjacent cells (Andrus et al., 2011; 
Chiu et al., 1990; Ploss et al., 2010; Treyer and Musch, 2013). A separation of basolateral 
and apical compartments easily amenable to biochemical investigations, such as that 
obtained by growing the epithelial cell lines MDCK or Caco-2 on trans-well filters has 
not been achieved for hepatocyte cell culture models. I am fortunate that Dr. Viet Loan 
Dao Thi and Dr. Xianfang Wu of the Rice lab are currently leading an effort to develop 
and characterize a promisingly useful hepatocyte polarity model. I am very thankful to 
Dr. Dao Thi, Dr. Wu, Dr. Ursula Andreo, and soon-to-be-Dr. Rachel Belote for their 
wonderful collaboration on this project. The system is still being characterized, and I only 
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mention here some preliminary findings that informed us that this system may aid in the 
analysis of polarized secretory transport by hepatocytes.  
Briefly, the system is based on in vitro differentiation of human embryonic stem 
cells along the endoderm/hepatocyte lineage. The resulting cells were called iHeps 
(induced hepatocyte-like cells). During differentiation, the iHeps were plated on trans-
well filters, where they were allowed to complete their differentiation. The resulting 
filter-grown iHep monolayer (Figure 4.3A) had the following properties (Viet Loan Dao 
Thi, Xianfang Wu, Ursula Andreo and Rachel Belote, personal communications): (i) the 
cells expressed hepatocyte-specific genes; (ii) the monolayer formed a tight diffusion 
barrier, as evidenced by measurement of high trans-epithelial resistance values and by 
impermeability of the monolayer to diffusion of fluorescent dextrans; (iii) the monolayer 
secreted bile acids exclusively in the inner chamber of the trans-well filter (Figure 4.3A), 
which I will refer to from here on as the "apical chamber"; (iv) the iHeps secreted 
ApoB100-containing lipoproteins which floated in a density gradient at density fractions 
consistent with those of properly lipidated VLDL particles; and (v) the cells formed a 








Figure 4.3. Hepatic cargo secretion by polarized iHeps (A) Schematic representation 
of the polarized iHeps growth setup. Cells were grown on a trans-well filter with media 
on both sides. The chamber within the insert was designated as “apical” compartment, 
while the chamber surrounding the insert was designated as “basolateral” compartment. 
(B) Preponderantly basolateral secretion of albumin and apolipoproteins by the polarized 
iHeps. Media from both apical and basolateral chambers was collected after a 6 h 
secretion assay and its cargo content was quantified by ELISA. The amount secreted in 
the basolateral chamber was expressed as fraction of the total (apical + basolateral) 
secreted cargo amount. Shown are means ± s.d. from n=3 trans-wells.  
 
The focus of this work is to investigate the regulation of the secretion of 
basolaterally-targeted hepatocyte cargoes. I therefore measured the amounts of albumin, 
ApoE, and ApoB100 that were released by trans-well-grown iHeps in both the apical and 
basolateral chambers of the growth set-up (Figure 4.3A). I expressed the cargo amounts 
secreted on the basolateral side as percentages of the total (basolateral + apical) secreted 
cargo amounts. The results of one such experiment are shown in Figure 4.3B. All cargoes 
were reproducibly secreted primarily on the basolateral side of the trans-well filter, as 
expected by the site of secretion of these cargoes in vivo. Furthermore, the percentages of 
cargo amounts secreted by the iHeps in the basolateral chamber (63% for albumin, 78% 
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for ApoE, and 75% for ApoB100, Figure 4.3B) were similar to the percentages of 
triglycerides (60-80%) or apolipoproteins (75-100%) shown to be secreted basolaterally 
by the polarized intestinal cell line Caco-2 (Traber et al., 1987). That the basolaterally-
secreted albumin fraction was slightly smaller than the fractions of the basolaterally-
secreted ApoE or ApoB100 (Figure 4.3B) was not surprising, since albumin may be 
transcytosed across epithelial barriers (Monks and Neville, 2004).  This result, together 
with the totality of the data obtained by my collaborators, indicated that the likely 
polarized filter-grown iHeps may become a useful cell culture model for the study of 
polarized hepatic secretion.  
To investigate the involvement of Rab11 and Rab8 in polarized hepatic cargo 
secretion from these iHeps, we are modifying the parental embryonic stem cells to allow 
for inducible expression of WT or DN Rab constructs. We will then differentiate these 
cells into filter-grown iHeps, induce the expression of the Rab constructs, and then 
quantify the amounts of cargoes released in the apical and basolateral chambers of the 
trans-well culture system. The effects of DN Rab11 or Rab8 constructs on total and 
chamber-specific albumin and lipoprotein secretion will be therefore measured. They will 
be contrasted to any changes in apical bile salt secretion that we will measure in the 
apical chamber. Since bile salt transporters are recycled through the Rab11-positive 
apical recycling endosome (Wakabayashi et al., 2005; Wakabayashi et al., 2004), I expect 
that Rab11 inhibition will decrease the amounts of bile salt secretion secondary to 
intracellular endosomal retention of the bile salt transporters. The apical bile salt 
measurements will therefore serve as a positive control for Rab11 inactivation. Barring of 
course any unexpected experimental difficulties, we are poised to determine to what 
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extent these basolaterally-secreted hepatic cargo transport processes are dependent on 
Rab11 or Rab8 function. 
4.6. Rab11 involvement in HCV secretion  
My interest in defining the involvement of Rab11 and Rab8 in hepatic cargo 
egress was also in part prompted by a recent report which proposed that Rab11a controls 
infectious HCV secretion (Coller et al., 2012). This conclusion was based on two main 
findings. First, the authors showed that treatment of Huh7.5 cells with a cocktail of 4 
small interfering RNAs (siRNAs) or with any of two individual siRNAs directed against 
the Rab11a message resulted in decreased release of infectious HCV, and concurrent 
accumulation of intracellular infectious virus (Coller et al., 2012). While the authors 
detected a substantial decrease in Rab11a message levels in siRNA-treated cells, they did 
not investigate whether Rab11a protein levels had decreased as well (Coller et al., 2012). 
Furthermore, the authors did not exclude the possibility that the observed phenotype was 
due to off-target effects of the two active siRNA molecules (Coller et al., 2012). Such 
off-target effects have been documented in other settings (Chung et al., 2014) and would 
need to be ruled out in order to better interpret the results of knockdown experiments. 
Indeed, an experiment attempting to rescue HCV infectivity release by expressing an 
siRNA-resistant Rab11a construct was not performed (Coller et al., 2012). The authors 
do however perform colocalization experiments showing that HCV Core, labeled using a 
tetracysteine-tagged HCV Core protein expressed from the viral genome and 
FlAsH/ReAsH staining (Griffin et al., 1998), colocalized with GFP-Rab11a (Coller et al., 
2012). The authors interpreted this observation to mean that HCV particles were secreted 
through Rab11a-positive recycling endosomes. Unfortunately, this conclusion is also 
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insufficiently supported for the following reasons. First, the FlAsH/ReAsH labeling 
involved treatment of the cells with 500 μM of the reducing agent 1,2-ethanedithiol 
(Coller et al., 2012). Significantly lower concentrations of a very similar reducing agent, 
dithiothreitol can be used to induce the unfolded protein stress response: 0.025-25.6 μM 
(Carpio et al., 2015) or 0.1-10 mM (Cox et al., 2011). As such, the possibility that the 
cells behaved aberrantly due to physiological stress was not excluded. Second, the 
labeled tetracysteine-Core puncta observed in these cells could have undergone non-
productive transport, by having become diverted from productive secretion routes into 
Rab11a-positive recycling endosomes and from there potentially into degradative 
compartments. Third, the cell line used in this study, Huh-7.5, expresses the full 
complement of HCV entry receptors and supports HCV entry (Evans et al., 2007; 
Lindenbach et al., 2005; Ploss et al., 2009). As a result, tetracysteine-Core could have 
made its way into Rab11a-positive recycling endosomes after first being secreted through 
Rab11a-independent pathway(s), followed by internalization and endocytic recycling 
transport. For these reasons, while the results of these experiments are consistent with the 
authors' conclusion that Rab11a controls HCV egress through the recycling endosome, 
the same experimental results may not add up to sufficiently strong evidence to rule out 
alternative scenarios.  
When considering the implications of HCV secretion through a Rab11-positive 
endosome, one must view this model in the larger context of the intra-host and inter-host 
virus transmission dynamics and evolutionary history. Studies of other viruses, such as 
influenza A virus (Amorim et al., 2011; Bruce et al., 2010; Chou et al., 2013; Eisfeld et 
al., 2011; Momose et al., 2011), HIV-I (Varthakavi et al., 2006), and Andes virus (Rowe 
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et al., 2008), have implicated Rab11a in virus release. Both influenza A virus (Rodriguez 
Boulan and Pendergast, 1980; Rodriguez Boulan and Sabatini, 1978) and Andes virus 
(Rowe and Pekosz, 2006) are released at the apical pole of infected cells, therefore Rab11 
involvement in the biogenesis of these viruses is not surprising. HCV epidemiological 
history suggests however that the primary (or at least the recent primary) route of virus 
transmission is through the blood or blood products, secondary to medical procedures, 
injection drug use, or risky sexual practices (Thomas, 2013). A potential implication of 
this mode of transmission is that HCV may be a virus that is primarily released at the 
basolateral sides of the hepatocytes. Therefore, Rab11 should not be involved in HCV 
release. Release of the virus at the apical side would also be problematic since HCV is an 
enveloped virus. HCV, unlike the non-enveloped hepatitis A and E viruses, which are 
primarily transmitted between hosts by a fecal-to-oral route (Protzer et al., 2012), might 
not survive the digestive environment of the duodenum where the bile products - and the 
apically released hepatotropic viruses - would access the digestive tube. Several questions 
arise then. Was Rab11 implicated in HCV release as a result of over interpretation of 
experimental findings, or as the manifestation of an in vitro phenotype with little 
significance for how HCV egress is regulated in the infected liver (Coller et al., 2012)? 
Does Rab11 carry an unexpected function in the transport of a presumably basolateral 
cargo, HCV, in the native hepatocyte? Or is the Rab11-HCV association an indication 
that HCV may indeed be released apically? If yes, how would such a finding fit into the 
larger picture of hepacivirus transmission and evolution? There is little information at the 
moment as to how HCV was transmitted before its modern efficient spread facilitated by 
advances in medical practice, or as to how the HCV-related hepaciviruses have evolved 
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and crossed species barriers (Pybus and Theze, 2015). The entire family could have been 
spread through blood-to-blood routes, perhaps mediated by tabanids such as horse flies 
(Pybus et al., 2007), similar to how the more distantly related flaviviruses use ticks and 
mosquitoes for transmission. If the hypothesized insect-mediated transmission was purely 
passive, with the insects simply carrying infected blood from one host to the other, there 
would be no need for the virus to possess capacity of being secreted apically. The virus 
could have nonetheless retained apical secretion capabilities from a distant ancestor 
which had been in fact released on the apical side of a producing cell. The virus may also 
require apical secretion capabilities if insect-mediated transmission involved virus 
replication in the vector's gut. Alternatively, vector-free transmission could have occurred 
through secretions (respiratory secretions, saliva) (Pybus and Theze, 2015), in which case 
apical secretion capabilities of the virus could be directly relevant. It is worth noting that 
hepacivirus RNA has been detected in respiratory secretions of likely infected animals 
(Kapoor et al., 2011), although it is unknown whether the presence of viral genetic 
material at that site was due to passive processes, such as leakage-mediated 
contamination of respiratory secretions by serum products in the context of an inflamed 
mucosa, or active processes, such as replication and assembly of the virus in cells of the 









The nature of Rab11 (and Rab8) involvement in hepatic cargo secretion, be that of 
the basolaterally targeted albumin and lipoproteins, or of HCV, remains at this time a 
mystery. Obviously, much work is needed to generate answers to the questions that I 
identified in this chapter, and my investigation into the regulation of these processes 
remains in its infancy. I hope nonetheless that the discussion of the possible involvement 
of Rab8 and Rab11 in cargo secretion, in both non-polarized Huh-7.5 cells or in polarized 
















Involvement of Rab1 in Hepatic Cargo Transport 
 
5.1. Rab1 and ER-to-Golgi transport 
Of the hits of the DN Rab screen (Chapter 3), Rab1b presented a peculiar 
phenotype. Compared to WT Rab1b expression, expression of Rab1bN121I apparently 
stimulated ApoE secretion when administered at an MOI dose of 25 (Figure 3.7) or 100 
(Figure 3.8) I.U./cell, and apparently impaired ApoB100 secretion when used at 100 
I.U./cell (Figure 3.8). This indicated that ApoE and ApoB100 secretion may respond 
differently to Rab1 inhibition. I have therefore proceeded to analyze Rab1b's involvement 
in cargo secretion in greater detail.  
The partially redundant Rab GTPases, Rab1a and Rab1b (Nuoffer et al., 1994), 
regulate anterograde vesicular transport from the ER to the Golgi system, and inhibition 
of their function impairs early anterograde transport of many secretory cargoes, the most 
extensively characterized being VSVg (Plutner et al., 1991; Tisdale et al., 1992). Other 
cargoes include the viral envelope glycoproteins of HIV-1 (Nachmias et al., 2012) and 
human herpes simplex-1 (Zenner et al., 2011); the Ebola virus VP40 capsid protein 
(Yamayoshi et al., 2010); the G-protein coupled receptors (GPCRs) rhodopsin (Satoh et 
al., 1997), angiotensin and adrenergic receptors (Filipeanu et al., 2004; Filipeanu et al., 
2006; Wu et al., 2001; Wu et al., 2003) and the calcium-sensing receptor (Zhuang et al., 
2010); ion channels (Flowerdew and Burgoyne, 2009; Robitaille et al., 2009); the β-
amyloid precursor protein (Dugan et al., 1995), and the secreted proteins human growth 
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hormone, interleukin-8 (Dong et al., 2012) and alkaline phosphatase (Ingmundson et al., 
2007).  
Rab1 localizes at the ER, at the Golgi, ERGIC, and on vesicles that transport 
cargo from the ER to the Golgi (Alvarez et al., 2003; Moyer et al., 2001b; Plutner et al., 
1991; Saraste et al., 1995). Rab1's function in early anterograde transport is underscored 
by the list of its known effectors. These include several Golgi tethers or Golgi structural 
proteins: p115 (Allan et al., 2000), GM130 (Moyer et al., 2001a; Weide et al., 2001), 
golgin-84 (Diao et al., 2003; Satoh et al., 2003) and giantin (Beard et al., 2005). Through 
these vesicle- and Golgi-associated proteins, Rab1 controls the delivery of secretory 
cargo into the Golgi compartment. Other effectors are: MICAL-1 (Weide et al., 2003), 
Iporin (Bayer et al., 2005), and GBF1 (Monetta et al., 2007). GBF1 is an Arf1 GEF that 
activates Arf1 on the surface of Golgi compartments and by doing so initiates COPI 
recruitment and therefore COPI-dependent vesicular transport (Alvarez et al., 2003; 
Claude et al., 1999; Garcia-Mata et al., 2003; Kawamoto et al., 2002; Monetta et al., 
2007; Niu et al., 2005; Szul et al., 2005; Zhao et al., 2002).  
Given that Rab1b inactivation as a consequence of expression of Rab1bN121I 
differentially affected the secretion of the several hepatic cargoes tested (Figure 3.8), and 
given that Rab1 controls anterograde transport from the ER to the Golgi, I inquired 
whether transport of albumin, ApoE and ApoB100 between these compartments may be 
differentially regulated. This idea was not unprecedented, since in vitro biochemical 
assays had already documented that ApoB and ApoE (Gusarova et al., 2007), or ApoB 
and albumin (Siddiqi, 2008), were packaged into distinct ER-derived vesicles. These 
findings, combined with my own observations, raised the possibility that Rab1b may 
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differentially control secretion of the cargoes that I investigated. I therefore set out to 
investigate in greater detail the function of Rab1 in hepatic cargo secretion.  
The main experimental approach that I utilized relied on inactivation of Rab1 
function by expression of DN Rab1 mutants. DN Rab1a or Rab1b mutants have been 
shown to inactivate Rab1 function (Nuoffer et al., 1994; Pind et al., 1994; Tisdale et al., 
1992). When VSVg anterograde transport was investigated, the GDP-restricted mutants 
(i.e. Rab1bS22N) and the nucleotide binding mutants (i.e. Rab1bN121I) blocked VSVg 
transport from the ER to the Golgi, while the WT versions and the GTPase-inactivating 
mutants (i.e. Rab1bQ67L) did not interfere with this process (Nuoffer et al., 1994; Pind et 
al., 1994; Tisdale et al., 1992). Furthermore, the transport stages at which the GDP-
restricted and the nucleotide binding mutants blocked VSVg progression were distinct. 
The GDP-restricted mutant blocked VSVg exit from the ER (Nuoffer et al., 1994), while 
the nucleotide binding mutant caused accumulation of VSVg in an ERGIC-like 
compartment (Pind et al., 1994). I therefore used this knowledge, and these Rab1 mutants 
to investigate the secretion of hepatic cargoes in greater detail. 
Before going onto describing the results, I wish to caution the reader that 
throughout this chapter I have used two methods to quantify cargo egress. In both 
methods, the amount of cargo that accumulated in the cell culture media was quantified 
by ELISA, but these measurements of secreted cargo by themselves were not sufficient to 
assess secretion. I needed to also control for the possibility - the fact even - that the 
various treatment conditions resulted in different amounts of cells being present in the 
culture at the time of the secretion assay, and therefore being responsible for the secretion 
activities measured. I utilized two methods to account for variation in cell mass. One took 
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advantage of luciferase activity measurements that I performed on cell lysates at the end 
of the secretion assay, the other used cell-associated cargo amounts measured in similar 
lysates. As I will explain throughout this chapter, the two methods estimated different 
aspects of secretion. While the overall results are facially different, I hope to convince the 
reader by the end of this chapter that the findings obtained using each of the methods do 
indeed agree with each other.  
5.2. Confirmation of DN Rab screen results 
I began my inquiry into how Rab1 controls hepatic cargo egress by repeating the 
type of secretion assays I performed as part of the DN Rab screen. I transduced Huh-7.5 
FLuc cells with lentiviruses expressing Rab1b or Rab1bN121I. In parallel, I also tested 
mCherry-tagged Rab1b constructs, both the WT form and the N121I mutant. I performed 
secretion assays and normalized the secreted cargo amounts by the luciferase activity of 
the cell lysates. The results were consistent with the previous observations (Figures 3.7 
and 3.8). Thus, untagged Rab1bN121I expression had only a small effect on albumin 
secretion (Figure 5.1A) while mCherry-Rab1bN121I had no detectable effect (Figure 5.1B). 
In contrast, ApoE secretion was stimulated by tagged or mCherry-tagged Rab1bN121I 
expression, while ApoB secretion was inhibited, by the same constructs (Figure 5.1A and 
B). As before, Rab1bN121I construct expression was associated with decreased luciferase 







Figure 5.1. Confirmation of Rab1bN121I effect on hepatic cargo secretion. Huh-7.5 
FLuc cells were infected with lentiviruses expressing WT (blue circles) or N121I mutant 
(red squares) versions of untagged Rab1b (A) or mCherry-Rab1b (B), respectively, all at 
an MOI of 100 I.U./cell. At 48 h post transduction, a 6 h secretion assay was performed. 
Albumin, ApoE, and ApoB100 amounts in the media were measured by ELISA, and the 
results were normalized by the luciferase activity in the cell lysates of the corresponding 
wells. Cargo secretion levels in the presence of the DN Rab1b constructs were plotted as 
relative to the secretion levels in the presence of WT Rab1b constructs, on a Log2 scale. 
(C) Relative luciferase (Luc) activities (Log2 scale) in the cell lysates from the 
experiments presented in panels (A) and (B), respectively. For each condition, means ± 
s.d. of values obtained in 3 parallel wells are presented. Significant differences (Student’s 
t-test): n.s., non-significant; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
5.3. Functional characterization of the mCherry-tagged Rab1b constructs 
Since mCherry-Rab1bN121I caused a secretion phenotype similar to the one caused 
by the untagged Rab1b mutant (Figure 5.1A-B), it was likely that mCherry tagging of 
Rab1b did not impair its activity. Indeed, GFP-Rab1 constructs have been shown to 
successfully carry out Rab1 functions (Alvarez et al., 2003; Moyer et al., 2001b). Since 
using mCherry-tagged Rab1b constructs in experiments would facilitate direct 
measurement of Rab construct expression levels and since the fusion proteins could be 
used in imaging experiments, I set out to more comprehensively characterize the 
functionality of these constructs. 
 
173 
Expression and localization of mCherry-Rab1b fusion proteins. I created 
constructs that encoded mCherry at the amino terminus of WT, N121I, S22N and Q67L 
Rab1b. When expressed in cells, these fusion proteins migrated on SDS-PAGE gels as 
single polypeptides of the expected ~ 49 kDa molecular weight (Figure 5.2A). 
Furthermore, the constructs displayed subcellular localizations (Figure 5.2B) similar to 
those previously described for GFP- and epitope-tagged Rab1 (Alvarez et al., 2003; 
Moyer et al., 2001b). These patterns of localization were: reticulate ER-like, perinuclear 
Golgi-like, and punctate vesicle-like signals for the WT and Q67L forms; ER-like and 




Figure 5.2. Expression and characterization of mCherry-Rab1b constructs. (A) 
Western blot of lysates of HEK293T cells transfected with mCherry- or mCherry-Rab1b 
expressing plasmids. mCherry was detected using an α-dsRed antibody. (B) Subcellular 
localization of mCherry-Rab1b constructs in Huh-7.5 cells. The cells were transduced 
with lentiviral particles expressing the indicated WT or mutant forms of mCherry-Rab1b 




Functionality of mCherry-Rab1b constructs. I next confirmed that the 
mCherry-Rab1b constructs could functionally interfere with VSVg anterograde transport. 
VSVg is amongst the best characterized Rab1 cargoes, and its tsO45 mutant allows for 
synchronized analysis of cargo egress (Bergmann et al., 1981). I co-transfected cells with 
a plasmid encoding mCherry or mCherry-Rab1b constructs and a plasmid encoding 
VSVgtsO45-GFP (Presley et al., 1997). I then allowed expression of the proteins at 39.5°C, 
under which conditions VSVgtsO45-GFP is retained in the ER (Kreis and Lodish, 1986; 
Presley et al., 1997) and its N-linked glycan chains are sensitive to digestion with both 
endoglycosidase H (Endo H) and peptide-N-glycosidase F (PNGase F). Next, I switched 
a set of the transfected cells to 32°C, a temperature which allows transport of this VSVg 
mutant out of the ER, through the Golgi system, to the plasma membrane (Bergmann et 
al., 1981). Transport of VSVg through the Golgi is accompanied by modification of its 
glycan chains by Golgi-resident enzymes, resulting in an Endo H-resistant, but PNGase 
F-sensitive form (Schwaninger et al., 1991). The cartoon in Figure 5.3A depicts the 
expected SDS-PAGE migration patterns of glycosidase-digested (Endo H- and PNGase 
F-sensitive) VSVg that has been retained in the ER either by the 39.5°C temperature 
block or by the lack of Rab1 activity (Figure 5.3A, the three bands at the left). The same 
cartoon also depicts the expected migration patterns of glycosidase-digested (Endo H-
resistant but PNGase F-sensitive) VSVg that has been transported out of the ER at  the 
permissive temperature and in the presence of active Rab1 (Figure 5.3A, the three bands 
at the right).  
In my hands, regardless of the construct expressed from the co-transfected 
plasmid, VSVg-transfected cells that had been incubated solely at 39.5°C displayed 
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VSVg migration patterns on the SDS-PAGE gel that were expected of ER-retained 
VSVg. In these conditions, VSVg was sensitive to both Endo H and PNGase F digestion 
(Figure 5.3B, left three columns of bands). After release from the 39.5°C block, and as 
predicted by previous studies (Tisdale et al., 1992), mCherry, or WT or Q67L mCherry-
Rab1b allowed processing of a significant fraction of the VSVg protein to an Endo H-
resistant form (Figure 5.3B, top three sets of bands). Some VSVg protein remained 
unprocessed in the presence of WT or Q67L mCherry-Rab1b, but not in the presence of 
mCherry, presumably due to DN-like effects of the high overexpression of otherwise 
functional mCherry-Rab1b constructs that can be achieved in some of the transfected 
cells. In contrast to the WT and Q67L constructs, overexpression of S22N or N121I 
mCherry-Rab1b potently inhibited VSVg processing to the Endo H-resistant form (Figure 










Figure 5.3. Effects of mCherry-Rab1b constructs on VSVg glycan chain processing. 
(A) Schematic depiction of expected ER-retained or ER-exported VSVg mobilities on 
SDS-PAGE gels. ER-retained VSVg is expected to be sensitive to deglycosylation by 
both Endo H and PNGase F and therefore to gain a higher mobility after digestion with 
either enzyme. VSVg that had been transported out of the ER is expected to become 
resistant to Endo H digestion, but to remain sensitive to PNGase F digestion. (B) 
VSVgtsO45-GFP and the noted mCherry or mCherry-Rab1b constructs were co-transfected 
into HEK293T cells maintained at 39.5°C. After 24 h, one set of plates was transferred to 
32°C to allow VSVg transport out of the ER and processing of its glycan chains. Next all 
cell lysates were harvested, digested with PNGase F, Endo H, or left undigested, and 
finally processed by Western blotting with an α-GFP antibody that recognized both the 








I also confirmed, in the Huh-7.5 cell line, that VSVg-GFP was able to reach the 
plasma membrane in the presence of mCherry, or of WT or Q67L mCherry-Rab1b 
expression, where it decorated the contours of the cells, while it was retained 
intracellularly in the presence of continued 39.5°C temperature block, or of S22N or 
N121I mCherry-Rab1b construct expression (Figure 5.4A-B). These biochemical and 
localization results document that the mCherry-Rab1b constructs affected the anterograde 
transport of VSVg as predicted by previous studies (Alvarez et al., 2003; Tisdale et al., 
1992). These findings further supported using WT and DN mCherry-Rab1 constructs to 



























Figure 5.4. Effects of mCherry-Rab1b constructs on VSVg transport to the plasma 
membrane (next page). (A) Huh-7.5 cells were transfected with VSVgtsO45-GFP and the 
indicated mCherry, or mCherry-Rab1b constructs, and maintained at 39.5°C before being 
switched to the indicated temperatures and then fixed and imaged. Representative single 
deconvolved planes in the GFP (left column), mCherry (middle column) and overlayed 
(right column) fluorescent channels are presented. Signal intensities along the white lines 
depicted on the overlay images were quantified and are shown in panel B. Scale bar, 10 
μm. (B) Line scan quantification of signal intensities in the GFP channel (green trace) 
and mCherry channel (red trace) along the white lines depicted in panel A. The mCherry 
or mCherry-Rab1b construct expressed in each of the cells is listed at the top of each 
graph, along with the temperature that the cells were exposed to before fixation. The left 
column of graphs shows examples where the VSVg-GFP signal was transported to the 
plasma membrane as denoted by the clear GFP signal peaks (black arrows) that encase 
the mCherry signal. Right column of graphs shows examples where the VSVg-GFP 
signal was retained intracellularly, as depicted by the absence of clear GFP signal peaks 
at the periphery of the mCherry and GFP signal traces, indicated by black arrowheads. 





















5.4. Endocytic activity in the presence of mCherry-Rab1b expression 
To alleviate the concern that expression of the DN mCherry-Rab1b constructs 
affected cargo secretion through general toxic effects on cell physiology, following 
inhibition of ER to Golgi traffic, I measured the ability of mCherry-Rab1b-expressing 
cells to endocytose fluorescently labeled transferrin. Transferrin endocytosis is mediated 
by a membrane transport process that is functionally, mechanistically and topologically 
divergent from the early exocytic events regulated by Rab1 (Luck and Mason, 2012). I 
therefore expressed WT or mutant mCherry-Rab1b constructs, or the control mCherry 
protein alone, in the Huh-7.5 cells, by lentiviral transduction. I detached these cells from 
the plate using a non-proteolytic method to help preserve integrity of cell surface 
transferrin receptors. I then allowed the Alexa Fluor 647-labeled transferrin (Tf-AF647) 
to bind to the cell surface at 4°C and split the cell culture in two samples. I washed one 
sample while keeping it at 4°C, while I allowed the second sample to undergo endocytic 
uptake at 37°C, before cooling it and washing it as well. I then quantified the amounts of 
fluorescent transferrin taken up by the cells in each condition. This transferrin-uptake 
assay was capable of discerning between non-specific transferrin staining (Figure 5.5A, 
4°C trace) and active uptake (Figure 5.5A, 37°C trace). Furthermore, live Huh-7.5 cells 
transduced with lentiviruses expressing mCherry or mCherry-Rab1b constructs took up 
transferrin to comparable levels (Figure 5.5B). These findings are consistent with 
previous reports documenting retention of endocytic activity concurrent with inactivation 





Figure 5.5. Effects of mCherry-Rab1b constructs on transferrin uptake. (A) Huh-7.5 
cells were transduced with 25 I.U./cell of a lentivirus expressing mCherry. At 48 h post 
transduction, the cells were harvested, a fluorescent transferrin uptake assay was 
performed, and the cells were analyzed by flow cytometry. Traces represent distributions 
of transferrin staining in live cells after incubation at 4°C (black trace) or 37°C (red 
trace). (B) Huh-7.5 cells were transduced with 25 I.U./cell of lentiviruses expressing the 
indicated constructs, then allowed to take up transferrin at 37°C. Traces show 
distributions of Alexa Fluor 647-labeled transferrin (Tf-AF647) signal levels in single 
live cells. 
 
5.5. Cell lines inducibly expressing mCherry-Rab1b 
To gain better control of the expression of the mCherry-Rab1b constructs, I once 
again used the Huh-7.5 TetON cells (Figure 2.2). I transduced the Huh-7.5 TetON Clone 
9 cell line (Luna et al., 2015), with retroviruses expressing mCherry-Rab1b constructs 
under the control of a tetracycline response element. I also transduced the resulting cells 
with a second luciferase-expressing vector to allow estimation of cell culture mass by 
luciferase activity measurements (Figure 3.2). Doxycycline treatment of these cultures 
induced mCherry-Rab1b expression in the overwhelming majority of the cells in culture, 
as detected by microscopy (Figure 5.6A), flow cytometry (Figure 5.6B) and Western 
blotting (Figure 5.6C). Furthermore, Huh-7.5-specific cell shapes were retained in the 





Figure 5.6. Cell lines inducibly expressing mCherry-Rab1b. (A) The cell lines 
expressing the indicated mCherry-Rab1b constructs were imaged either in the absence of, 
or after 2 days of treatment with doxycycline. For each cell line, the left column shows 
brightfield images, while the right column shows epifluorescence images acquired with 
mCherry-specific filters. Scale bars, 50 μm. (B) The cell lines expressing the indicated 
mCherry-Rab1b constructs were analyzed by flow cytometry after growth for 24 h in the 
presence (Dox, red traces) or absence (Control, blue traces) of 3 μg/mL doxycycline. (C) 
Lysates from these were harvested after 24 h of induction with doxycycline and analyzed 
by Western blotting with antibodies against dsRed and β-actin. 
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5.6. Inducible mCherry-Rab1b: cargo secretion normalized to cell lysate 
luciferase activity 
Using the doxycycline-inducible mCherry-Rab1b cell lines, I further investigated 
the effects of mCherry-Rab1b construct expression on the secretion of albumin, ApoE 
and ApoB100. Once again I used the luciferase activity of the cell lysates to normalize 
the ELISA measurements of the cargo amounts secreted in the media. Induction of 
expression of WT or Q67L mCherry-Rab1b had no detectable effect on the luciferase 
activity values, while induction of expression of the S22N and N121I mutant constructs 
caused at most a 2-fold activity decrease over 48 h of growth, when compared to the 
uninduced condition (Figure 5.7A). When compared to the uninduced control condition, 
induction of mCherry-Rab1bN121I expression for various lengths of time caused an 
increase in ApoE secretion, and a decrease in albumin and ApoB100 secretion (Figure 
5.7B). This effect was specific for the N121I mutant, since expression of the WT (Figure 
5.7C), Q67L (Figure 5.7D) or S22N (Figure 5.7E) constructs only minimally affected, if 
at all, the secretion of the three cargoes tested, as detected by this method of estimating 
secretion. These results paralleled those obtained using lentivirus-mediated delivery of 






Figure 5.7. Effects of inducible mCherry-Rab1b construct expression on cargo 
secretion. I: Secretion normalized by cell lysate luciferase activity. (A-E) Inducible 
cell lines expressing the noted mCherry-Rab1b constructs were treated with doxycycline 
(Dox) for the indicated durations, or were left untreated, before a 6 h secretion assay was 
performed and the amounts of albumin, ApoB100, and ApoE secreted in the media from 
each well were quantified by ELISA, and normalized by the luciferase activity of the 
corresponding well's cell lysate. The values (mean ± s.d., n=3 parallel wells for secretion 
assays, and 4 parallel wells for the luciferase assay) are depicted relative to those 
obtained from uninduced cells, on a Log2 scale. (A) Relative luciferase activities in the 
cell lysates harvested at the indicated time points. (B-D) Relative cargo secretion levels in 
the presence of induction of the indicated constructs.  
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5.7. mCherry-Rab1bN121I upregulates ApoE and ApoB100 expression 
The method that I employed so far to measure cargo secretion accounted for 
changes in the mass of the cells that were responsible for secretion by normalizing the 
secreted cargo amounts using the luciferase activity of the cell lysates. However, this 
method did not account for any cargo expression changes that may be associated with 
expression of the Rab1 constructs. Rab1 overexpression has been shown to induce 
transcriptional changes in cells (Romero et al., 2013). To investigate whether such an 
effect existed in my experimental setting, I quantified, using qRT-PCR, the transcript 
levels of all three cargoes and of Rab1 in cells induced to express mCherry-Rab1b 
constructs and compared them to their transcript levels in uninduced cells. As expected, 
doxycycline-mediated induction of mCherry-Rab1 constructs caused an increase (3-8 
fold in magnitude, depending on the construct expressed) in Rab1b message levels 
(Figure 5.8). I note that the primers used in the qRT-PCR assay are predicted to recognize 
both the natively-expressed Rab1b and the induced mCherry-Rab1b species. Of note, this 
level of mRNA overexpression, if translated into protein amount changes, is similar to 
the amount of excess Rab1bS25N that was used to achieve transport inhibition in a 
previous in vitro study (Nuoffer et al., 1994). In my experimental setup, WT, Q67L or 
S22N mCherry-Rab1b induction affected ApoE, ApoB and albumin mRNA levels very 
little, if at all. In contrast, mCherry-Rab1bN121I expression caused an increased (up to 2-
fold) expression of ApoE and ApoB100 transcripts, while having little effect on albumin 
mRNA expression (Figure 5.8). This observation may be explained either by increased 
transcription of ApoE and ApoB100 mRNAs in the presence of Rab1bN121I expression, or 
by their increased stability. In a recent study, WT Rab1b overexpression in non-secretory 
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cell types was shown to cause increased expression of transcripts encoding proteins 
involved in the functioning of the secretory system (Romero et al., 2013). Under those 
conditions, Rab1bN121I had no detectable transcription-inducing activity (Romero et al., 
2013). The differences between (Romero et al., 2013) and the current findings may be 
explained by the use of different experimental systems: the secretory cell-derived Huh-
7.5 line used here versus the non-secretory cell-derived HeLa line. Alternatively, the 
complex mechanisms involved in the regulation of lipoprotein transcript expression may 
be involved (Zannis et al., 2001a; Zannis et al., 2001b). For example, cholesterol loading 
was shown to cause upregulation of ApoE and ApoB100 mRNA levels (Dashti, 1992; 
Mazzone et al., 1987). Since Rab1bN121I expression reduced ApoB100 egress (Figures 
5.1, 5.7, as well as 5.10 and 5.11 below), it is plausible that it also inhibited ApoB100-
mediated cholesterol egress and the resulting accumulation of intracellular cholesterol 
may be invoked as one of the mechanisms that could explain the observed upregulation 





Figure 5.8. Effects of mCherry-Rab1b expression on cargo mRNA levels. Cell lines 
inducibly expressing the noted mCherry-Rab1b constructs were treated with doxycycline 
(black bars) or left untreated (white bars) for the indicated durations. mRNA was 
harvested and analyzed by qRT-PCR. Relative mRNA levels for Rab1b, ApoE, ApoB100 
and albumin transcripts are shown (mean ± s.d., n=3 parallel wells). Statistical 
significance (Student’s t-test): *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
Since mCherry-Rab1bN121I expression caused an increase in the transcript levels 
of ApoE and ApoB100 (Figure 5.8), I next inquired whether this induction of gene 
expression manifested itself at the protein level as well. I thank Dr. Ursula Andreo for 
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performing all radioactivity experiments described here. We compared the relative 
incorporation of 35S-cysteine and methionine into newly synthesized cargo molecules 
during a 20-min pulse. In cells expressing mCherry-Rab1bN121I or in control cells, we 
divided the newly synthesized cargo amounts by the total amounts of newly synthesized 
protein in the cells, and compared the resulting values. Under these experimental 
conditions we observed an increase of the relative albumin synthesis, but this increase 
was not statistically significant (Figure 5.9). In contrast, both ApoE and ApoB100 
synthesis was significantly increased, to a magnitude of about two-fold, in the presence 
of mCherry-Rab1bN121I expression (Figure 5.9). Furthermore, this increase in the relative 
amount of ApoE and ApoB100 translation closely paralleled the observed elevated 
mRNA levels for these two species (Figure 5.8).  
 
 
Figure 5.9. Effects of mCherry-Rab1bN121I on cargo translation rate. mCherry-
Rab1bN121I expression was induced using 3 μg/mL doxycycline for 24 h (black bars) or 
left uninduced (control, white bars), then the cells were pulsed with 35S-cysteine and 
methionine for 20 min and lysed. Albumin, ApoE, and ApoB100-specific incorporation 
of radiolabeled amino acids was quantified and was reported to the total radioactivity 
incorporated into the sample. The values (mean ± s.d. of 3 parallel wells) are expressed 
relative to the control condition. Statistical significance (Student's t-test): n.s., non-
significant;  *, p<0.05; **, p<0.01. 
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5.8. Alternative means to quantify cargo secretion 
As highlighted above, the use of cell lysate luciferase activity, while accounting 
for variations of cell mass between wells and experimental conditions, did not account for 
changes in apparent secretion due to changes in pre-transport processes, such as cargo 
synthesis. Since mCherry-Rab1bN121I increased the synthesis of ApoB100 and of ApoE 
(Figures 5.8 and 5.9), it became important to calculate the effective secretion of cargo 
while taking into account the changes in total cargo mass. I therefore used ELISA to 
quantify not just the amounts of secreted cargo, but also the amounts cargo that had 
remained cell-associated at the end of the secretion assay. I then expressed the amount of 
secreted cargo as fraction of total (secreted + cell-associated) cargo, or calculated a 
secretion index, defined as the ratio of secreted cargo to cell-associated cargo. Secretion 
index measurements have previously been used to monitor changes in cargo secretion in 





The major difference between the two values is that while the values for the 
fraction secreted can vary from 0 to 1, the values for the secretion index can vary from 0 
to infinity. As such, large changes in the secretion index of a cargo efficiently secreted 
(for which the secretion fraction is closer to 1) will nonetheless translate into small 






Fraction secreted analysis. I once more performed secretion assays in the 
mCherry-Rab1b inducible cell lines in the presence or absence of doxycycline-mediated 
mCherry-Rab1b expression. This time I quantified both secreted and cell-associated 
cargo amounts by ELISA in an attempt to simultaneously account for variations in cell 
mass as well as cargo expression levels. Expression of mCherry-Rab1b did not alter the 
secretion of ApoE, ApoB100, or albumin (Figure 5.10A). In contrast, expression of 
mCherry-Rab1bN121I impaired the secretion of the same set of cargoes (Figure 5.10B). 
The magnitude of the secretion impairment differed as the ApoE secreted fraction 
decreased by 18% or 19% from the control value at 24 h or 48 h, respectively. The 
albumin secreted fraction decreased by 31% or 32%, and the ApoB100 secreted fraction 
decreased the most, by 39% or 50%, for the 24 h or 48 h time points, respectively (Figure 
5.10B). I note that expression of the S22N construct impaired the secretion of albumin 
and of ApoB100, but not that of ApoE (Figure 5.10C). Lastly, expression of the Q67L 
construct reproducibly impaired only albumin secretion (Figure 5.10D). Taken together, 
these results establish the involvement of Rab1 function in the secretion of albumin, 





Figure 5.10. Effects of inducible mCherry-Rab1b construct expression on cargo 
secretion. II: Percent secretion. Cell lines inducibly expressing the noted mCherry-
Rab1b constructs were treated with doxycycline for the indicated durations (black bars), 
or left uninduced (white bars) before a 6 h secretion assay was performed. Secreted and 
cell-associated amounts of albumin, ApoE and ApoB100 were measured by ELISA and 
the amounts of secreted cargo were expressed as fraction of total (secreted + cell-
associated) amounts. Shown are means ± s.d., n=3 parallel wells. Statistical significance 
(Student's t-test): *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
Secretion index analysis. The pattern of the effects of the mCherry-Rab1b 
mutants on the secretion of the tested cargoes (Figure 5.10) was preserved when secretion 
indexes were compared (Figure 5.11). Expression of the WT construct did not affect the 
secretion of either of the three cargoes (Figure 5.11A), while expression of mCherry-
Rab1bN121I impaired secretion across the board (Figure 5.11B). Once again, the S22N 
mutant affected the secretion of both albumin and ApoB, but not that of ApoE while the 
Q67L mutant affected albumin secretion but not ApoE or ApoB secretion (Figure 5.11C-
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D). Since even small, but significant changes in the fractions of cargo secreted (Figure 
5.10), corresponded to significant and substantial changes in the cargo secretion indexes 
(Figure 5.11), I argue that small magnitudes of secreted fraction differences are unlikely 
to have been caused by technical variations in how the secretion was measured, but are 
rather true reflections of differences between the secretion capabilities of the cells under 
these experimental conditions.   
 
 
Figure 5.11. Effects of inducible mCherry-Rab1b construct expression on cargo 
secretion. III: Secretion index analysis. Cell lines inducibly expressing the noted 
mCherry-Rab1b constructs were treated with doxycycline for the indicated durations 
(black bars), or left uninduced (white bars) before a 6 h secretion assay was performed. 
Secretion indexes were calculated by dividing the amounts of cargo secreted by the 
amounts of cargo that had remained cell-associated. Shown are means ± s.d., n=3 parallel 
wells. This data was obtained from the same samples as the data shown in Figure 5.10. 





5.9. mCherry-Rab1bN121I impairs secretion of newly synthesized cargo 
I next inquired, again with the help of Dr. Ursula Andreo, whether the observed 
impairment of cargo secretion caused by mCherry-Rab1bN121I expression (Figures 5.10 
and 5.11) was correlated with a decreased rate of secretion of newly synthesized cargo. 
We thus followed cells that had been pulsed with 35S-cysteine and methionine as they 
secreted cargo during a chase in the presence of excess cold cysteine, methionine and 
cycloheximide. At regular time intervals we collected the media and the cell lysates, 
immunoprecipitated albumin, ApoB100 and ApoE and measured the radioactivity 
associated with each species. We expressed the amount of newly synthesized cargo 
species present at any given time point in the cell media as fraction of the total (secreted 
+ cell-associated) amount of newly synthesized cargo recovered at that time point. Using 
this analysis, we observed that lower fractions of newly synthesized albumin, ApoE and 
ApoB100 were secreted in the presence of mCherry-Rab1bN121I expression, compared to 
control, by magnitudes in the range of 10-30% (Figure 5.12). The decrease in total cargo 
secretion observed in the presence of mCherry-Rab1bN121I expression (Figures 5.10 and 
5.11) thus correlates with a decrease in the rate of secretion of newly synthesized cargo 








Figure 5.12. Effects of mCherry-Rab1bN121I on the secretion of newly synthesized 
hepatic cargoes. mCherry-Rab1bN121I expression was induced for 24 h (red trace) or left 
uninduced (blue trace), then the cells were pulsed with 35S-cysteine and methionine for 
20 min and then chased. Newly synthesized amounts of albumin, ApoE and ApoB100 
were quantified at the indicated chase time points in both media and cell lysates. The 
radioactivity of secreted cargo at each time point is expressed as a fraction of the total 
(secreted + cell-associated) radioactivity of that cargo. Means ± s.d. of 3 parallel wells 
are depicted. 
 
5.10. Inactivation of endogenous Rab1 function 
In the work presented so far, secretion of cargo was impaired by overexpressing 
DN Rab constructs. To test whether inactivation of endogenous Rab1 function also 
affected cargo secretion, I engineered the Huh-7.5 TetON cells to inducibly express a L. 
pneumophila protein, DrrA, which has been shown to be exported by the bacterium into 
the cytosol of infected cells where it interferes with Rab1 function (Machner and Isberg, 
2006; Murata et al., 2006). DrrA, also known as SidM (Machner and Isberg, 2006; 
Murata et al., 2006), possesses several functional domains: a Rab1 AMPylation domain 
(Hardiman and Roy, 2014; Muller et al., 2010), a Rab1 binding domain and a Rab1 
GDF/GEF domain (Ingmundson et al., 2007; Murata et al., 2006; Schoebel et al., 2009; 
Suh et al., 2010; Zhu et al., 2010) and a phosphatidylinositol 4-phosphate lipid binding 
domain (Brombacher et al., 2009; Del Campo et al., 2014; Schoebel et al., 2010; Zhu et 
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al., 2010). The DrrA construct which I used, GFP-DrrA61-647, but which I will refer to 
from here on simply as GFP-DrrA, has part of the AMPylation domain (Muller et al., 
2010) deleted and does not exhibit the general cytotoxic effects of full length DrrA 
(Murata et al., 2006). This construct also preferentially binds and acts on Rab1 GTPases, 
and its expression interferes with ER to Golgi transport of β-1,4-galactosyl-transferase 
and disrupts Golgi structure (Machner and Isberg, 2006; Murata et al., 2006), as expected 
of a Rab1 inhibitor. I also engineered a TetON-GFP control cell line, and I transduced 
both the GFP-DrrA and GFP cell lines with a luciferase-expressing lentivirus in order to 
easily monitor the effects of construct expression on cell mass. In secretion assays, GFP 
expression alone did not affect the secretion of either of the three cargoes tested (Figure 
5.13A). In contrast, GFP-DrrA impaired the secretion of albumin and ApoB100, but not 
that of ApoE (Figure 5.13B), mirroring the effect of mCherry-Rab1bS22N expression 
(Figures 5.10C and 5.11C). The GFP and the GFP-DrrA proteins were detected in lysates 
of the respective cell lines only after induction with doxycycline (Figure 5.13C). GFP 
protein levels were significantly higher than GFP-DrrA levels, since the GFP-DrrA blot 
required use of a more sensitive chemiluminescence substrate system to allow detection 
of the GFP-DrrA band. At the same time GFP-DrrA expression did not decrease the 
luciferase activity of the cell lysates (Figure 5.13D), thus alleviating concerns regarding 
cytotoxicity, which is consistent with previous findings (Murata et al., 2006). Overall, 
these results established that inhibition of endogenous Rab1 function impairs hepatic 
cargo secretion and provided independent confirmation of the results obtained by 






Figure 5.13. Inactivation of endogenous Rab1 function impairs hepatic cargo egress.  
Cell lines inducibly expressing GFP (A), or GFP-DrrA (B) were induced with 
doxycycline (black bars) or left uninduced (white bars) for the indicated durations, then a 
6 h secretion assay was performed. Secreted and cell-associated amounts of albumin, 
ApoE and ApoB100 were measured by ELISA and the amounts of secreted cargo were 
expressed as fraction of total (secreted + cell-associated) amounts. Means ± s.d. of values 
obtained in three parallel wells are shown. Statistical significance (Student's t-test): *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. (C) Western blotting of cell lysates 
from inducible GFP or GFP-DrrA cell lines after 2 days of induction with 0 or 3 μg/mL 
Doxycycline (Dox). Proteins were detected with α-GFP and α-actin antibodies. Molecular 
weight markers (kDa) are listed at the left of the blots. The GFP blot (top left) and the 
actin blots (bottom) were developed with the less sensitive ECL Prime detection reagent, 
while the GFP-DrrA blot (top right) was developed with the more sensitive West Femto 






5.11. Rab1 and HCV secretion 
HCV secretion and infectivity requires expression of amphipathic helix-
containing apolipoproteins (such as ApoE and ApoB100) by the HCV-producing cells 
(Fukuhara et al., 2014; Hueging et al., 2014), raising the possibility that HCV employs 
some of the same secretion route(s) as the lipoproteins. Having established that Rab1 
inactivation impairs the secretion of the lipoprotein components ApoE and ApoB100 and 
of the non-lipoprotein cargo albumin from the Huh-7.5 cell line, I next investigated the 
effect of Rab1 inactivation on the secretion of HCV. In order to discern between a 
previously proposed Rab1 function in genome replication (Nevo-Yassaf et al., 2012; 
Sklan et al., 2007a; Sklan et al., 2007b) and its putative function in virus particle 
secretion, I allowed the viral genome replication machinery to become established for 
two days following viral RNA electroporation. Then, I induced mCherry-Rab1bN121I 
expression to inactivate Rab1 function, and performed secretion assays (Figure 5.14A). I 
performed several variations of this experiment, by varying either the duration of 
mCherry-Rab1bN121I expression, or the length of the secretion assay (Figure 5.14A-B) 
Despite varying these experimental parameters, inhibition of Rab1 function consistently 
caused a significant increase of the fraction of HCV infectivity that remained cell-
associated (Figure 5.14B). This result is consistent with expression of mCherry-
Rab1bN121I impairing the transport of newly assembled infectious HCV particles from the 
ER to the Golgi and causing their concomitant accumulation in an ER-related 
compartment. These observations are also similar to those noted when anterograde 
transport of HCV was inhibited by treatment of HCV producing cells with brefeldin A, a 
potent, widely-used blocker of ER to Golgi transport (Gastaminza et al., 2008; 
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Lippincott-Schwartz et al., 1989). Furthermore, I found that intracellular HCV RNA 
levels were also slightly elevated in cells expressing the DN Rab1b construct (Figure 
5.14C), consistent with impaired release of HCV RNA via the secretory pathway. 
Without ruling out a Rab1b function in HCV replication, these results do not favor a 
massive inhibition of this process by mCherry-Rab1bN121I. Lastly, the magnitudes of the 
sensitivity of ApoE, albumin, and ApoB100 secretion from HCV-infected cells (Figure 
5.14D) retained the same relative order as in HCV-free cells (Figures 5.1A-B, 5.7, 5.10 
and 5.11).  Thus, ApoB100 secretion remained most potently impaired, while ApoE 
secretion was the least negatively affected, and albumin secretion displayed an 









Figure 5.14. Effects of mCherry-Rab1bN121I on HCV infectivity release. (A) 
Experimental design: cells were electroporated with HCV RNA, allowed to establish 
HCV infection for 2 days, then induced to express mCherry-Rab1bN121I by treatment with 
doxycycline for a duration designated T1 (1 or 2 days), then a secretion assay was 
performed for a period designated T2 (6 or 24 h). Control cells were treated identically 
except that they were not induced with doxycycline. (B) Effects of mCherry-Rab1bN121I 
expression on secretion of infectious HCV particles. The experimental format outlined in 
panel A was followed, while varying T1 and T2, as listed under the graph. For each 
experiment, 3 parallel HCV RNA electroporations were performed. For each 
electroporation, 3 wells were induced to express mCherry-Rab1bN121I (black bars) and 3 
wells were left uninduced (white bars). Secreted and cell-associated infectivity was 
measured and the cell-associated infectivity in each well was expressed as fraction of the 
total infectivity in that well. (C). Total cell-associated HCV RNA was quantified by qRT-
PCR in additional wells from the experiment for which T1 = 2 days and T2 = 6 h. (D) 
Secreted cargo amounts were quantified by ELISA and normalized to the luciferase 
activity of the corresponding wells (T1 = 2 days and T2 = 6 h). (B-D) Bars represent 
means ± standard error of the mean for the 3 replicate electroporations. Statistical 




Technical concerns. Before discussing the general findings of this Rab1-focussed 
body of work, I wish to address two technical concerns. The first deals with potential 
toxic effects caused by inhibition of ER-to-Golgi traffic by expression of the DN Rab1b 
constructs. This concern stems from the knowledge that ER-to-Golgi traffic is essential 
for cell viability, as evidenced by the findings that Ypt1 loss of function is lethal in yeast 
(Haubruck et al., 1989; Schmitt et al., 1986; Segev and Botstein, 1987; Segev et al., 1988; 
Wagner et al., 1987). Rab1 is the mammalian homolog of Ypt1 (Haubruck et al., 1989; 
Segev et al., 1988; Touchot et al., 1987; Vielh et al., 1989; Zahraoui et al., 1989). Due to 
this concern I have employed several means to assess cell health. The luciferase activity 
measurements (Figures 5.1C and 5.7A) did indeed document decreased luciferase 
activities in cells expressing the DN Rab1b constructs. These decreases were generally no 
larger than a 2-fold change over 54 h of expression (48 h from the time of lentivirus 
transduction or doxycycline induction + 6 hours of secretion assay). Such small decreases 
are inconsistent with massive cell death, but could in turn be caused by growth delays 
secondary to reduced rates of exocytic transport. Second, effects of DN Rab1 expression 
on cargo secretion were evident even at early time points after induction (Figure 5.7B), 
when the luciferase activity in the cell lysates had not changed or had decreased only 
slightly (Figure 5.7A, 12 and 24 h time points). Third, a divergent membrane transport 
process, transferrin endocytosis, remained unaffected by expression of various Rab1b 
constructs, a finding inconsistent with the Rab constructs having caused overwhelming 
toxicity (Figure 5.5). Fourth, while morphological changes did become noticeable in DN 
Rab1-expressing cells, many cells in the culture retained the morphology specific to the 
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Huh-7.5 cell line (Figure 5.6A). Fifth, that cells expressing mCherry-Rab1bN121I 
synthesized cargo proteins at higher rates than the control cells (Figure 5.9), that this 
increase in the rate of synthesis correlated with increased expression of cargo messages 
(Figure 5.8), and that the secretion of the newly synthesized cargoes was decreased in the 
same conditions (Figure 5.12), served as further evidence that, while affected in some 
aspects, cell physiology retained a high degree of functionality. I thus argue that, 
regardless of adverse effects on cell health caused by inhibition of anterograde transport 
from the ER to the Golgi, the results of the experiments presented above were properly 
interpreted to yield the conclusion that Rab1 was indeed involved in anterograde 
transport of these cargoes.  
The second technical issue deals with apparent differences between the results 
obtained using the luciferase activity-based method of normalization (Figures 3.8, 5.1, 
and 5.7), and those obtained using the normalization method using cell-associated cargo 
amounts (Figures 5.10, 5.11, and 5.12). Both methods took into account the cell mass 
responsible for the measured secretion. The later method also accounted for the observed 
changes in cargo mRNA expression and cargo synthesis (Figures 5.8 and 5.9). For ApoE, 
a two-fold increase in its translation rate (Figure 5.9) could overcome a 10-20% decrease 
in transport rate (Figure 5.12), to cause an overall apparent increase in the amount of 
cargo accumulated in the cell culture media (Figures 3.7, 3.8, 5.1A-B, and 5.7B). For 
albumin, a smaller increase in expression counteracted by the observed decrease in 
secretion could account for the relatively small observed net change in secretion amounts 
(Figures 5.1A-B and 5.7B). ApoB100, in contrast, would have been expected to display a 
phenotype similar to that of ApoE, since their rates of translation and of secretion had 
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changed in similar ways in response to DN Rab1b expression (Figures 5.8 and 5.9). 
However, ApoB100 also undergoes significant degradation associated with the ER 
(Ginsberg and Fisher, 2009), which does not appear to be the case for ApoE or albumin 
(Ye et al., 1992; Ye et al., 1993). Thus, although more ApoB100 was being synthesized, 
if a significant portion of it was degraded along the secretion route, combined with a 
slower secretion rate overall, these phenomena may well account for the observed overall 
decrease in secretion. I believe therefore that the results obtained using luciferase-based 
normalization and those obtained using the cell-associated cargo amounts for 
normalization, while facially different, were nevertheless consistent with each other as 
well as with a model in which Rab1 controls the secretion of the analyzed cargoes.  
Rab1 functions in hepatic cargo secretion. As described in this chapter, I 
investigated whether Rab1 mediated ER to Golgi transport of several hepatic secretory 
cargoes. I found that inactivation of Rab1 function - by expression of DN mutants or of a 
bacterial effector targeting Rab1 - impaired the secretion of albumin, ApoE, ApoB100 
and infectious HCV particles. I propose that Rab1 mediates anterograde transport of these 
cargoes, as it does for many other cargoes investigated to date (Dong et al., 2012; Dugan 
et al., 1995; Filipeanu et al., 2004; Filipeanu et al., 2006; Flowerdew and Burgoyne, 
2009; Ingmundson et al., 2007; Nachmias et al., 2012; Plutner et al., 1991; Robitaille et 
al., 2009; Satoh et al., 1997; Wu et al., 2001; Wu et al., 2003; Yamayoshi et al., 2010; 
Zenner et al., 2011; Zhuang et al., 2010). My findings are consistent with the documented 
Rab1 association with in vitro-made vesicles loaded with VLDL (Rahim et al., 2012). 
Further corroborating evidence comes from the documented functional association of 
Rab1 with vesicle coat complexes COPII and COPI implicated in ER to Golgi transport. 
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COPII mediates sorting of hepatic cargo into anterograde transport vesicles during ER 
exit (Gusarova et al., 2003; Jones et al., 2003; Siddiqi, 2008; Siddiqi et al., 2003). COPI, 
in turn, can mediate cargo transport from the ERGIC  to the Golgi (Garcia-Mata et al., 
2003; Pepperkok et al., 1993; Peter et al., 1993; Shima et al., 1999; Stephens et al., 2000). 
Rab1 interacts with and may be activated downstream of both COPII and COPI (Kim et 
al., 2006; Slavin et al., 2011; Yamasaki et al., 2009). Once activated on the surface of 
transport carriers, Rab1 may interact with a series of effectors, including the Golgi 
tethering factor p115 (Allan et al., 2000), and GBF1, which is the GEF that activates Arf1 
and thus initiates COPI recruitment (Alvarez et al., 2003; Monetta et al., 2007). The 
ability of mCherry-Rab1bN121I to interfere with hepatic cargo transport could, for 
example, be mediated through disruption of the function of these effectors. Indeed, 
expression of Rab1bN121I has been shown to increase the mobility of p115, likely by 
increasing the rate of its exchange between cytosolic and membrane-bound pools 
(Brandon et al., 2006). Expression of the N121I mutant construct may also interfere with 
COPII and/or COPI function in anterograde transport (Alvarez et al., 2003; Monetta et 
al., 2007; Slavin et al., 2011), which may in turn impair cargo secretion.  
Distinct pathways are likely involved in anterograde transport of albumin, 
ApoE and ApoB100. A recurring observation in the experiments that I presented here 
was that the various means used to impair Rab1 function differentially affected albumin, 
ApoE and ApoB100 secretion. This was evident in the different magnitudes of the 
disruption caused by the N121I mutant (Figures 5.10 and 5.11), and also in the lack of 
effect of the S22N mutant or of GFP-DrrA on ApoE secretion (Figure 5.13). Since 
measurements of the amounts of each cargo were performed in parallel in each sample, I 
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do not view potential variations in cargo quantification efficiencies as a likely 
explanation of these results. I cannot presently exclude confounding effects of other 
biological processes, such as cargo degradation known to occur during secretion, or 
lipoprotein particle maturation processes (Ginsberg and Fisher, 2009; Rutledge et al., 
2010; Ye et al., 1992; Ye et al., 1993). I nonetheless note that these results are consistent 
with a model, supported by in vitro experiments (Gusarova et al., 2007; Siddiqi, 2008), in 
which various hepatic cargoes are transported out of the ER in distinct carriers. 
Furthermore, a quantitative electron microscopy study has shown that VSVg sorting into 
ER-derived transport carriers is accompanied by a concentration of this cargo, to levels 
maintained throughout exocytic transport (Balch et al., 1994). A similar observation was 
described regarding the transport of human serum albumin from the ER to the Golgi in 
the HepG2 human hepatoma cell line (Mizuno and Singer, 1993). This packing of cargo 
in transport carriers, if sufficiently specific, may well yield the different populations of 
cargo-specific carriers previously identified biochemically (Gusarova et al., 2007; 
Siddiqi, 2008) and inferred from the different sensitivity of their transport to inhibition of 
Rab1 function, as described here. Lastly, such differential regulation of anterograde 
traffic appears not to be limited to hepatocyte function since dendrite and axon growth, 
respectively, displayed distinct sensitivity to inactivation of the function of the early 
exocytic regulators Sec23, Sar1 and Rab1 (Ye et al., 2007), while secreted and 
transmembrane protein transport exhibited distinct sensitivities to GBF1 knockdown 
(Szul et al., 2007). Further supporting this model, some anterograde cargoes may 
undergo, under certain experimental conditions, Rab1-independent transport from the ER 
to the cell periphery (Filipeanu et al., 2006; Wu et al., 2003; Yoo et al., 2002). 
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Varied effects of the Rab1 inhibition methods. In my hands, albumin secretion 
was inhibited by all three Rab1 mutants, and by the L. pneumophila effector DrrA. ApoB 
secretion was not inhibited by the Q67L mutant, while ApoE secretion was only inhibited 
by the N121I mutant. These differences raise questions as to how the various means of 
blocking Rab1 function actually affected transport. The effect of the Q67L mutant on 
albumin secretion stands out to begin with, since this mutant does not impair transport of 
the model cargo VSVg (Tisdale et al., 1992). Rab1bQ67L possesses low intrinsic GTPase 
activity, but is expected to have normal GAP-stimulated GTPase activity, since this Q67 
residue, unlike the equivalent glutamine in other small GTPases, including other Rabs, 
does not enact GTP hydrolysis in the presence of the cognate Rab1 GAP, TBC1D20 
(Gavriljuk et al., 2012). Instead, TBC1D20 provides a catalytic glutamine residue 
(Gavriljuk et al., 2012). As such, if transport of VSVg, ApoE and ApoB100 primarily 
involve GAP-mediated GTP hydrolysis, then the lack of effect of the Q67L mutant is 
unsurprising. Furthermore, it is plausible that albumin transport relies more heavily on 
unstimulated Rab1 GTPase activity, which may in turn explain the current findings. 
Alternatively, it is conceivable that Arf1 stabilization on membranes by Rab1bQ67L 
(Monetta et al., 2007) may affect albumin secretion, although this would raise the 
question as to why only albumin was affected. 
The other means of Rab1 inactivation may affect cargo transport through different 
mechanisms. Rab1bS22N is likely to compete with endogenous Rab1 for either a Rab1 
GEF or for GDI (Nuoffer et al., 1994). GFP-DrrA, a protein which displays Rab1 GEF 
activity and potentially concurrent Rab1 GDF activity (Ingmundson et al., 2007; Machner 
and Isberg, 2007; Schoebel et al., 2009; Suh et al., 2010; Zhu et al., 2010), caused similar 
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changes in cargo secretion as did mCherry-Rab1bS22N. DrrA may recruit Rab1 - and 
activate it - at ectopic, PI4P-containing membranes, such as the plasma membrane 
(Murata et al., 2006), thereby removing it from the native pathway of ER to Golgi 
transport. It appears likely, therefore, that the similar effects of the Rab1bS22N and DrrA 
constructs might be achieved through disruption - in distinct ways - of the activation of 
Rab1 at the ER.  In contrast, the unstable binding of nucleotides by the N121I mutant 
likely causes a rapid oscillation between the GDP and GTP-bound forms, which likely 
destabilizes effector recruitment to membranes (Alvarez et al., 2003; Brandon et al., 
2006; Monetta et al., 2007; Pind et al., 1994). The pan-cargo effects that we observed 
when we used the N121I mutant imply that the ability of Rab1 to cycle between GTP- 
and GDP-bound forms, or to bind effectors for a long-enough duration may be 
universally required for the transport of Rab1-dependent cargoes. Since the N121I mutant 
blocks VSVg transport at the ERGIC (Alvarez et al., 2003; Pind et al., 1994; Tisdale et 
al., 1992), it is likely that the initial, COPII-mediated transport from the ER to the ERGIC 
does not require lengthy Rab1-effector interaction. This would be further supported by 
the spatial proximity between ER exit sites and the ERGIC (Bannykh et al., 1996). The 
S22N, in contrast, causes retention of VSVg in the ER (Alvarez et al., 2003; Nuoffer et 
al., 1994; Tisdale et al., 1992). VSVg, and likely albumin and ApoB as well, presumably 
require Rab1 function for their COPII-mediated transport from the ER to the ERGIC. It is 
surprising that ApoE secretion is insensitive to the Rab1bS22N or DrrA-mediated shift in 
the GDP-Rab1/GTP-Rab1 balance. Whether ApoE utilizes a novel transport pathway out 
of the ER may warrant further investigation.  
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Rab1 functions in infectious HCV particle secretion. By documenting Rab1 
involvement in infectious HCV particle secretion, this work complements previous 
findings implicating Rab1, and its cognate GAP, TBC1D20, in HCV genome replication 
(Haas et al., 2007; Nevo-Yassaf et al., 2012; Sklan et al., 2007a; Sklan et al., 2007b). 
TBC1D20 interacts with HCV NS5A (Sklan et al., 2007b). Rab1b (Sklan et al., 2007a) or 
TBC1D20 (Sklan et al., 2007b) knockdowns decrease HCV genome replication. 
Expression of GFP-Rab1bN121I caused fragmentation of lipid droplets, organelles 
implicated in HCV particle assembly (Miyanari et al., 2007), as well as changes in the 
pattern of NS5A localization (Nevo-Yassaf et al., 2012). However, the effects of Rab1b 
inactivation on the secretion of infectious HCV particles have not been assessed. Under 
experimental conditions described above, DN Rab1b expression did not decrease the 
abundance of cell-associated HCV genomes implying that HCV genome replication was 
not greatly affected by expression of this mutant, while particle egress was impaired. It is 
plausible that the Rab1 function in ER to Golgi transport that is inhibited by expression 
of the N121I mutant be dispensable for HCV genome replication. I did not investigate 
whether Rab1 function is important for earlier steps of the HCV life cycle, spanning from 
entry through the establishment of the replication machinery, which could further explain 
the documented Rab1b knockdown phenotype (Sklan et al., 2007a).  Indeed, I inactivated 
Rab1 function only after allowing replication to become established for 2 days following 
electroporation of the HCV RNA. Presumably, by this stage, HCV RNA replication has 
become largely insensitive to (DN-mediated) inhibition of Rab1 function. Another 
difference between my work and the previous study (Nevo-Yassaf et al., 2012) is the 
method of DN Rab1 expression. While (Nevo-Yassaf et al., 2012) employed plasmid 
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transfection, in my hands this method of expression was accompanied by considerable 
cytotoxic effects, potentially due to high levels of construct overexpression in transfected 
cells. I was therefore necessitated to employ inducible gene expression from stable cell 
lines, which may account for some of the observed differences. Nevertheless, our results 
remain in agreement with previously published studies, and overall document the 





















Functional Characterization of an ApoE-GFP Fusion 
 
6.1. Introduction 
The investigation into how hepatic cargo secretion is regulated, which I described 
in the previous three chapters, was based primarily on genetic and biochemical assays. To 
more comprehensively analyze hepatic cargo egress, I wanted to complement these 
approaches with live cell imaging studies. Live cell imaging assays have the advantage of 
providing both spatial and temporal dynamic views of the cellular processes studied 
(Lippincott-Schwartz et al., 2001; Liu et al., 2015; Wouters et al., 2001). Furthermore, 
live cell imaging of vesicular transport of secreted cargo may provide single-event-level 
description of this process and therefore reveal unexpected behaviors otherwise lost by 
the averaging of unsynchronized behaviors, which is inherent to many biochemical 
approaches (Wennmalm and Simon, 2007). Expression of fluorescent protein-tagged 
constructs has become a standard and powerful method used to study spatial and 
temporal dynamics of proteins, membranes and organelles in live cells. The method relies 
on fusing, in frame, a DNA fragment encoding one of an ever-growing list of fluorescent 
proteins (Chudakov et al., 2010) to the 5'- or 3'-end of a DNA fragment encoding a 
protein whose dynamics are to be studied, followed by expression of the resulting 
chimeric gene. Powerful spatio-temporal studies may be carried out and their results 
properly interpreted if fluorescent protein tagging does not detectably interfere with the 
process studied (Jacobs et al., 1999). Unfortunately, fluorescent protein tagging may also 
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result in DN, non-functional, or mislocalized fusion proteins, as outlined in greater detail 
in a previous study (Rappoport and Simon, 2008). Thus, to avoid collecting and 
interpreting artifactual data caused by expression of aberrantly-behaving fluorescent 
protein fusions, an initial battery of functional tests should be performed (Rappoport and 
Simon, 2008). I present in this chapter such a functional characterization of an ApoE-
GFP fusion protein for use in the investigation of lipoprotein and HCV secretion from 
hepatic cells.  
 6.2. A roadmap for investigating ApoE-GFP functionality 
Previous studies have described ApoE-GFP constructs that were used to image 
microtubule-dependent ApoE secretion from macrophages (Kockx et al., 2007), or to 
colocalize ApoE with fluorescently-labeled HCV Core-containing entities (Coller et al., 
2012). In the macrophage study, ApoE-GFP secretion from cells was comparable to that 
of untagged ApoE. Additionally, its localization at the ER, Golgi, and within secretory 
vesicles, as well as its movement along microtubules, was consistent with behaviors 
expected of this secreted protein (Kockx et al., 2007), suggesting that this ApoE-GFP is a 
good marker for the secretion of ApoE from macrophages. Whether ApoE-GFP is also a 
useful marker for monitoring ApoE secretion from hepatic cells, in the presence or 
absence of HCV infection, has not been formally addressed to date.  
As I mentioned in Chapter 1, some of the lipid metabolic functions of ApoE are 
mediated through its interaction with ApoB100-containing VLDL (Blum et al., 1980; 
Havel et al., 1980). Hepatocyte-made ApoE, in particular, may associate intracellularly 
with VLDL particles (Dolphin, 1981; Fazio and Yao, 1995; Gusarova et al., 2007), and 
promote the secretion of VLDL-associated triglycerides (Huang et al., 1998; Kuipers et 
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al., 1997).  Furthermore, ApoE is incorporated into HCV particles that assemble at the 
ER of infected hepatocytes (Andre et al., 2002; Catanese et al., 2013; Chang et al., 2007; 
Lindenbach, 2013; Lindenbach and Rice, 2013; Miyanari et al., 2007; Nielsen et al., 
2006). This ApoE-HCV association is important for efficient production of HCV 
particles and for the infectivity of the released virions (Chang et al., 2007; Fukuhara et 
al., 2014; Hishiki et al., 2010; Hueging et al., 2014; Lee et al., 2014; Long et al., 2011; 
Vogt et al., 2013).  
Given these hepatocyte-specific functions of ApoE in lipoprotein and HCV 
particle formation and release, I outlined several functional assays that are needed to 
determine whether ApoE-GFP functionally reproduces the behavior of untagged ApoE 
with respect to lipoprotein and infectious HCV particle release from hepatic cells. These 
tests aimed to determine whether: i) ApoE-GFP was properly expressed in cells; ii) 
ApoE-GFP colocalized with untagged ApoE; iii) ApoE-GFP was secreted from cells with 
similar efficiency as untagged ApoE; iv) ApoE-GFP associated with secreted lipoprotein 
particles; and v) tagged ApoE retained the ability to support infectious HCV production. 
Overall, the results of the experiments designed to address these questions indicated that 
ApoE-GFP faithfully reproduced known aspects of ApoE association with secreted 
hepatic lipoproteins, and support its use in future imaging studies aimed at elucidating 
dynamic spatio-temporal aspects of lipoprotein secretion. 
 6.3. ApoE-GFP expression 
I tagged ApoE with GFP by fusing the fluorescent protein to the carboxyl-
terminus of full length human ApoE3. Silent mutations were introduced in the ApoE-
coding region to confer resistance to shRNA-mediated knockdown. I am grateful to Dr. 
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Margaret Scull and Joshua Horwitz for their efforts in making this shRNA-resistant 
ApoE-expressing cDNA clone. I tagged this ApoE sequence at its carboxyl-terminus with 
monomeric enhanced GFP (mEGFP), which has a dimerization-disrupting A206K 
mutation (Zacharias et al., 2002). I used the mEGFP variant to prevent potential GFP-
mediated artifactual aggregation of the resulting fusion protein. The linker between ApoE 
and GFP is predicted to be identical with that found in the ApoE-GFP construct that was 
previously characterized in macrophages (Kockx et al., 2007). From here on, I refer to the 
shRNA-resistant ApoE3-mEGFP construct that I made as ApoE-GFP. 
To characterize ApoE-GFP, I stably expressed it in human hepatoma Huh-7.5 
cells, which secrete both ApoB100- and ApoE-containing lipoproteins and support the 
complete HCV life cycle (Lindenbach et al., 2005; Meex et al., 2011). Huh-7.5/ApoE-
GFP cells expressed both ApoE-GFP (62 kDa predicted unglycosylated molecular 
weight) and untagged endogenous ApoE (predicted 34 kDa), as detected using a 
polyclonal α-ApoE antibody (Figure 6.1A). The ApoE-GFP fusion was also detected 
using an α-GFP antibody (Figure 6.1B), but was not detected using a monoclonal α-ApoE 
antibody (clone EP1374Y) raised against the C-terminus of ApoE (Figure 6.1C). C-
terminal tagging of the ApoE sequence presumably renders this antibody's epitope 
unrecognizable. ApoE-GFP was not detected in the parental Huh-7.5 cell line, nor in the 
empty vector (EV) transduced control cell line Huh-7.5/EV Hygro (Figure 6.1A-B). 
Similar amounts of cell lysate from each of the three cell lines were loaded, as detected 





Figure 6.1. Expression of ApoE-GFP in Huh-7.5 cells. Lysates from Huh-7.5 cells, 
from Huh-7.5/EV Hygro cells, or from Huh-7.5/ApoE-GFP cells were immunoblotted  
with the following antibodies: (A) α-ApoE, AB947 goat polyclonal, (B) α-GFP, (C) α-
ApoE, clone EP1374Y, rabbit monoclonal, and (D) α-actin. Molecular weights (kDa) are 
listed at the left of the blots. ApoE and ApoE-GFP bands are labeled at the right. 
 
 6.4. ApoE-GFP colocalizes with endogenous ApoE 
I used the fortuitously discovered EP1374Y monoclonal antibody, which only 
recognizes the untagged form of ApoE, to characterize the intracellular localization of 
endogenously-expressed,  untagged ApoE, relative to that of ApoE-GFP. We first 
confirmed that this monoclonal antibody did not recognize ApoE-GFP in 
immunofluorescence experiments. Neither HeLa cells, which do not express endogenous 
ApoE (Smith et al., 1988), nor HeLa cells that had been transduced with the ApoE-GFP 
construct, showed staining with the α-ApoE antibody, while HeLa cells expressing a 
GFP-ApoE fusion (with GFP at the amino-terminus) became brightly stained under the 
same conditions (Figure 6.2). Both ApoE-GFP and GFP-ApoE transduced HeLa cells 
stained with an α-GFP antibody (Figure 6.2). I thank Caroline Gleason for performing 





Figure 6.2. An α-ApoE antibody does not recognize ApoE-GFP in immuno-
fluorescence assays. The following cells were stained with the rabbit α-ApoE 
monoclonal antibody EP1374Y: HeLa cells (do not express endogenous ApoE), HeLa 
cells expressing ApoE-GFP, and HeLa cells expressing GFP-ApoE. An α-GFP antibody 
was used to boost the GFP signal. While GFP staining occurred in both ApoE-GFP- and 
GFP-ApoE-expressing cells, ApoE staining occurred only in the GFP-ApoE expressing 
cells, where the C terminus of ApoE (the immunogen for EP1374Y) presumably 
remained accessible. No staining was observed in untransduced HeLa. Scale bars, 50 μm. 
 
Since the α-ApoE antibody did not recognize the ApoE-GFP fusion protein in 
Western blotting (Figure 6.1C) or immunofluorescence (Figure 6.2) experiments, I 
processed the Huh-7.5/ApoE-GFP cells for immunofluorescence using an α-GFP 
antibody to boost the signal from the GFP, and with the monoclonal α-ApoE antibody. 
The resulting signals displayed reticular and punctate distributions (Figure 6.3A), 
consistent with expected ER and secretory vesicle localization. Perinuclear accumulation 
of signal consistent with Golgi localization was also apparent. (Figure 6.3A, arrowhead). 
Importantly, the ApoE-GFP and the ApoE signals overlapped, particularly within puncta 





Figure 6.3. ApoE-GFP colocalizes with endogenous ApoE in Huh-7.5 cells. (A) Huh-
7.5/ApoE-GFP cells were processed for immunofluorescence using α-ApoE (EP1374Y) 
and α-GFP (JL-8) and corresponding secondary antibodies. A single deconvolved slice is 
shown. The GFP and ApoE signals colocalized throughout the cell. Arrow heads indicate 
perinuclear signal concentrations consistent with Golgi localization. Scale bar, 10 μm. 
(B) Detail view of the region highlighted in the overlay image of panel A. The arrow 
heads indicate colocalized ApoE and ApoE-GFP puncta. 
 
6.5. ApoE-GFP and endogenous ApoE secretion rates are indistinguishable 
ApoE is a secreted protein (Dashti et al., 1980). To characterize ApoE-GFP's 
kinetics of secretion from cells, we performed radioactivity pulse-chase experiments in 
the Huh-7.5/ApoE-GFP cells and in the control Huh-7.5/EV Hygro cells. Once again, I 
thank Dr. Ursula Andreo for lending to the project her experience with radioactivity 
pulse-chase assays. After a short 35S-cysteine and methionine pulse, we chased the cells 
in the absence of label while measuring ApoE- and ApoE-GFP- associated radioactivity 
in both media and cell lysates at regular intervals. The percent of total ApoE-GFP (Figure 
6.4, blue trace) that was recovered from the media was at all times undistinguishable 
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from the percent of endogenously-expressed ApoE recovered from the same Huh-
7.5/ApoE-GFP cells (Figure 6.4, red trace) or from control Huh-7.5/EV Hygro cells 
(Figure 6.4, black trace). ApoE-GFP thus possessed the same capacity to be secreted 




Figure 6.4. ApoE-GFP and ApoE are secreted from cells at undistinguishable rates. 
The rates of secretion of ApoE and of ApoE-GFP were measured using a radioactivity 
pulse-chase experiment. At each time point, the amount of secreted radiolabeled cargo is 
shown as percent of the amount of total (cell-associated + secreted) radiolabeled cargo. 
ApoE amounts were measured during secretion from Huh-7.5/EV Hygro and Huh-
7.5/ApoE-GFP cells, and the ApoE-GFP amounts were measured in Huh-7.5/ApoE-GFP 
cells, as noted in the legend at the right.   
 
6.6. ApoE-GFP associates with secreted ApoE and ApoB100 
ApoE is secreted from cells as lipoprotein particles of various sizes and lipid 
compositions that include ApoB100-containing VLDL/LDL and ApoB100-free HDL 
particles (Vance et al., 1984). To be a useful marker of lipoprotein egress, ApoE-GFP 
should retain untagged ApoE's ability to associate with itself and with secreted ApoB100. 
To test if this was the case, I performed immunoprecipitation assays on media 
conditioned by either Huh-7.5/ApoE-GFP cells or control Huh-7.5/EV Hygro cells. 
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These experiments were done in the absence of detergent, to preserve the integrity of the 
lipoprotein particles. Immunoprecipitation of Huh-7.5/ApoE-GFP conditioned media 
with an α-GFP antibody pulled down ApoE-GFP, as expected, but also untagged ApoE 
and ApoB100 (Figure 6.5A, lane a). Reciprocal immunoprecipitation of the same media 
with α-ApoB100 pulled down ApoB100, ApoE-GFP, and untagged ApoE (Figure 6.5A, 
lane b). These results indicate that secreted ApoE-GFP associated with both ApoB100 
and untagged ApoE, likely as part of lipoprotein particles. To establish the specificity of 
the immunoprecipitation assay, I performed a control pull-down with normal species-
matched IgG, as well as pull-downs of media conditioned by Huh-7.5/EV with the same 
sets of antibodies. Immunoprecipitation of ApoE-GFP-free media with the α-ApoB100 
antibody resulted in recovery of only untagged ApoE, as expected (Figure 6.5A, lane e), 
while the other conditions resulted in minimal or no recovery of ApoE, ApoE-GFP or 
ApoB100 (Figure 6.5A, lanes c, d, and f). I note that the media samples used in these 
assays were conditioned by similar cellular amounts (Figure 6.5B), and contained 
comparable total amounts of ApoB100 and ApoE (Figure 6.5C). All in all, these 
localization, kinetic and biochemical assays established ApoE-GFP as a useful marker for 





Figure 6.5. ApoE-GFP associates with secreted untagged ApoE and ApoB100. (A) 
Media was conditioned by Huh-7.5/ApoE-GFP cells or by Huh-7.5/EV Hygro cells, then 
immunoprecipitated with antibodies listed at the top of the figure. The pulled down 
material was then blotted using antibodies against ApoB100 and ApoE, as listed at the 
left. Letters between the two panels correspond to the lane labeling described in the text. 
(B) The cells that secreted the material analyzed in panel A were lysed and processed by 
Western blotting using the antibodies listed at the left. (C) Input media used in the 
immunoprecipitation experiment in panel (A) was processed by Western blotting using 
the antibodies listed at the left. (A-C) The ApoE and the ApoE-GFP bands are marked at 
the right of each blot.  
 
 
6.7. ApoE-GFP and infectious HCV egress 
Since ApoE is a functionally important component of infectious HCV particles 
(Chang et al., 2007; Fukuhara et al., 2014; Hishiki et al., 2010; Hueging et al., 2014; Lee 
et al., 2014; Long et al., 2011; Vogt et al., 2013), I investigated whether ApoE-GFP 
expression supported infectious HCV production. To test this, I performed rescue 
experiments in the context of ApoE knockdown. Dr. Margaret Scull had made and 
characterized Huh-7.5-derived clonal cell lines in which ApoE expression was knocked 
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down (clones ApoE KD1 and ApoE KD2, respectively) and a control Huh-7.5 derived 
clonal cell line transduced with an empty shRNA vector (clone EV KD). She was very 
gracious in sharing these cell lines with me. The ApoE knockdown cell lines ApoE KD1 
and ApoE KD2 expressed barely detectable levels of ApoE, compared to parental Huh-
7.5 cells, or to the control knockdown cell line, EV KD (data not shown), consistent with 
previous reports (Chang et al., 2007; Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al., 
2014). I transduced these cell lines with lentiviruses expressing shRNA-resistant 
untagged ApoE, shRNA-resistant ApoE-GFP, or with an empty control lentivirus (EV). 
As expected, ApoE expression was not rescued by transduction of these cells with the 
empty lentiviral expression vector (Figure 6.6A). In contrast, transduction with the 
lentivirus expressing untagged ApoE resulted in rescue of ApoE expression, and 
transduction with the lentivirus expressing ApoE-GFP resulted in comparable levels of 
expression of the fusion protein (Figure 6.6A). I then launched HCV infection in these 
cells by HCV RNA electroporation. I measured intracellular HCV RNA levels at 6 h and 
at 72 h post electroporation, and also measured supernatant HCV infectivity titers 
accumulated over 72 h post electroporation. The expression of ApoE-GFP in the EV KD 
background, where endogenous ApoE remains expressed (Figure 6.6A), did not 
significantly change HCV infectivity release compared to control, EV-transduced cells 
(Figure 6.6B, left pair of bars). I interpret this result to mean that ApoE-GFP did not act 
as a DN factor with respect to release of infectious HCV particles. Unfortunately, ApoE-
GFP expression in the ApoE knockdown cell lines did not rescue infectious HCV particle 
release (Figure 6.6B), compare second and third black bars to the second and third white 
bars, respectively). In these cells, the release of infectious HCV particles was 
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indistinguishable from that observed when the ApoE KD clones were mock-rescued by 
transduction with an EV (Figure 6.6B, white bars). In contrast, exogenous expression of 
untagged ApoE partly rescued HCV infectious particle release (Figure 6.6B, compare 
second and third gray bars to the second and third white bars, respectively). In all but one 
cell population, intracellular HCV RNA accumulated to similar levels (Figure 6.6C). 
Comparable HCV RNA amounts were delivered into these cells, as quantified at 6 h post 
electroporation (Figure 6.6D). Overall, these findings ruled out a major inhibitory effect 











Figure 6.6. ApoE-GFP does not support infectious HCV particle production. (A) 
Huh-7.5 cells, Huh-7.5 cells engineered to downregulate endogenous ApoE protein 
expression (clones ApoE KD1 and ApoE KD2) and control knockdown cells (clone EV 
KD) were transduced with the rescue vectors: empty (EV), ApoE, or ApoE-GFP. Cell 
lysates were immunoblotted using α-ApoE (top) and α-actin (bottom) antibodies. 
Molecular weight marker positions (kDa) are at the left of the blots. (B) Infectivity of 
HCV particles released by the indicated cell lines at 72 h post electroporation. The cells 
expressed the following rescue vectors: EV (white bars), ApoE (gray bars) or ApoE-GFP 
(black bars). Shown are means ± standard error of the mean obtained from 2 or 3 
independent electroporations, with 3 virus samples analyzed for each electroporation. (C) 
Cell-associated HCV RNA copies quantified by qRT-PCR at 72 h post electroporation in 
samples from the experiment presented in panel B. (D) Cell-associated HCV RNA copies 
quantified by qRT-PCR at 6 h post electroporation in parallel samples to those presented 
in panels B and C. The lower RNA levels in the ApoE KD2/ApoE-GFP cells both at 6 h 
(panel D) and at 72 h (panel C) likely reflected a lower electroporation efficiency in that 
cell background. Statistical differences (Student's t-test: ns, p>0.05; *, p<0.05; **, 




Previous studies have shown that knockdown of ApoE expression results in 
decrease of infectious HCV release from Huh-7.5 cells (Benga et al., 2010; Chang et al., 
2007; Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al., 2014), and that infectivity 
release may be at least partly rescued by re-expression of knockdown-resistant ApoE 
(Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al., 2014). Our findings are consistent 
with these studies. Since in our experimental system ApoE-GFP did not possess any 
capacity to rescue HCV infectivity release, its usefulness in imaging experiments 
analyzing spatio-temporal dynamics of HCV particle release may be severely limited. 
ApoE-GFP might not associate with HCV particles, might associate with HCV particles 
that are degraded before being released, or might promote the production of ApoE-GFP-
containing HCV particles which remain nonetheless non-infectious. A putative defect of 
ApoE-GFP association with HCV particles would be unsurprising if the GFP tag 
interfered with ApoE-HCV association. ApoE specifically binds the transmembrane 
domain of the HCV glycoprotein E2 (Lee et al., 2014) and the GFP tag could cause a 
conformational change in the ApoE polypeptide that could interfere with the E2 
interaction. Alternatively, the relatively bulky GFP tag might sterically clash with the 
E1E2 glycoprotein ectodomains on the surface of the HCV particle, or might mask 
lipoprotein or glycoprotein domains involved in entry receptor interaction. If ApoE-GFP 
associated with HCV particles, and the structure and rate of production of these putative 
ApoE-GFP-containing HCV non-infectious particles were indistinguishable from the 
structure and rate of production of infectious ApoE-containing HCV particles, then 
ApoE-GFP may still be used in the analysis of HCV particle secretion. Unfortunately, 
 
223 
only a small portion of released HCV particles are infectious, and they appear to be 
difficult to purify and characterize structurally (Catanese et al., 2013; Gastaminza et al., 
2010). As such, documenting structural and compositional similarity between infectious 
ApoE-containing HCV particles and the hypothesized non-infectious ApoE-GFP-
containing HCV particles would be challenging at best. I thus conclude that ApoE-GFP is 
unlikely to be suitable to unambiguously mark and image infectious HCV particles 
during secretion from hepatic cells.  
Nonetheless, the results I present here do document a behavior of ApoE-GFP that 
closely mirrors that of untagged ApoE with respect to lipoprotein release. We showed 
that ApoE-GFP and untagged ApoE colocalized intracellularly and were secreted at 
similar rates. I further showed that ApoE-GFP interacted with both endogenous ApoE 
and ApoB100, as expected for a proper lipoprotein particle-associated marker. Our 
findings are further corroborated by a battery of functional tests previously performed in 
macrophages (Kockx et al., 2007) using the same construct that we used. I propose 
therefore that ApoE-GFP (or similarly made constructs) may be used in studies aiming, 
for example, to identify the route(s) of vesicular transport which shuttle ApoE-containing 
lipoproteins out of producing cells. Colocalization - or lack thereof - between Rabs and 
intracellular ApoE-GFP, for example, will inform whether a particular Rab protein 
functions in ApoE-containing lipoprotein egress. Furthermore, quantitative kinetic 
imaging studies, including the study of whether and how the various ApoE isoforms 
affected the rates of lipoprotein secretion, may be performed using such fluorescent 
protein tagged ApoE constructs. Besides characterizing ApoE-GFP behavior, this study 
provides a framework for testing other fluorescently tagged markers of lipoprotein 
 
224 
particles. Lastly, since ApoE has also been implicated in neurodegenerative diseases 
(Corder et al., 1994; Corder et al., 1993) and cancer (Pencheva et al., 2012), ApoE-GFP 
may likely be used in other disease-specific cellular contexts to answer cell biology 

























Throughout the past several years, aided by wonderfully skilful assistance from 
my friends and collaborators, I have pursued several lines of investigation, all converging 
towards a larger unified goal: to molecularly characterize the vesicular transport 
pathways involved in the secretion of such hepatic cargoes as serum albumin, the 
lipoprotein components ApoE and ApoB100, and HCV. Some of the avenues of 
investigation that I followed have yielded interesting results. Other branches of my 
investigation have established experimental tools and protocols that may prove useful in 
parsing out the functional details of other cellular processes. Finally, some of the 
approaches that I initially undertook have failed, or I have chosen not to pursue them 
further due to time restraints. I will not repeat here the individual discussion points that I 
have expanded upon at the conclusion of the previous chapters. I will, however, re-
emphasize that the DN Rab GTPase screen may be adapted for use in other experimental 
systems to parse out Rab family involvement in other secretion settings; that an elaborate 
description of Rab11 and Rab8 function in polarized hepatic cargo secretion may yield 
interesting revelations on how the hepatocytes handle the tremendous burden of 
intracellular traffic functions that they must harmoniously juggle; that the peculiar 
differences in the sensitivities of albumin, ApoE and ApoB100 to Rab1 inhibition may 
reveal interesting regulation methods of ER to Golgi traffic; and that ApoE-GFP may 




Were I to have more time to delve deeper into the investigation of hepatic cargo 
secretion, not only would I like to continue pursuing the lines of investigation that I have 
advanced as part of this work, but I would also like to reprise pursuing some other 
projects that I have envisaged, and even commenced, during my graduate student tenure. 
I have not included in the results section of this thesis a detailed description of all the bits 
and pieces of work that I have done as part of the several projects that did not advance 
significantly, beyond the Rab11 and Rab8 analysis. Those temporarily stalled lines of 
inquiry may nonetheless be reprised and used to complement the genetic and biochemical 
analysis of cargo transport that I presented in the pages above. For example, live cell 
imaging experiments contrasting the transport of fluorescently labeled albumin, ApoE, 
and HCV particles, with each other and with markers of individual secretion steps, 
including the Rab GTPases, may provide a trove of information regarding the dynamic 
spatial and temporal regulation of these model hepatic cargoes. Indeed, with assistance 
from Caroline Gleason, I have made fluorescent protein-tagged albumin constructs. I 
have also made HCV genomes expressing fluorescent protein-tagged E2 glycoproteins, 
or encoding bacteriophage RNA loop arrays (Buxbaum et al., 2015) that may be used to 
fluorescently label the HCV genome, as a collaboration between the Simon and Bieniasz 
labs has successfully achieved in the case of the HIV-I genome (Itano et al., 2015; 
Jouvenet et al., 2008).  These fluorescent beacon-tagged constructs would need to be 
tested in functional assays, as I have described for ApoE-GFP in Chapter 6. Once such 
characterization is complete, imaging experiments will need to be performed, likely 
combining several techniques. I am encouraged that such live cell imaging experiments 
will be facilitated by advances in imaging techniques. Beyond the total internal reflection 
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microscopy technique that has long been used in the Simon lab (Fix et al., 2004; Jouvenet 
et al., 2008; Jouvenet et al., 2009; Jouvenet et al., 2011), just recently, super-resolution 
imaging protocols and multi-focus simultaneous imaging techniques have been 
developed here and have been successfully applied to address biological questions (Bleck 
et al., 2014; Itano et al., 2015). These novel experimental techniques, which were not yet 
available when I started my thesis work, will only hasten the pace of the inquiry. I hope 
that whoever further pursues this investigation may find useful inspiration in the work 
that I have done over the past several years, and the work that I have envisaged 
continuing doing. 
I also hope that one day scientists may be able to look back and say: "We know 
all there is to know about hepatic lipoprotein and HCV secretion by the hepatocyte." This 
likely is an unachievable dream. But advancements have been made, and will be made. I 
am happy to think that I may have contributed something useful to the field, yet I am 
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